	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  i	
  	
  Title:	
  Pilot	
   Study	
   to	
  Prevent	
  the	
   Nephrotoxicity	
  of	
   High-­‐Dose	
   Methotrexate	
   by	
  Prolonging	
   the	
   Infusion	
   Duration	
  and	
  Prevent	
   the	
   Nephrotoxicity	
   and	
  Ototoxicity	
  of	
  Cisplatin	
   with	
   Pantoprazole	
   in	
   Children,	
  Adolescents	
  and	
  Young	
  Adults	
  with	
  Osteosarcoma	
  	
  Study	
  Key	
  Name:	
  CHP12ST051	
  OS	
  Nephrotoxicity	
  and	
  Ototoxicity	
  Protocol	
  Number:	
  CHP12ST051	
  Drug	
  Name:	
  Pantoprazole	
  FDA	
  IND:	
  Exempt	
  Protocol	
  Date:	
  April	
  2,	
  2013	
  Amendments:	
  Amendment	
  1	
  date:	
  Amendment	
  2	
  date:	
  Sponsor:	
  The	
  Gateway	
  for	
  Cancer	
  Research	
  Principal	
  Investigator:	
  Frank	
  M.	
  Balis,	
  M.D.	
  Center	
  for	
  Childhood	
  Cancer	
  Research	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB	
  4024	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐426-­‐5414	
  FAX:	
  267-­‐425-­‐0113	
  Email:	
  balisf@email.chop.edu	
  Co-­‐Investigators:	
  Rochelle	
  Bagatell,	
  M.D.	
  Center	
  for	
  Childhood	
  Cancer	
  Research	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB	
  4022	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐426-­‐9737	
  Email:	
  bagatellr@email.chop.edu	
  	
  Naomi	
  Balamuth,	
  M.D.	
  Center	
  for	
  Childhood	
  Cancer	
  Research	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB	
  10050	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  215-­‐590-­‐3437	
  Email:	
  balamuth@email.chop.edu	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  ii	
  	
  John	
  P.	
  Dormans,	
  M.D.	
  Chief,	
  Division	
  of	
  Orthopedics	
  Department	
  of	
  Surgery	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3401	
  Civic	
  Center	
  Blvd	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  215-­‐590-­‐1527	
  Email:	
  dormans@email.chop.edu	
  	
  Elizabeth	
  Fox,	
  M.D.	
  Center	
  for	
  Childhood	
  Cancer	
  Research	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB	
  4022	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐425-­‐3010	
  Email:	
  foxe@email.chop.edu	
  	
  Bruce	
  Pawel,	
  M.D.	
  Department	
  of	
  Pathology	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  34th	
  and	
  Civic	
  Center	
  Blvd.	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  215-­‐590-­‐1762	
  Email:	
  pawelb@email.chop.edu	
  	
  Lisa	
  States,	
  M.D.	
  Department	
  of	
  Radiology	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3401	
  Civic	
  Center	
  Blvd.	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐425-­‐7146	
  Email:	
  states@email.chop.edu	
  Richard	
  Womer,	
  M.D.	
  Center	
  for	
  Childhood	
  Cancer	
  Research	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB	
  10409	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  215-­‐590-­‐2229	
  Email:	
  womer@email.chop.edu	
  	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  iii	
  Statistician:	
  Study	
  Coordinator:	
  Yimei	
  Li,	
  Ph.D.	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB10207	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐425-­‐3084	
  Email:	
  liy3@email.chop.edu	
  Sarah	
  Strange	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB104021	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐425-­‐3142	
  Email:	
  stranges@email.chop.edu	
  Research	
  Nurse:	
  	
  Theresa	
  DiSipio	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  3501	
  Civic	
  Center	
  Blvd.	
  CTRB4023	
  Philadelphia,	
  PA	
  19104	
  Phone:	
  267-­‐426-­‐8194	
  Email:	
  disipiot@email.chop.edu	
  	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  iv	
  	
  TABLE	
  OF	
  CONTENTS	
  ABBREVIATIONS	
  AND	
  DEFINITIONS	
  OF	
  TERMS	
  ............................................................................	
  vii	
  PROTOCOL	
  SYNOPSIS	
  ....................................................................................................................	
  ix	
  SCHEDULE	
  OF	
  STUDY	
  PROCEDURES	
  ............................................................................................	
  xiii	
  STUDY	
  DIAGRAM	
  ..........................................................................................................................	
  xv	
  1.	
  BACKGROUND	
  INFORMATION	
  AND	
  RATIONALE	
  .....................................................................	
  1	
  1.1	
  Introduction	
  .......................................................................................................................	
  1	
  1.2	
  Compliance	
  Statement	
  ......................................................................................................	
  1	
  1.3	
  Relevant	
  Literature	
  and	
  Data	
  ............................................................................................	
  2	
  1.3.1	
  Osteosarcoma	
  .............................................................................................................	
  2	
  1.3.2	
  Nephrotoxicity	
  ............................................................................................................	
  3	
  1.3.3	
  Biomarkers	
  of	
  Acute	
  Kidney	
  Injury	
  .............................................................................	
  7	
  1.3.4	
  Ototoxicity	
  ..................................................................................................................	
  9	
  1.3.5	
  Pantoprazole	
  ..............................................................................................................	
  9	
  1.3.6	
  Serum	
  biomarkers	
  for	
  osteosarcoma	
  .......................................................................	
  11	
  1.3.7	
  Study	
  Rationale	
  .........................................................................................................	
  11	
  2.	
  STUDY	
  OBJECTIVES	
  ................................................................................................................	
  13	
  3.	
  INVESTIGATIONAL	
  PLAN	
  ........................................................................................................	
  13	
  3.1	
  General	
  Schema	
  of	
  Study	
  Design	
  .....................................................................................	
  13	
  3.1.1	
  Screening,	
  Diagnosis,	
  and	
  Staging	
  ............................................................................	
  14	
  3.1.2	
  Baseline	
  (Pretreatment)	
  Research	
  Studies	
  ...............................................................	
  15	
  3.1.3	
  Treatment	
  with	
  MAP	
  Regimen	
  .................................................................................	
  15	
  3.1.4	
  Criteria	
  for	
  Starting	
  Treatment	
  .................................................................................	
  18	
  3.1.5	
  Dose	
  Modifications	
  ...................................................................................................	
  19	
  3.1.6	
  Local	
  Control	
  of	
  Primary	
  Tumor	
  ...............................................................................	
  19	
  3.1.7	
  Management	
  of	
  Metastatic	
  Tumors	
  .........................................................................	
  20	
  3.2	
  Randomization	
  .................................................................................................................	
  20	
  3.3	
  Study	
  Duration,	
  Enrollment	
  and	
  Number	
  of	
  Sites	
  ...........................................................	
  20	
  3.3.1	
  Duration	
  of	
  Study	
  .....................................................................................................	
  20	
  3.3.2	
  Number	
  of	
  Subjects	
  and	
  Number	
  of	
  Study	
  Sites	
  ......................................................	
  20	
  3.4	
  Study	
  Population	
  .............................................................................................................	
  21	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  v	
  3.4.1	
  Study	
  Enrollment/Registration	
  .................................................................................	
  21	
  3.4.2	
  Inclusion	
  Criteria	
  .......................................................................................................	
  21	
  3.4.3	
  Exclusion	
  Criteria	
  ......................................................................................................	
  22	
  4.	
  RESEARCH	
  PROCEDURES	
  .......................................................................................................	
  22	
  4.1	
  Research	
  Studies	
  during	
  Treatment	
  ................................................................................	
  22	
  4.2	
  Post-­‐Therapy	
  Follow-­‐up	
  ..................................................................................................	
  23	
  4.3	
  Concomitant	
  Medications	
  ...............................................................................................	
  23	
  4.4	
  Subject	
  Completion/Withdrawal	
  .....................................................................................	
  23	
  5.	
  STUDY	
  ENDPOINTS	
  AND	
  EVALUATIONS	
  ................................................................................	
  24	
  5.1	
  Primary	
  Endpoints	
  ...........................................................................................................	
  24	
  5.2	
  Secondary	
  Endpoints	
  .......................................................................................................	
  24	
  5.3	
  Efficacy	
  Evaluations	
  .........................................................................................................	
  25	
  5.4	
  Safety	
  Evaluations	
  ...........................................................................................................	
  25	
  6.	
  STATISTICAL	
  CONSIDERATIONS	
  .............................................................................................	
  26	
  6.1	
  Statistical	
  Analysis	
  Plan	
  ...................................................................................................	
  26	
  6.1.1	
  Primary	
  Endpoints	
  ....................................................................................................	
  26	
  6.1.2	
  Secondary	
  Endpoints	
  ................................................................................................	
  27	
  6.2	
  Sample	
  Size	
  and	
  Power	
  ....................................................................................................	
  28	
  6.3	
  Interim	
  Analysis	
  ...............................................................................................................	
  29	
  7.	
  STUDY	
  MEDICATIONS	
  ............................................................................................................	
  30	
  7.1	
  Intravenous	
  Pantoprazole	
  (PROTONIX	
  I.V.)	
  .....................................................................	
  30	
  8.	
  SAFETY	
  MANAGEMENT	
  .........................................................................................................	
  31	
  8.1	
  Clinical	
  adverse	
  events	
  ....................................................................................................	
  32	
  8.2	
  Adverse	
  Event	
  Reporting	
  .................................................................................................	
  32	
  8.3	
  Definition	
  of	
  an	
  Adverse	
  Event	
  ........................................................................................	
  32	
  8.4	
  Definition	
  of	
  a	
  Serious	
  Adverse	
  Event	
  (SAE)	
  ....................................................................	
  32	
  8.4.1	
  Relationship	
  of	
  SAE	
  to	
  study	
  drug	
  or	
  other	
  intervention	
  or	
  procedure	
  ...................	
  33	
  8.4.2	
  IRB/IEC	
  Notification	
  of	
  SAEs	
  .....................................................................................	
  33	
  8.4.3	
  Follow-­‐up	
  report	
  .......................................................................................................	
  33	
  9.	
  STUDY	
  ADMINISTRATION	
  ......................................................................................................	
  33	
  9.1	
  Data	
  collection	
  and	
  management	
  ...................................................................................	
  33	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  vi	
  9.1.1	
  Confidentiality	
  ..........................................................................................................	
  33	
  9.1.2	
  Security	
  .....................................................................................................................	
  34	
  9.1.3	
  Anonymization,	
  de-­‐identification,	
  or	
  destruction	
  ....................................................	
  34	
  9.2	
  Confidentiality	
  .................................................................................................................	
  34	
  9.3	
  Regulatory	
  and	
  ethical	
  considerations	
  ............................................................................	
  34	
  9.3.1	
  Data	
  safety	
  and	
  monitoring	
  plan	
  ..............................................................................	
  34	
  9.3.2	
  Risk	
  assessment	
  ........................................................................................................	
  34	
  9.3.3	
  Potential	
  benefits	
  of	
  trial	
  participation	
  ....................................................................	
  35	
  9.3.4	
  Risk-­‐benefit	
  assessment	
  ...........................................................................................	
  35	
  9.4	
  Recruitment	
  strategy	
  .......................................................................................................	
  35	
  9.5	
  Informed	
  consent/assent	
  ................................................................................................	
  35	
  9.6	
  Payments	
  to	
  subjects/families	
  ........................................................................................	
  36	
  10.	
  	
  PUBLICATION	
  ......................................................................................................................	
  36	
  11.	
  REFERENCES	
  ........................................................................................................................	
  36	
  APPENDIX	
  1	
  SAMPLE	
  TREATMENT	
  DELIVERY	
  MAP	
  ....................................................................	
  43	
  APPENDIX	
  2	
  PEDIATRIC	
  NEUROTOXICITY	
  GRADING	
  SCALE	
  .......................................................	
  44	
  APPENDIX	
  3	
  PATIENT	
  REPORTED	
  OUTCOME	
  SURVEY	
  ...............................................................	
  46	
  	
  	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  vii	
  ABBREVIATIONS	
  AND	
  DEFINITIONS	
  OF	
  TERMS	
  	
  Term	
  Definition	
  AKI	
  Acute	
  kidney	
  injury	
  AUC	
  Area	
  under	
  the	
  plasma	
  concentration-­‐time	
  curve	
  Block	
  Two	
  consecutive	
  treatment	
  cycles	
  (Cycles	
  1	
  &	
  2	
  or	
  Cycles	
  3	
  &	
  4)	
  BMP	
  Basic	
  mineral	
  panel	
  BSAP	
  Bone-­‐specific	
  alkaline	
  phosphatase	
  CBC	
  Complete	
  blood	
  counts	
  CL	
  Clearance	
  Cmax	
  Peak	
  concentration	
  CMP	
  Comprehensive	
  mineral	
  panel	
  COG	
  Children’s	
  Oncology	
  Group	
  Course	
  A	
  course	
  of	
  cisplatin	
  is	
  60	
  mg/m2	
  daily	
  x	
  2	
  days	
  (total	
  dose	
  120	
  mg/m2);	
  a	
  course	
  of	
  doxorubicin	
  is	
  37	
  mg/m2	
  daily	
  x	
  2	
  days	
  (total	
  dose	
  75	
  mg/m2);	
  a	
  course	
  of	
  HDMTX	
  is	
  two	
  12	
  g/m2	
  infusions	
  administered	
  1	
  week	
  apart	
  Cr	
  Creatinine	
  CrCL	
  Creatinine	
  clearance	
  CR	
  Complete	
  Response	
  Cycle	
  A	
  course	
  of	
  cisplatin	
  and	
  doxorubicin	
  followed	
  3	
  weeks	
  later	
  by	
  a	
  course	
  of	
  HDMTX	
  (cycles	
  1-­‐4;	
  duration	
  5	
  weeks);	
  OR	
  A	
  course	
  of	
  doxorubicin	
  followed	
  2	
  weeks	
  later	
  by	
  a	
  course	
  of	
  HDMTX	
  (cycles	
  5&6;	
  duration	
  4	
  weeks)	
  	
  EOI	
  End	
  of	
  infusion	
  EOT	
  End	
  of	
  therapy	
  FEMg	
  Fraction	
  excretion	
  of	
  magnesium	
  GFR	
  Glomerular	
  filtration	
  rate	
  H&P	
  History	
  and	
  physical	
  exam	
  HDMTX	
  High-­‐dose	
  methotrexate	
  (12	
  g/m2)	
  IV	
  Intravenous	
  KIM-­‐1	
  Kidney	
  Injury	
  Molecule-­‐1	
  	
  LV	
  Leucovorin	
  MAP	
  Methotrexate,	
  Adriamycin	
  (doxorubicin),	
  cisPlatin	
  Mg	
  Magnesium	
  MTX	
  Methotrexate	
  NAG	
  N-­‐Acetyl-­‐β-­‐D-­‐Glucosamidase	
  NGAL	
  Neutrophil	
  Gelatinase-­‐Associated	
  Lipocalin	
  OCT2	
  Organic	
  cation	
  transporter	
  2	
  OS	
  Osteosarcoma	
  PK	
  Pharmacokinetics	
  Pre-­‐op	
  Preoperatively	
  PPI	
  Proton	
  pump	
  inhibitor	
  PR	
  Partial	
  Response	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  viii	
  Pre-­‐Rx	
  Pretreatment	
  PRO	
  Patient	
  reported	
  outcome	
  PS	
  Performance	
  score	
  (Lansky	
  or	
  Karnofsky)	
  T1/2	
  Half-­‐life	
  TDM	
  Treatment	
  delivery	
  map	
  (roadmap)	
  UA	
  Urinalysis	
  	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  ix	
  PROTOCOL	
  SYNOPSIS	
  STUDY	
  TITLE	
  Pilot	
  Study	
  to	
  Prevent	
  the	
  Nephrotoxicity	
  of	
  High-­‐Dose	
  Methotrexate	
  by	
  Prolonging	
  the	
  Infusion	
  Duration	
  and	
  Prevent	
  the	
  Nephrotoxicity	
  and	
  Ototoxicity	
  of	
  Cisplatin	
  with	
  Pantoprazole	
  in	
  Children,	
  Adolescents	
  and	
  Young	
  Adults	
  with	
  Osteosarcoma	
  SPONSOR	
  The	
  Gateway	
  for	
  Cancer	
  Research	
  CLINICAL	
  PHASE	
  Pilot	
  clinical	
  trial	
  PARTICIPATING	
  SITES	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
  STUDY	
  RATIONALE	
  Current	
   osteosarcoma	
   treatment	
   regimens	
   include	
   drugs	
   that	
   are	
   nephrotoxic	
   and	
  ototoxic,	
   and	
   the	
   damage	
   to	
   kidneys	
   and	
   cochlear	
   hair	
   cells	
   may	
   be	
   irreversible.	
  Preventing	
  these	
  toxicities	
  will	
  improve	
  the	
  outcome	
  in	
  long-­‐term	
  survivors	
  and	
  may	
  also	
  prevent	
  short-­‐term	
  treatment	
  delays	
  and	
  dose	
  reductions	
  that	
  can	
  compromise	
  the	
   efficacy	
   of	
   the	
   treatment	
   regimen	
   and	
   allow	
   for	
   administration	
   of	
   higher	
  cumulative	
   doses	
   of	
   cisplatin.	
   This	
   pilot	
   study	
   evaluates	
   pharmacologically-­‐based	
  approaches	
  to:	
  • prevent	
   the	
   nephrotoxic	
   effect	
   of	
  high-­‐dose	
   methotrexate	
   (HDMTX)	
  by	
  prolonging	
   the	
   infusion	
   duration	
   and	
   thereby	
   lowering	
   the	
   risk	
   of	
   drug	
  precipitation	
  in	
  renal	
  tubules,	
  and	
  • selectively	
  block	
  the	
  uptake	
  of	
  cisplatin	
  into	
  renal	
  tubular	
  cells	
  and	
  cochlear	
  hair	
  cells	
  by	
  inhibiting	
  the	
  organic	
  cation	
  transporter	
  2	
  (OCT2)	
  with	
  the	
  proton	
  pump	
  inhibitor,	
  pantoprazole.	
  These	
  pharmacologically-­‐based	
  approaches	
  to	
  prevent	
  nephrotoxicity	
  and	
  ototoxicity	
  may	
  also	
  be	
  applicable	
  in	
  other	
  cancers	
  treated	
  with	
  cisplatin	
  or	
  HDTX.	
  	
  STUDY	
  OBJECTIVES	
  Primary	
  objective	
  The	
   primary	
   objective	
   is	
   to	
   identify	
   more	
   rational,	
   pharmacologically-­‐based	
   drug	
  delivery	
   approaches	
   to	
   prevent	
   nephrotoxicity	
   from	
   HDMTX	
   and	
   cisplatin	
   and	
  ototoxicity	
  from	
  cisplatin	
  in	
  patients	
  with	
  OS	
  by:	
  • comparing	
   biomarkers	
   of	
   acute	
   kidney	
   injury	
  (AKI),	
  glomerular	
   function	
  and	
  plasma	
  and	
  urine	
  MTX	
  concentrations	
  after	
  12	
  g/m2	
  of	
  MTX	
  infused	
  over	
  4	
  and	
  12	
  hours,	
  • comparing	
   biomarkers	
   of	
  AKI,	
   glomerular	
   function	
  and	
   fractional	
   excretion	
  of	
  magnesium	
  (FEMg)	
  after	
   cisplatin	
   administered	
   with	
   and	
   without	
   the	
   OCT2	
  inhibitor,	
  pantoprazole,	
  and	
  • comparing	
   audiograms	
   after	
   cisplatin	
   administered	
   with	
   and	
   without	
  pantoprazole.	
  Secondary	
  objectives	
  • compare	
  the	
  incidence	
  and	
  severity	
  (grade)	
  of	
  common	
  toxicities	
  from	
  cisplatin/	
  doxorubicin	
  administered	
   with	
   and	
   without	
   pantoprazole	
   and	
   from	
   HDMTX	
  administered	
  as	
  a	
  4	
  and	
  12	
  h	
  infusion,	
  • compare	
  radiographic	
   response	
   (log	
   ratio	
   of	
   tumor	
   volumes)	
   and	
   histological	
  response	
   (percent	
  tumor	
  necrosis)	
   to	
  two	
  cycles	
   (10	
   weeks)	
   of	
  neoadjuvant	
  chemotherapy	
   for	
   the	
  two	
  infusion	
   durations	
   of	
   HDMTX	
   and	
   for	
   cisplatin	
   with	
  and	
  without	
  pantoprazole,	
  • correlate	
  urinary	
   markers	
   of	
   AKI	
  and	
   GFR	
   estimated	
   from	
   serum	
   cystatin	
  C	
   to	
  standard	
   measures	
   of	
   renal	
   function	
   (serum	
   creatinine,	
   urinalysis,	
  estimated	
  creatinine	
  clearance,	
  FEMg),	
  • build	
  a	
  tissue	
  microarray	
  from	
  biopsy,	
  primary	
  resection	
  and	
  resected	
  metastatic	
  tumors	
  to	
  evaluate	
  the	
  expression	
  of	
  proteins	
  that	
  are	
  responsible	
  for	
  resistance	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  x	
  to	
  the	
  drugs	
  in	
  the	
  MAP	
  regimen	
  and	
  to	
  assess	
  expression	
  of	
  proteins	
  that	
  are	
  targeted	
  by	
  new	
  anticancer	
  drugs	
  under	
  development	
  for	
  childhood	
  cancers,	
  • evaluate	
  serum	
  BSAP	
  as	
  a	
  potential	
  biomarker	
  for	
  OS,	
  	
  • monitor	
  nutritional	
  status	
  (weight,	
  arm	
  circumference,	
  skin	
  fold	
  thickness,	
  pre-­‐albumin)	
  in	
  patients	
  receiving	
  the	
  MAP	
  chemotherapy	
  regimen,	
  and	
  • pilot	
  an	
  osteosarcoma-­‐specific	
  patient	
  reported	
  outcomes	
  survey	
  to	
  assess	
  the	
  incidence	
  and	
  severity	
  of	
  tumor-­‐related	
  and	
  treatment-­‐related	
  symptoms.	
  TEST	
  ARTICLE	
  Pantoprazole	
  STUDY	
  DESIGN	
  A	
  randomized	
  cross-­‐over,	
  2	
  x	
  2	
  factorial	
  design,	
  in	
  which	
  patients	
  serve	
  as	
  their	
  own	
  control,	
  will	
  be	
  used	
  to	
  maximize	
  the	
  potential	
  to	
  detect	
  differences	
  in	
  biomarkers	
  of	
  AKI	
  (NAG,	
   NGAL,	
   KIM-­‐1,	
   cystatin	
  C)	
   and	
   audiograms	
   resulting	
   from	
   altering	
   the	
  infusion	
  duration	
  of	
  HDMTX	
  and	
  from	
  adding	
  pantoprazole	
  to	
  cisplatin.	
  Two	
  infusion	
   durations	
   of	
   HDMTX	
   will	
   be	
   studied	
  –	
  the	
   standard	
   4	
   h	
   duration	
   and	
  more	
  prolonged	
  12	
  h	
  infusion	
  duration.	
  Leucovorin	
  rescue	
  will	
  commence	
  24	
  h	
  from	
  the	
  start	
  of	
  the	
  infusion.	
  The	
  HDMTX	
  infusions	
  will	
  be	
  divided	
  into	
  2	
  blocks	
  (cycles	
  1	
  &	
  2,	
   cycles	
   3	
   &	
   4),	
   each	
   of	
   which	
   include	
   4	
   HDMTX	
   infusions.	
   The	
   order	
   of	
   infusion	
  duration	
  studied	
  in	
  each	
  block	
  will	
  be	
  randomly	
  determined.	
  Pantoprazole	
  will	
  either	
  be	
  administered	
  with	
  the	
  first	
  two	
  courses	
  of	
  cisplatin	
  during	
  cycles	
  1	
  &	
  2	
  or	
  with	
  the	
  third	
  and	
  fourth	
  courses	
  during	
  cycles	
  3	
  &	
  4,	
  and	
  the	
  order	
  will	
   be	
  assigned	
   by	
   randomization.	
   Cisplatin	
   is	
   administered	
   as	
   a	
   60	
   mg/m2	
  dose	
  infused	
  over	
  4	
  h	
  daily	
  x	
  2	
  d.	
  At	
  steady	
  state,	
  7.2	
  mg/m2	
  of	
  active	
  cisplatin	
  is	
  in	
  the	
  body,	
   and	
   by	
   the	
   end	
   of	
   the	
   4	
   h	
   infusion,	
   88%	
   of	
   the	
   total	
   dose	
   has	
   been	
   cleared.	
  Therefore,	
  adequate	
  concentrations	
  to	
  inhibit	
  OCT2	
  should	
  be	
  present	
  for	
  at	
  least	
  4	
  h	
  to	
  prevent	
  cisplatin	
  nephrotoxicity	
  and	
  ototoxicity.	
  Pantoprazole	
  has	
  a	
  short	
  half-­‐life	
  (1.2	
  h),	
  and	
  when	
  administered	
  at	
  a	
  dose	
  of	
  1.6	
  mg/kg	
  as	
  a	
  standard	
  15	
  min	
  infusion,	
  plasma	
   pantoprazole	
   concentration	
   by	
   the	
   end	
   of	
   the	
   4	
   h	
   cisplatin	
   infusion	
   is	
   1.3	
  mcM.	
  By	
  administering	
  the	
  same	
  dose	
  as	
  a	
  0.3	
  mg/kg	
  loading	
  dose	
  infused	
  over	
  15	
  min	
   followed	
   by	
   a	
   4	
   h	
   infusion	
   of	
   the	
   remaining	
   1.3	
   mg/kg,	
   plasma	
   pantoprazole	
  concentration	
  is	
  5.9	
  mcM	
  at	
  4	
  h.	
  The	
   primary	
   endpoint	
   to	
   assess	
   nephrotoxicity	
   will	
   be	
   the	
   AKI	
   markers	
   (cystatin	
   C,	
  KIM-­‐1,	
  NGAL,	
  NAG)	
  and	
  fractional	
  excretion	
  of	
  magnesium	
  (FEMg).	
  This	
  will	
  allow	
  us	
  to	
  assess	
  each	
  course	
  of	
  HDMTX	
  and	
  cisplatin	
  independently.	
  Standard	
  renal	
  function	
  tests	
  (urinalysis,	
  serum	
  creatinine,	
  estimated	
  creatinine	
  clearance,	
  and	
  FEMg)	
  will	
  also	
  be	
  monitored.	
  Audiograms	
  will	
  be	
  performed	
  after	
  each	
  course	
  of	
  cisplatin	
  to	
  assess	
  ototoxicity.	
   Radiographic	
   and	
   histological	
   response	
   in	
   the	
   resected	
   tumor	
   specimen	
  after	
  neoadjuvant	
  chemotherapy	
  will	
  be	
  assessed	
  to	
  ensure	
  that	
  changes	
  in	
  HDMTX	
  infusion	
   duration	
   and	
   the	
   addition	
   of	
   pantoprazole	
   to	
   cisplatin	
   do	
   not	
   alter	
   the	
  efficacy	
  of	
  chemotherapy.	
  A	
  brief	
  survey	
  to	
  assess	
  the	
  patient’s	
  view	
  of	
  disease-­‐related	
  and	
  drug	
  toxicity-­‐related	
  symptoms	
   will	
   be	
   piloted	
   prior	
   to	
   each	
   treatment	
   cycle,	
   post-­‐op	
   and	
   at	
   the	
   end	
   of	
  therapy,	
  and	
  nutritional	
  status	
  will	
  be	
  monitored	
  over	
  the	
  course	
  of	
  therapy.	
  The	
  use	
  of:	
  • sensitive,	
   short-­‐term	
   biomarkers	
  as	
   endpoints	
  to	
   assess	
   the	
   effect	
   of	
  interventions, • continuous,	
   rather	
   than	
   categorical,	
   variables	
  that	
   are	
  analyzed	
   by	
  course	
  or	
  cycle	
  rather	
  than	
  by	
  patient,	
  and • a	
  crossover	
  design	
  with	
  patients	
  serving	
  as	
  their	
  own	
  control,	
  will	
  minimize	
  the	
  number	
  of	
  subjects	
  and	
  time	
  required	
  to	
  complete	
  this	
  pilot	
  study	
  in	
  a	
  limited	
  patient	
  population	
  with	
  a	
  rare	
  form	
  of	
  cancer,	
  increase	
  statistical	
  power,	
  and	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  xi	
  maximize	
  the	
  amount	
  of	
  data	
  collected	
  in	
  this	
  pilot	
  study.	
  SUBJECT	
  POPULATION	
  Children,	
  adolescents	
  and	
  young	
  adults	
  with	
  previously	
  untreated	
  osteosarcoma	
  Inclusion	
  Criteria	
  • Age:	
  <30	
  years	
  of	
  age	
  • Diagnosis:	
  histological	
  diagnosis	
  of	
  high-­‐grade	
  osteosarcoma	
  • Site:	
   Extremity	
   or	
   central	
   axis	
   (including	
   craniofacial)	
   primary	
   tumor;	
   localized	
   or	
  metastatic	
  • Prior	
   therapy:	
   No	
   prior	
   chemotherapy	
   or	
   radiation	
   therapy	
   for	
   osteosarcoma.	
  Subjects	
  who	
  develop	
  osteosarcoma	
  as	
  a	
  second	
  cancer	
  are	
  eligible	
  if	
  they	
  have	
  not	
  previously	
  received	
  cisplatin,	
  doxorubicin	
  or	
  MTX	
  • Kidney	
  function:	
  Normal	
  serum	
  creatinine	
  for	
  age	
  and	
  gender	
  • Cardiac	
  function:	
  Shortening	
  fraction	
  on	
  echocardiogram	
  >28%	
  • Hearing:	
   Hearing	
   level	
   threshold	
   ≤25	
   dB	
   at	
   all	
   frequencies	
   in	
   both	
   ears	
   to	
   be	
  evaluable	
  for	
  assessment	
  of	
  pantoprazole’s	
  effect	
  on	
  cisplatin	
  ototoxicity.	
  Patients	
  with	
  hearing	
  loss	
  can	
  be	
  enrolled	
  but	
  will	
  not	
  be	
  evaluable	
  for	
  ototoxicity	
  objective.	
  • Hematological	
  function:	
  Absolute	
  neutrophil	
  count	
  >1,000/mcL	
  and	
  platelet	
  count	
  >100,000/mcL	
  Exclusion	
  Criteria	
  • Receiving	
   H2	
  antagonists	
   (cimetidine,	
   ranitidine,	
   famotidine,	
   nizatidine)	
   or	
   proton	
  pump	
   inhibitors	
   (lansoprazole,	
   omeprazole,	
   pantoprazole,	
   esomeprazole,	
  raberprazole,	
  dexlansoprazole)	
  AND	
  unable	
  to	
  hold	
  the	
  drug	
  for	
  24	
  h	
  prior	
  to	
  and	
  24	
  h	
  after	
  each	
  cisplatin	
  course	
  on	
  cycles	
  1-­‐4.	
  • Pregnant	
  or	
  breastfeeding	
  • Unable	
  to	
  cooperate	
  with	
  research	
  procedures	
  NUMBER	
  OF	
  SUBJECTS	
  24	
  DURATION	
  OF	
  SUBJECT	
  PARTICIPATION	
  40	
  weeks	
  STUDY	
  DURATION	
  24-­‐36	
  months	
  STUDY	
  PHASES	
  Pilot	
  clinical	
  trial	
  EFFICACY	
  EVALUATION	
  Radiographic	
  and	
  histological	
  response	
  to	
  neoadjuvant	
  therapy,	
  survival	
  PHARMACOKINETIC	
  EVALUATION	
  Plasma	
  and	
  urine	
  methotrexate	
  concentrations	
  at	
  the	
  end	
  of	
  each	
  HDMTX	
  infusion	
  on	
  cycles	
  1-­‐4	
  SAFETY	
  EVALUATION	
  Nadir	
   neutrophil	
   count	
   and	
   duration	
   of	
   severe	
   (ANC	
   <500/mcL)	
   neutropenia,	
   nadir	
  platelet	
   count	
   and	
   number	
   of	
   platelet	
   transfusions,	
   hospital	
   admissions/days	
   for	
  neutropenia	
  with	
  fever	
  or	
  infection,	
  highest	
  value	
  for	
  serum	
  ALT	
  and	
  total	
  bilirubin,	
  grade	
  3	
  or	
  4	
  mucositis,	
  treatment	
  delays	
  or	
  missed	
  chemotherapy	
  doses	
  to	
  allow	
  for	
  recovery	
   from	
   toxicity,	
   dose	
   modifications	
   for	
   toxicity,	
   and	
   deaths	
   attributed	
   to	
  chemotherapy	
  toxicity	
  will	
  be	
  monitored	
  and	
  collected	
  by	
  cycle.	
  After	
  the	
  first	
  12	
  patients	
  have	
  completed	
  therapy,	
  the	
  incidence	
  and	
  severity	
  of	
  the	
  events	
   listed	
   above	
   as	
   well	
   as	
   the	
   nephrotoxicity	
   and	
   ototoxicity	
   endpoints	
   will	
   be	
  assessed	
  by	
  Cycle	
  according	
  to	
  HDMTX	
  infusion	
  duration	
  (4	
  h	
  vs.	
  12	
  h)	
  and	
  according	
  to	
  whether	
  or	
  not	
  IV	
  pantoprazole	
  was	
  administered	
  with	
  cisplatin	
  to	
  ensure	
  that	
  the	
  experimental	
  dosing	
  methods	
  are	
  not	
  associated	
  with	
  excessive	
  toxicity.	
  After	
   the	
   first	
   12	
   patients	
   have	
   undergone	
   resection	
   of	
   their	
   primary	
   tumor,	
   the	
  radiographic	
  response	
  (log	
  ratio)	
  and	
  histologic	
  response	
  (%	
  necrosis)	
  will	
  be	
  assessed	
  according	
  to	
  HDMTX	
  infusion	
  duration	
  (4	
  h	
  vs.	
  12	
  h)	
  during	
  Cycles	
  1	
  &	
  2	
  and	
  according	
  to	
  whether	
  or	
  not	
  IV	
  pantoprazole	
  was	
  administered	
  with	
  cisplatin	
  during	
  Cycles	
  1	
  &	
  2	
  to	
   ensure	
   that	
   the	
   anti-­‐tumor	
   effect	
   of	
   the	
   MAP	
   chemotherapy	
   regimen	
   is	
   not	
  compromised	
  by	
  the	
  experimental	
  dosing	
  methods.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  xii	
  STATISTICAL	
  AND	
  ANALYTIC	
  PLAN	
  This	
  pilot	
  study	
  uses	
  a	
  2	
  x	
  2	
  factorial,	
  randomized	
  crossover	
  design,	
  which	
  will	
  allow	
  patients	
  to	
  serve	
  as	
  their	
  own	
  control.	
  Nephrotoxicity	
  data	
  will	
  be	
  analyzed	
  by	
  course	
  for	
  cisplatin	
  and	
  by	
  dose	
  for	
  HDMTX,	
  and	
  ototoxicity	
  data	
  will	
  be	
  analyzed	
  by	
  cycle.	
  	
  The	
   primary	
   endpoints	
   are	
   sensitive	
   urinary	
   biomarkers	
   of	
   AKI,	
   standard	
   renal	
  function	
   tests,	
  and	
   audiograms,	
   and	
   all	
   endpoints	
  will	
   be	
   analyzed	
   as	
   continuous	
  variables.	
  Twenty-­‐four	
  patients	
  will	
  be	
  enrolled	
  and	
  patients	
  serve	
  as	
  their	
  own	
  control.	
  Over	
  the	
   past	
   5	
   years,	
  57	
   newly	
   diagnosed	
   patients	
   with	
   osteosarcoma	
   were	
   seen	
   and	
  treated	
  at	
  CHOP.	
  This	
  is	
  an	
  average	
  of	
  11.5	
  patients	
  per	
  year,	
  indicating	
  that	
  we	
  can	
  complete	
   accrual	
   to	
   this	
   study	
   in	
   about	
   two	
   years.	
  For	
   each	
   primary	
   endpoint,	
  separate	
  linear	
  mixed	
  effects	
  models	
  will	
  be	
  constructed	
  for	
  comparison	
  of	
  cisplatin	
  with	
  vs.	
  without	
  pantoprazole	
  and	
  for	
  comparison	
  of	
  the	
  4	
  vs.	
  12	
  h	
  infusion	
  durations	
  of	
  HDMTX.	
  DATA	
  AND	
  SAFETY	
  MONITORING	
  PLAN	
  The	
  research	
  team	
  led	
  by	
  the	
  protocol	
  PI	
  will	
  monitor	
  adverse	
  events	
  related	
  to	
  the	
  protocol	
   therapy	
   in	
   real	
   time.	
   The	
   progress	
   of	
   every	
   patient	
   actively	
   receiving	
  treatment	
  on	
  this	
  study	
  will	
  be	
  discussed	
  weekly	
  in	
  the	
  Solid	
  Tumor	
  Team	
  Meeting.	
  An	
  interim	
  analysis	
  to	
  assess	
  the	
  safety	
  of	
  the	
  interventions	
  will	
  be	
  performed	
  after	
  the	
  first	
  12	
  patients	
  have	
  completed	
  therapy.	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  xiii	
  SCHEDULE	
  OF	
  STUDY	
  PROCEDURES	
  PROCEDURE	
  Baseline	
  Cycle	
  1	
  Cycle	
  2	
  Surgery	
  Cycle	
  3	
  Cycle	
  4	
  Cycle	
  5	
  Cycle	
  6	
  End	
  therapy	
  Standard	
  of	
  care	
  procedures	
  Tumor	
  biopsy	
  X	
  	
  	
  	
  	
  	
  	
  	
  	
  H&P,	
  PS,	
  weight,	
  height	
  X	
  D1,	
  22,	
  29	
  D1,	
  22,	
  29	
  Pre-­‐op	
  D1,	
  22,	
  29	
  D1,	
  22,	
  29	
  D1,	
  15,	
  22	
  D1,	
  15,	
  22	
  X	
  CBC	
  +	
  Differential	
  X	
  D1	
  &	
  weekly	
  D1	
  &	
  weekly	
  Pre-­‐op	
  D1	
  &	
  weekly	
  D1	
  &	
  weekly	
  D1	
  &	
  weekly	
  D1	
  &	
  weekly	
  X	
  CMP	
  +	
  PO4,	
  Mg	
  X	
  D1,	
  22	
  D1,	
  22	
  Pre-­‐op	
  D1,	
  22	
  D1,	
  22	
  D1,	
  15	
  D1,	
  15	
  X	
  BMP	
  	
  D29	
  D29	
  	
  D29	
  D29	
  D22	
  D22	
  	
  UA	
  w/o	
  micro	
  X	
  D1,	
  221,	
  291	
  D1,	
  221,	
  291	
  	
  D1,	
  221,	
  291	
  D1,	
  221,	
  291	
  D1,	
  151,	
  221	
  D1,	
  151,	
  221	
  X	
  Urine	
  pregnancy	
  test2	
  X	
  	
  	
  	
  	
  	
  	
  	
  	
  Serum	
  creatinine3	
  	
  D22,	
  29	
  D22,	
  29	
  	
  D22,	
  29	
  D22,	
  29	
  D15,	
  22	
  D15,	
  22	
  	
  Serum	
  MTX3	
  	
  D22,	
  29	
  D22,	
  29	
  	
  D22,	
  29	
  D22,	
  29	
  D15,	
  22	
  D15,	
  22	
  	
  Creatinine	
  clearance4	
  X	
  	
  	
  	
  Pre-­‐Rx	
  	
  Pre-­‐Rx	
  	
  X	
  Echocardiogram5	
  X	
  	
  	
  	
  Pre-­‐Rx	
  	
  Pre-­‐Rx	
  	
  X	
  Audiogram	
  X	
  	
  Pre-­‐Rx	
  	
  Pre-­‐Rx	
  Pre-­‐Rx	
  	
  	
  X	
  Plain	
  X-­‐ray	
  of	
  primary	
  X	
  	
  	
  Pre-­‐op	
  Pre-­‐Rx	
  	
  	
  	
  X	
  MRI	
  of	
  primary	
  X	
  	
  	
  Pre-­‐op	
  Pre-­‐Rx6	
  	
  	
  	
  X6	
  Chest	
  CT	
  scan	
  X	
  	
  	
  Pre-­‐op	
  	
  	
  Pre-­‐Rx7	
  	
  X	
  Bone	
  or	
  PET	
  scan	
  X	
  	
  	
  Pre-­‐op	
  	
  	
  Pre-­‐Rx7	
  	
  X7	
  Dexrazoxane	
  	
  D1,	
  2	
  D1,	
  2	
  	
  D1,	
  2	
  D1,	
  2	
  D1,	
  2	
  D1,	
  2	
  	
  Doxorubicin	
  	
  D1,	
  2	
  D1,	
  2	
  	
  D1,	
  2	
  D1,	
  2	
  D1,	
  2	
  D1,	
  2	
  	
  Cisplatin	
  	
  D1,	
  2	
  D1,	
  2	
  	
  D1,	
  2	
  D1,	
  2	
  	
  	
  	
  Pegfilgrastim	
  	
  D3	
  D3	
  	
  D3	
  D3	
  D3	
  D3	
  	
  HDMTX	
  +	
  LV	
  rescue	
  	
  D22,	
  29	
  D22,	
  29	
  	
  D22,	
  29	
  D22,	
  29	
  D15,	
  22	
  D15,	
  22	
  	
  Tumor	
  resection	
  	
  	
  	
  X	
  	
  	
  	
  	
  	
  %	
  Tumor	
  necrosis	
  	
  	
  	
  X	
  	
  	
  	
  	
  	
  Research	
  procedures	
  IV	
  Pantoprazole	
  	
  D1,	
  28	
  D1,	
  28	
  	
  D1,	
  28	
  D1,	
  28	
  	
  	
  	
  Urinary	
  AKI	
  markers,	
  Cr9	
  X	
  D1,	
  2,	
  7,	
  22,	
  23,	
  29,	
  30	
  D1,	
  2,	
  7,	
  22,	
  23,	
  29,	
  30	
  Pre-­‐op	
  D1,	
  2,	
  7,	
  22,	
  23,	
  29,	
  30	
  D1,	
  2,	
  7,	
  22,	
  23,	
  29,	
  30	
  D1	
  	
  	
  Serum	
  Cystatin	
  C10	
  X	
  D1,	
  7,	
  22,	
  29	
  D1,	
  7,	
  22,	
  29	
  Pre-­‐op	
  D1,	
  7,	
  22,	
  29	
  D1,	
  7,	
  22,	
  29	
  D1	
  	
  X	
  Plasma/Urinary	
  Mg,	
  Cr11	
  X	
  D1,	
  2,	
  7	
  D1,	
  2,	
  7	
  	
  D1,	
  2,	
  7	
  D1,	
  2,	
  7	
  D1	
  	
  X	
  BSAP	
  X	
  	
  	
  Pre-­‐op	
  D1	
  	
  	
  	
  X	
  Pre-­‐albumin	
  X	
  	
  D1	
  Pre-­‐op	
  D1	
  D1	
  D1	
  D1	
  X	
  Urine	
  MTX12	
  	
  EOI	
  D22,	
  29	
  EOI	
  D22,	
  29	
  	
  EOI	
  D22,	
  29	
  EOI	
  D22,	
  29	
  	
  	
  	
  PRO	
  survey13	
  X	
  	
  D1	
  Pre-­‐op	
  D1	
  D1	
  D1	
  D1	
  X	
  Arm	
  circum/Skin	
  fold	
  X	
  	
  D1	
  Pre-­‐op	
  D1	
  D1	
  D1	
  D1	
  X	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  xiv	
  1	
  Check	
  urine	
  pH	
  prior	
  to	
  the	
  start	
  of	
  HDMTX	
  and	
  every	
  shift	
  (q8h)	
  until	
  serum	
  MTX	
  <1	
  mcM.	
  2	
  For	
  females	
  ≥11	
  years	
  of	
  age	
  3	
  At	
  the	
  end	
  of	
  the	
  HDMTX	
  infusion,	
  hour	
  24,	
  and	
  daily	
  until	
  MTX	
  <0.1	
  mcM	
  4	
  12	
  or	
  24	
  hour	
  urine	
  collection	
  to	
  measure	
  creatinine	
  excretion	
  plus	
  serum	
  creatinine	
  5	
  Repeat	
  prior	
  to	
  every	
  course	
  of	
  doxorubicin	
  if	
  SF	
  <30%	
  on	
  prior	
  cycle	
  6	
  Substitute	
  CT	
  scan	
  if	
  metal	
  in	
  endoprothesis	
  does	
  not	
  allow	
  for	
  MRI	
  to	
  be	
  performed	
  7	
  Perform	
  chest	
  CT	
  or	
  bone	
  scan	
  only	
  if	
  positive	
  for	
  metastatic	
  disease	
  at	
  baseline	
  8	
  Pantoprazole	
  will	
  be	
  administered	
  either	
  on	
  cycles	
  1	
  &	
  2	
  or	
  cycles	
  3	
  &	
  4	
  based	
  on	
  the	
  treatment	
  arm	
  to	
  which	
  the	
  subject	
  is	
  randomized	
  9	
  Baseline;	
  prior	
  to	
  cisplatin	
  on	
  day	
  1,	
  at	
  end	
  of	
  cisplatin	
  infusion	
  on	
  day	
  2,	
  and	
  day	
  7;	
  prior	
  to	
  HDMTX	
  and	
  24	
  h	
  after	
  the	
  start	
  of	
  the	
  infusion	
  on	
  days	
  22/23	
  &	
  29/30	
  (cycles	
  1-­‐4);	
  pre-­‐op	
  and	
  day	
  1	
  of	
  cycle	
  5.	
  A	
  separate	
  aliquot	
  of	
  same	
  urine	
  specimen	
  saved	
  for	
  urine	
  creatinine.	
  See	
  Section	
  4.0	
  for	
  sample	
  collection,	
  processing	
  and	
  storage	
  instructions.	
  10	
  Baseline;	
  prior	
  to	
  each	
  course	
  of	
  cisplatin	
  and	
  each	
  dose	
  of	
  HDMTX	
  (cycles	
  1-­‐4)	
  and	
  post-­‐treatment	
  IF	
  serum	
  creatinine	
  increases	
  by	
  ≥50%	
  compared	
  to	
  pretreatment	
  value;	
  pre-­‐op	
  and	
  day	
  1	
  of	
  cycle	
  5.	
  Draw	
  simultaneous	
  BMP	
  with	
  serum	
  cystatin	
  C.	
  See	
  Section	
  4.1	
  for	
  sample	
  collection,	
  processing	
  and	
  storage	
  instructions	
  11	
  Serum	
  Mg	
  and	
  creatinine	
  and	
  spot	
  urine	
  for	
  Mg	
  and	
  creatinine	
  at	
  baseline,	
  prior	
  to	
  the	
  start	
  of	
  the	
  cisplatin	
  infusions	
  on	
  day	
  1	
  and	
  day	
  2	
  and	
  on	
  day	
  7	
  of	
  cycles	
  1-­‐4,	
  day	
  1	
  of	
  cycle	
  5,	
  and	
  at	
  the	
  end	
  of	
  therapy	
  12	
  End	
  of	
  each	
  HDMTX	
  infusion	
  (cycles	
  1-­‐4).	
  See	
  Section	
  4.1	
  for	
  sample	
  collection,	
  processing	
  and	
  storage	
  instructions	
  13	
  Appendix	
  3	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,,	
  2013	
  
	
  xv	
  STUDY	
  DIAGRAM	
  
	
  	
  4h#MTX#C#+#PTZ#12h#MTX#C#4h#MTX#C#12h#MTX#C#+#PTZ#12h#MTX#C#+#PTZ#4h#MTX#C#12h#MTX#C#4h#MTX#C#+#PTZ#1#2#3#4#Cycles#1#&#2#Cycles#3#&#4#Randomize#
MTX:#High?dose#methotrexate#by#4h#or#12h#infusion#C:#CisplaGn#PTZ:#Pantoprazole#
Treatment	
  arm	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  1	
  1.	
  BACKGROUND	
  INFORMATION	
  AND	
  RATIONALE	
  1.1	
  Introduction	
  Conventional	
   chemotherapy	
   administered	
   neoadjuvantly	
   (prior	
   to	
   surgical	
   resection	
   of	
   the	
  primary	
  tumor)	
  and	
  adjuvantly	
  after	
  tumor	
  resection	
  improves	
  survival	
  in	
  children,	
  adolescents	
  and	
  young	
  adults	
  with	
  non-­‐metastatic	
  osteosarcoma	
  from	
  15%	
  with	
  surgery	
  alone	
  to	
  65%	
  by	
  combining	
  chemotherapy	
  with	
  surgery.2,7	
  However,	
  survival	
  has	
  not	
  improved	
  since	
  the	
  efficacy	
  of	
  adjuvant	
  chemotherapy	
  was	
  demonstrated	
  in	
  the	
  mid-­‐1980s,	
  as	
  illustrated	
  in	
  Figure	
  1.2,8-­‐10	
  Survival	
  in	
  the	
  10	
  to	
  20%	
  of	
  patients	
  who	
  present	
  with	
  overt	
  metastatic	
  disease	
  at	
  diagnosis	
  is	
  poor	
  despite	
   intensive	
   treatment,11-­‐13	
  and	
   the	
  subsequent	
  development	
   of	
   overt	
   metastatic	
  disease	
  is	
   the	
   primary	
  factor	
   limiting	
  survival	
   in	
   patients	
   who	
   present	
   with	
   localized	
   disease.	
  Conventional	
   cytotoxic	
   chemotherapy	
  eradicates	
   micrometastatic	
   disease	
   in	
  about	
  half	
   the	
  patients	
  with	
  localized	
  osteosarcoma,	
  but	
  the	
  most	
  effective	
  known	
  treatment	
  regimens	
  cause	
  substantial	
   acute	
   and	
   long-­‐term	
   toxicity,	
   including	
   nephrotoxicity,	
   cardiotoxicity,	
   ototoxicity	
  and	
   neurotoxicity.7,14-­‐17	
  Improving	
   the	
   outcome	
   for	
   patients	
   with	
   osteosarcoma	
   in	
   the	
   short	
  term	
  can	
  be	
  achieved	
  by	
  lessening	
  the	
  toxicity	
  of	
  standard	
  cytotoxic	
  treatment	
  regimens,	
  but	
  we	
  must	
  also	
  identify	
  new	
  treatment	
  targets	
  in	
  tumors	
  cells	
  from	
  patients	
  with	
  osteosarcoma	
  in	
  order	
  to	
  develop	
  more	
  effective	
  and	
  less	
  toxic	
  drugs	
  for	
  this	
  disease.	
  
	
  1.2	
  Compliance	
  Statement	
  This	
  study	
  is	
  being	
  conducted	
  in	
  full	
  accordance	
  with	
  all	
  applicable	
  The	
  Children’s	
  Hospital	
  of	
  Philadelphia	
   Research	
   Policies	
   and	
   Procedures	
  and	
   all	
   applicable	
   Federal	
   and	
   State	
   laws	
   and	
  regulations	
  including	
  45	
  CFR	
  46,	
  and	
  the	
  HIPAA	
  Privacy	
  Rule.	
  Any	
  episode	
  of	
  noncompliance	
  will	
  be	
  documented.	
  The	
  investigators	
  will	
  perform	
  the	
  study	
  in	
  accordance	
  with	
  this	
  protocol,	
  will	
  obtain	
  consent	
  and	
   assent	
   when	
   appropriate,	
   and	
   will	
   report	
   unexpected	
   problems	
   in	
   accordance	
   with	
   The	
  Children’s	
   Hospital	
   of	
   Philadelphia	
   IRB	
   Policies	
   and	
   Procedures	
   and	
   all	
   Federal	
   requirements.	
  
	
  Figure	
  1	
  Overall	
  5-­‐yr	
  survival	
  for	
  osteosarcoma	
  diagnosed	
  during	
  different	
  time	
  periods.2	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  2	
  Collecting,	
  recording,	
  and	
  reporting	
  of	
  data	
  will	
  be	
  accurate	
  and	
  will	
  ensure	
  the	
  privacy,	
  health,	
  and	
  welfare	
  of	
  research	
  subjects	
  during	
  and	
  after	
  the	
  study.	
  1.3	
  Relevant	
  Literature	
  and	
  Data	
  1.3.1	
  Osteosarcoma	
  Osteosarcoma	
  is	
  the	
  most	
  common	
  type	
  of	
  bone	
  cancer	
  in	
  children	
  and	
  adolescents	
  under	
  the	
  age	
  of	
  20	
  yrs.	
  Four	
  hundred	
  cases	
  occur	
  annually	
  in	
  the	
  U.S.,	
  and	
  the	
  peak	
  incidence	
  occurs	
  at	
  the	
  time	
  of	
  the	
  adolescent	
  growth	
  spurt.18	
  The	
  cell	
  of	
  origin	
  for	
  osteosarcomas	
  is	
  believed	
  to	
  be	
  primitive	
   bone-­‐forming	
   mesenchymal	
   stem	
   cells.	
  Osteosarcomas	
  arise	
   primarily	
   in	
   the	
  metaphyses	
  of	
  long	
  bones	
  –	
  78%	
  in	
  the	
  lower	
  extremities	
  (64%	
  around	
  the	
  knee)	
  and	
  10%	
  in	
  the	
  humerus.19	
  More	
  than	
  85%	
  of	
  patients	
  present	
  with	
  localized	
  disease.	
  The	
  most	
  common	
  sites	
   of	
   metastases	
   at	
   presentation	
   are	
   the	
   lung	
   (85%)	
   and	
   other	
   bones	
   (20%).19	
  Pain	
   and	
  swelling	
  are	
  the	
  most	
  common	
  presenting	
  symptoms,	
  and	
  the	
  median	
  duration	
  of	
  symptoms	
  prior	
  to	
  diagnosis	
  is	
  69	
  days.	
  The	
   standard	
   management	
   of	
   osteosarcoma	
  starts	
   with	
  a	
   biopsy	
   of	
   the	
   primary	
   tumor	
   for	
   a	
  histological	
   diagnosis.	
   Suspected	
   metastatic	
  lesions	
  in	
   the	
   lung	
  may	
   also	
   be	
   resected	
   at	
  presentation.	
   Patients	
   then	
   receive	
   pre-­‐operative	
   (neoadjuvant)	
   multi-­‐agent	
   chemotherapy	
  followed	
   by	
   surgical	
   resection	
   of	
   the	
   primary	
   tumor,	
   and	
   then	
   additional	
   adjuvant	
  chemotherapy	
  for	
  a	
  total	
  of	
  6	
  to	
  8	
  months	
  of	
  treatment.20	
  Limb	
  salvage	
  procedures,	
  in	
  which	
  the	
   tumor	
   and	
   involved	
   bone	
   are	
   replaced	
   by	
   an	
   endoprosthesis,	
  are	
  the	
   preferred	
   surgical	
  approach	
  when	
   feasible,	
   rather	
   than	
   amputation.	
   The	
   chemosensitivity	
   of	
   the	
   tumor	
   to	
   the	
  neoadjuvant	
  chemotherapy	
  is	
  assessed	
  in	
  the	
  resected	
  specimen	
  by	
  microscopically	
  quantifying	
  the	
   percent	
   of	
   the	
   tumor	
   that	
  is	
   necrotic,	
   which	
   is	
   predictive	
   for	
   outcome.21	
  The	
   efficacy	
   of	
  adjuvant	
   chemotherapy	
   for	
   localized	
   osteosarcoma	
   has	
   been	
   demonstrated	
   in	
   randomized	
  clinical	
  trials.7,22	
  Four	
  conventional	
  cytotoxic	
  anticancer	
  drugs	
  have	
  activity	
  in	
  osteosarcoma	
  (Table	
  1).	
  Adjuvant	
  regimens	
   include	
   2,	
   3,	
   or	
   all	
   4	
   of	
   these	
   agents.	
  A	
   meta-­‐analysis	
   comparing	
   event-­‐free	
   and	
  overall	
   survival	
   for	
   regimens	
   containing	
   2	
   drugs	
   (n=4),	
   3	
   drugs	
   (n=8)	
   or	
   4	
   drugs	
   (n=6)	
  demonstrated	
  better	
  survival	
  for	
  3	
  drug	
  regimens	
  than	
  regimens	
  containing	
  2	
  drugs	
  (HR	
  0.70	
  [95%	
   CI	
   0.68-­‐0.93]	
   for	
   EFS)	
  but	
   no	
  additional	
  advantage	
   for	
   4	
   drug	
   regimens.2	
  The	
   3	
   drug	
  combination	
   used	
   in	
   7	
   of	
   the	
   8	
   regimens	
  in	
   this	
   analysis	
   included	
   high-­‐dose	
   methotrexate	
  (HDMTX),	
  doxorubicin	
  and	
  cisplatin	
  (MAP),	
  which	
  is	
  also	
  the	
  standard	
  regimen	
  in	
  the	
  recently	
  completed	
   COG	
   trial	
   (AOST0331).	
   The	
   prior	
   COG	
   trial,	
   which	
   evaluated	
   the	
   addition	
   of	
  ifosfamide	
   and	
   MTP-­‐PE	
   to	
   the	
   standard	
   MAP	
   regimen	
   using	
   a	
   2	
  x	
  2	
   factorial	
   design	
   failed	
   to	
  show	
   a	
   survival	
  advantage	
   for	
   the	
  addition	
   of	
   ifosfamide,	
  but	
   the	
   results	
   were	
  confounded	
   by	
   a	
  possible	
  interaction	
  between	
   ifosfamide	
  and	
   MTP-­‐PE.23,24	
  A	
  
Table	
  1	
  Response	
  rates	
  for	
  drugs	
  used	
  to	
  treat	
  osteosarcoma.2	
  Drug	
  Dose	
  Range	
  [mg/m2/course]	
  No.	
  of	
  Patients	
  Response	
  Rates	
  [%]	
  CR	
  PR	
  Doxorubicin	
  35-­‐90	
  108	
  13	
  30	
  Ifosfamide	
  5,000-­‐15,000	
  246	
  12	
  20	
  Methotrexate	
  80-­‐15,000	
  164	
  16	
  16	
  Cisplatin	
  120-­‐625	
  174	
  10	
  16	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  3	
  recent	
   Italian	
   study	
   did	
   not	
   find	
   an	
   advantage	
   to	
   adding	
   ifosfamide	
   to	
   MAP.25	
  The	
   current	
  international	
  study,	
   which	
   recently	
   completed	
   enrollment,	
   is	
   evaluating	
   the	
   utility	
   of	
   adding	
  ifosfamide	
  post-­‐operatively	
  in	
  patients	
  with	
  a	
  poor	
  histological	
  response	
  (≤90%	
  tumor	
  necrosis)	
  to	
   neoadjuvant	
   MAP	
   chemotherapy	
  and	
   adding	
   interferon-­‐α	
  to	
   MAP	
   in	
   patients	
   who	
  experience	
   a	
   good	
   histological	
   response.	
  Until	
   the	
   results	
   of	
   this	
   most	
   recent	
   study	
   are	
  available,	
  MAP	
  (Figure	
  2)	
  remains	
  the	
  standard	
  of	
  care	
  for	
  osteosarcoma.	
   	
  
1.3.2	
  Nephrotoxicity	
  Osteosarcoma	
  chemotherapy	
  regimens	
  are	
  associated	
  with	
  acute	
  and	
  long-­‐term	
  nephrotoxicity	
  from	
  cisplatin,	
  HDMTX,	
  and	
  ifosfamide.26	
  The	
  mechanism	
  of	
  kidney	
  injury	
  differs	
  for	
  the	
  three	
  drugs.	
  MTX	
   can	
   transiently	
   alter	
   glomerular	
   filtration	
   but	
   is	
   not	
   tubulotoxic,	
   cisplatin	
   directly	
  damages	
   renal	
   tubular	
   epithelium	
   resulting	
   in	
   decreased	
   glomerular	
   filtration	
   and	
   electrolyte	
  wasting,	
  and	
  ifosfamide	
  is	
  toxic	
  to	
  renal	
  tubules	
  and	
  primarily	
  affects	
  the	
  proximal	
  renal	
  tubules	
  but	
  can	
  also	
  alter	
  glomerular	
  function.	
  Hydration,	
  alkalinization	
  (HDMTX),	
  and	
  slowing	
  the	
  dose	
  rate	
  (cisplatin)	
  can	
   lessen	
  (but	
   not	
   prevent)	
  nephrotoxicity	
   from	
   cisplatin	
   and	
   HDMTX.	
  A	
  prospective	
   evaluation	
   of	
   long	
   term	
  (post-­‐treatment)	
   renal	
   function	
   in	
   patients	
   with	
  osteosarcoma	
   treated	
   with	
   HDMTX,	
   cisplatin	
   and	
   ifosfamide	
   demonstrated	
   persistent	
  glomerular	
   and	
   tubular	
   impairment.27	
  Half	
   had	
   a	
   reduction	
   in	
   creatinine	
   clearance	
   and	
  proteinuria	
  and	
  25%	
  had	
  glycosuria	
  and	
  impaired	
  phosphate	
  reabsorption.	
  1.3.2.1	
  High-­‐Dose	
  Methotrexate	
  Methotrexate	
   inhibits	
   dihydrofolate	
   reductase	
  (DHFR)	
  and	
   depletes	
   intracellular	
   pools	
   of	
  tetrahydrofolates,	
   which	
   are	
   required	
   for	
   the	
   synthesis	
   of	
   thymidine	
   and	
   purines.	
   MTX	
   is	
  administered	
  in	
  high	
  doses	
  by	
  prolonged	
  intravenous	
  infusion	
  because	
  prolonged	
  exposure	
  to	
  a	
  cytotoxic	
   drug	
   concentration	
   is	
   the	
   primary	
   determinant	
   of	
   MTX’s	
  antitumor	
   effect.28	
  High	
  doses	
  of	
   MTX	
  are	
  also	
   thought	
  to	
   overcome	
   mechanisms	
   of	
   resistance	
  to	
  MTX,	
   such	
   as	
  increased	
  expression	
  of	
  DHFR	
  and	
  decreased	
  expression	
  of	
  the	
  reduced	
  folate	
  carrier,	
  which	
  is	
  responsible	
  for	
  uptake	
  of	
  the	
  drug	
  into	
  tumor	
  cells.	
  HDMTX	
  can	
  also	
  enhance	
  the	
  intracellular	
  formation	
  of	
  MTX-­‐polyglutamates,	
  which	
  are	
  retained	
  in	
  cells	
  and	
  prolong	
  the	
  drug’s	
  effect.28,29	
  HDMTX	
   requires	
   the	
   subsequent	
   administration	
   of	
  leucovorin	
  (5-­‐formyl-­‐tetrahydrofolate)	
  to	
  rescue	
  patients	
  from	
  the	
  potentially	
  lethal	
  toxic	
  effects	
  of	
  HDMTX.	
  Leucovorin	
  is	
  administered	
  
	
  Figure	
  2	
  Schema	
  of	
  the	
  MAP	
  regimen	
  used	
  in	
  the	
  treatment	
  of	
  osteosarcoma.	
  The	
  first	
  two	
  5-­‐week	
  cycles	
  are	
  administered	
  neoadjuvantly.	
  Surgery	
  is	
  performed	
  at	
  week	
  11,	
  followed	
  by	
  4	
  additional	
  treatment	
  cycles	
  (MAP	
  x	
  2	
  and	
  MA	
  x	
  2).	
  Numbers	
  at	
  the	
  top	
  are	
  the	
  week	
  of	
  treatment	
  regimen.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  4	
  until	
   plasma	
   concentrations	
   of	
   MTX	
   fall	
   below	
   0.1	
  mcM.	
  MTX	
  is	
  eliminated	
  by	
  renal	
  excretion	
  –	
  more	
  than	
  90%	
  of	
  the	
  administered	
  dose	
  appears	
  in	
  the	
  urine	
   as	
   parent	
   (unchanged)	
   drug.30	
  A	
   small	
  fraction	
   of	
   methotrexate	
   is	
   metabolized	
   to	
   7-­‐OH-­‐MTX.6	
  HDMTX	
   nephrotoxicity	
   is	
   dose	
   related	
   and	
   is	
  thought	
  to	
  result	
  from	
  precipitation	
  of	
  MTX	
  in	
  urine	
  in	
  renal	
  tubules	
  as	
  a	
  result	
  of	
  MTX’s	
  limited	
  solubility	
  in	
  acidic	
  solutions.31-­‐33	
  MTX-­‐induced	
   nephrotoxicity	
  results	
   in	
   delayed	
   excretion	
   of	
  MTX,	
  sustained	
  and	
  elevated	
  plasma	
  MTX	
  concentrations,	
  which	
  may	
  not	
  be	
  effectively	
  rescued	
  by	
   leucovorin,	
   and	
   marked	
   enhancement	
   of	
   MTX’s	
   other	
   systemic	
   toxicities,	
   such	
   as	
  myelosuppression,	
   mucositis,	
   dermatitis,	
  and	
  hepatotoxicity.	
  The	
   incidence	
   of	
   severe	
  nephrotoxicity	
  from	
  HDMTX	
  in	
  osteosarcoma	
  is	
  1.8%	
  and	
  in	
  4%	
  of	
  cases	
  it	
  is	
  fatal.32	
  Severe	
  MTX	
  nephrotoxicity	
   is	
  a	
   medical	
   emergency	
   that	
   requires	
   high	
   doses	
   of	
   leucovorin	
   to	
   protect	
   the	
  patient	
  and	
  glucarpidase	
  (carboxypeptidase-­‐G2	
  –	
  metabolizes	
  MTX	
  to	
  an	
  inactive	
  metabolite)	
  or	
  hemodialysis	
  to	
  remove	
  MTX.	
  Less	
  severe	
  nephrotoxicity	
  is	
  more	
  common34	
  and	
  requires	
  more	
  prolonged	
  leucovorin	
  rescue,	
  which	
  can	
  compromise	
  the	
  antitumor	
  effect	
  of	
  MTX.35	
  This	
  may	
  result	
   in	
  delays	
  in	
  subsequent	
   therapy,	
  thus	
   reducing	
   dose	
   intensity.	
  At	
   CHOP	
   in	
   2011,	
   240	
  courses	
   of	
   high	
   dose	
   methotrexate	
   (HDMTX	
   ≥1	
   g/m2)	
   were	
   administered	
   to	
   children	
   with	
  osteosarcoma	
   (n=15)	
   or	
   leukemia/lymphoma	
   (n=45);	
  5%	
   of	
   courses	
   were	
   associated	
   with	
  delayed	
   excretion	
   of	
   methotrexate,	
   likely	
   due	
   to	
   acute	
   changes	
   in	
   renal	
   function.	
  Infusion	
   of	
  HDMTX	
  over	
  4	
  hours	
  in	
  osteosarcoma	
  regimens	
  puts	
  patients	
  at	
  higher	
  risk	
  for	
  nephrotoxicity	
  because	
  of	
  the	
  high	
  peak	
  plasma	
  concentrations	
  and	
  high	
  urinary	
  concentrations	
  of	
  the	
  drug.	
  Standard	
   methods	
   to	
   prevent	
   kidney	
   damage	
   from	
   HDMTX	
   include	
   vigorous	
   hydration	
   and	
  alkalinization,	
  which	
  improves	
  MTX	
  solubility	
  in	
  the	
  urine	
  (Table	
  2).6	
  At	
  a	
  pH	
  of	
  7.0,	
  MTX	
  (pKa,	
  4.8	
  and	
  5.7)	
  is	
  more	
  than	
  98%	
  ionized,	
  so	
  further	
  increases	
  in	
  the	
  pH	
  are	
  not	
  likely	
  to	
  improve	
  solubility.	
  
Table	
  2	
  pH-­‐dependent	
   solubility	
   of	
   MTX	
   and	
  its	
  metabolite	
  (7-­‐OH-­‐MTX)	
  at	
  37°C.6	
  	
  Solubility	
  [mM]	
  Compound	
  pH	
  5.0	
  pH	
  6.0	
  pH	
  7.0	
  MTX	
  0.97	
  3.5	
  19.6	
  7-­‐OH-­‐MTX	
  0.28	
  0.79	
  3.3	
  	
  
	
  	
  Figure	
  3	
  Plasma	
  (in	
  mcM)	
  and	
  urine	
  (in	
  mM)	
  MTX	
  concentrations	
  with	
  12	
  g/m2	
  infused	
  over	
  4	
  h.	
  Horizontal	
  lines	
  represent	
  the	
  solubility	
  limit	
  of	
  MTX	
  at	
  a	
  pH	
  of	
  5.0	
  and	
  7.0.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  5	
  We	
  fit	
  a	
  2-­‐compartment	
  pharmacokinetic	
  model	
   to	
   the	
   mean	
   plasma	
   MTX	
  concentrations	
  from	
  1,045	
  infusions	
  of	
  12	
  g/m2	
  over	
   4	
   h	
   (Figure	
   3).5	
  The	
   urinary	
  concentration-­‐time	
   profile	
  could	
   then	
   be	
  simulated	
  assuming	
  that	
  the	
  rate	
  of	
  urine	
  production	
   was	
   equal	
  to	
   the	
   IV	
   fluid	
  hydration	
   rate	
   of	
   100	
   ml/m2/h	
   used	
   at	
  CHOP	
  with	
  the	
  equation:	
  CUrineMTX=CcentralMTX•Vcentral•kelIV!rate•0.9	
  where	
  Curine	
  is	
  the	
  MTX	
  in	
  urine,	
  Ccentral	
  is	
  the	
   MTX	
   concentration	
   in	
   the	
   central	
  compartment,	
  Vcentral	
  is	
  the	
  volume	
  of	
  the	
  central	
   compartment,	
   kel	
  is	
   the	
  elimination	
   rate	
  constant	
   and	
   0.9	
  accounts	
   for	
   the	
   fraction	
   of	
   the	
   MTX	
   dose	
   excreted	
   in	
   the	
   urine	
   unchanged.	
   The	
   urine	
   MTX	
  concentration-­‐time	
   profile	
   is	
   shown	
   in	
   Figure	
   3.	
  The	
   urine	
   MTX	
   concentration	
   exceeds	
   the	
  solubility	
  limit	
  in	
  urine	
  at	
  a	
  pH	
  of	
  7.0	
  for	
  4.8	
  h,	
  putting	
  the	
  kidneys	
  at	
  risk	
  for	
  injury	
  from	
  MTX	
  precipitation.	
  Figure	
   4	
   shows	
   the	
   urine	
   MTX	
   concentration-­‐time	
   profiles	
   for	
   12	
   g/m2	
  infused	
  over	
  4,	
  8,	
  12	
  and	
  24	
  h.	
  With	
  the	
  longer	
  infusion	
  durations,	
  urine	
  MTX	
  concentrations	
  are	
  below	
  the	
  solubility	
  limit,	
  and	
  the	
  risk	
  of	
  MTX	
  precipitation	
  should	
  be	
  lower.	
  In	
  addition	
  to	
  lowering	
  peak	
  plasma	
  and	
  urine	
  concentrations	
  and	
  potentially	
  lowering	
  the	
  risk	
  of	
  nephrotoxicity,	
  prolonging	
  HDMTX	
  infusions	
  has	
  a	
  strong	
  pharmacological	
  rationale	
  because	
  the	
  duration	
  of	
  exposure	
  to	
  a	
  cytotoxic	
  MTX	
  concentration	
  is	
  the	
  primary	
  determinant	
  of	
  the	
  drug’s	
  anti-­‐tumor	
  effect.28	
  Retrospective	
   analyses	
  from	
   European	
   studies	
  have	
   demonstrated	
  an	
  association	
  between	
  high	
  peak	
  (end	
  of	
  infusion)	
  plasma	
  MTX	
  concentration	
  and	
  improved	
  survival.5,36,37	
  However,	
  the	
  role	
  of	
  peak	
  plasma	
  MTX	
  concentration	
  in	
  determining	
  outcome	
  is	
  not	
  supported	
  by	
  the	
  observations	
  that:	
  • peak	
  plasma	
  concentrations	
  were	
  highly	
  correlated	
  with	
  area	
  under	
  the	
  curve	
  (AUC)	
  and	
  other	
   pharmacokinetic	
   parameters	
   in	
   these	
   studies,5,36	
  making	
   difficult	
   to	
   ascertain	
  whether	
  the	
  peak	
  concentration	
  was	
  the	
  critical	
  determinant;	
  • the	
   critical	
   peak	
   MTX	
   concentration	
   varied	
   depending	
   on	
   the	
   dose	
   and	
   infusion	
  duration.	
  For	
  12	
  g/m2	
  of	
  MTX	
  infused	
  over	
  4	
  h,	
  peak	
  concentrations	
  >1,000	
  mcM	
  were	
  associated	
  with	
  better	
  survival,	
  whereas	
  for	
  doses	
  of	
  8-­‐10	
  gm/m2,	
  the	
  cut	
  point	
  for	
  peak	
  concentration	
  was	
  700	
  mcM,	
  indicating	
  that	
  an	
  absolute	
  peak	
  concentration	
  is	
  not	
  the	
  critical	
  determinant	
  of	
  outcome;37	
  • in	
   other	
  osteosarcoma	
  studies,	
   no	
  relationship	
   was	
   found	
   between	
   peak	
   MTX	
  concentration	
   and	
   survival,38-­‐40	
  and	
   in	
   one	
   study,	
   very	
   high	
   MTX	
   exposures	
   were	
  associated	
  with	
  a	
  poorer	
  outcome;41	
  and	
  
	
  Figure	
  4	
  Simulations	
   of	
   urine	
   MTX	
   concentrations	
   with	
  12	
  g/m2	
  infused	
  over	
  4,	
  8,	
  12	
  and	
  24	
  h.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  6	
  • disease-­‐free	
   survival	
  was	
   similar	
   for	
   7,500	
   mg/m2	
  of	
   MTX	
   infused	
   over	
   6	
   h	
   and	
   690	
  mg/m2	
  infused	
  over	
  42	
  h	
  in	
  a	
  randomized	
  clinical	
  trial	
  in	
  OS.42	
  These	
   observations	
  along	
   with	
  data	
  that	
   demonstrate	
   that	
   prolonged	
   infusions	
   of	
   MTX	
   are	
  more	
  efficacious	
  for	
  other	
  cancers29	
  do	
  not	
  support	
  the	
  importance	
  of	
  peak	
  concentration	
  as	
  the	
  critical	
  determinant	
  of	
  HDMTX	
  efficacy	
  in	
  OS.	
  1.3.2.2	
  Cisplatin	
  Cisplatin	
  is	
  an	
  inorganic	
  compound	
  that	
  has	
  a	
  broad	
  spectrum	
  of	
  activity	
  in	
  cancers	
  occurring	
  in	
  adults	
   and	
   children,	
   including	
   osteosarcoma.	
   Its	
   mechanism	
   of	
   action,	
   platination	
   of	
   DNA,	
   is	
  analogous	
   to	
   alkylation	
   by	
   the	
   nitrogen	
   mustards	
   and	
   other	
   bifunctional	
   alkylating	
   agents.	
   A	
  reactive	
  intermediate,	
  which	
  is	
  formed	
  spontaneously	
  in	
  solution	
  through	
  aquation	
  by	
  the	
  loss	
  of	
   chloride	
   (leaving	
   group),	
   non-­‐discriminately	
   forms	
   a	
   covalent	
   bond	
   with	
   any	
   nearby	
  nucleophilic	
  group.	
  The	
  platination	
  of	
  a	
  nucleotide	
  in	
  DNA	
  damages	
  the	
  DNA	
  template	
  and	
  can	
  lead	
  to	
  inter-­‐	
  and	
  intra-­‐strand	
  crosslinks.43	
  Cisplatin	
   is	
   neurotoxic,	
   ototoxic,	
   highly	
   emetogenic	
   and	
   nephrotoxic,	
   and	
   these	
   toxicities	
   can	
  limit	
   our	
  ability	
   to	
   administer	
   the	
   drug	
  to	
   some	
   patients.	
  Cisplatin	
   nephrotoxicity	
   is	
  acutely	
  manifested	
  as	
   lower	
   glomerular	
   filtration	
   rate	
   and	
   electrolyte	
   (magnesium,	
   potassium,	
  phosphate)	
   wasting	
   in	
   urine,44	
  and	
  these	
   effects	
   appear	
   to	
   be	
  cumulative	
   and	
  only	
   partially	
  reversible.45,46	
  The	
  mean	
  decrease	
  in	
  glomerular	
  filtration	
  rate	
  for	
  a	
  dose	
  of	
  100	
  mg/m2	
  was	
  8%	
  per	
  dose	
  but	
  was	
  highly	
  variable	
  across	
  patients	
  in	
  one	
  study.46	
  In	
  some	
  cases,	
  the	
  severity	
  of	
  nephrotoxicity	
  compromises	
   our	
   ability	
   to	
   administer	
   subsequent	
   doses	
   of	
   cisplatin	
   and	
   can	
  also	
   effect	
   HDMTX	
   elimination	
   by	
   the	
   kidneys.	
  Current	
   methods	
   of	
  attenuating	
  cisplatin	
  nephrotoxicity	
  can	
  reduce	
  its	
  severity	
  but	
  do	
  not	
  prevent	
  it.	
  Intravenous	
  fluid	
  hydration	
  with	
  normal	
  saline	
  prior	
  to	
  and	
  after	
  cisplatin	
  infusion	
  and	
  fractionating	
  the	
  dose	
  over	
  several	
  days	
  or	
  prolonging	
  the	
  duration	
  of	
  drug	
  infusion	
  have	
  been	
  the	
  most	
  successful	
  methods.47	
  The	
  role	
  of	
  diuretics	
  (mannitol	
  or	
  furosemide)	
  remains	
  controversial.	
  Cisplatin-­‐related	
   renal	
   tubular	
   and	
   vascular	
   injury	
   is	
   a	
   complex,	
   multi-­‐factorial	
   process.44	
  Cisplatin	
   uptake	
   into	
   and	
   efflux	
   from	
   cancer	
   cells	
   appears	
   to	
   be	
   mediated	
   by	
   copper	
  transporters	
   (CTR1,	
   ATP7B).44	
  However,	
   in	
   the	
   renal	
   tubule,	
   the	
   polyspecific	
   organic	
   cation	
  transporters	
  (OCTs),	
  and	
  specifically	
  the	
  renal	
  isoform	
  OCT2,	
  mediate	
  cisplatin	
  uptake.48	
  OCTs	
  in	
  the	
  kidney	
  mediate	
  basolateral	
  to	
  apical	
  transport	
  of	
  cations,	
  and	
  on	
  the	
  apical	
  surface,	
  cations	
  are	
  secreted	
  into	
  urine	
  by	
  MATEs	
  (multidrug	
  and	
  toxin	
  extrusion	
  transporters).49	
  Cisplatin	
  is	
  not	
  transported	
   by	
   MATEs,	
   and	
   therefore	
   it	
   accumulates	
   in	
   renal	
   tubular	
   cells.	
   Several	
   lines	
   of	
  evidence	
   indicate	
   that	
   this	
   interaction	
   of	
   cisplatin	
   with	
   OCT2	
   accounts	
   for	
   its	
   selective	
  nephrotoxic	
   effects.	
   The	
   less	
   nephrotoxic	
   platinum	
   analog,	
   carboplatin	
   is	
   not	
   an	
   OCT2	
  substrate;	
   OCT2	
   inhibitors	
   (e.g.,	
   cimetidine)	
   can	
   block	
   cisplatin	
   renal	
   tubular	
   cell	
   uptake	
   and	
  damage	
  in	
  vitro	
  and	
  in	
  vivo;	
  and	
  OCT2-­‐deficient	
  animals	
  and	
  humans	
  with	
  OCT2	
  polymorphisms	
  are	
  not	
  as	
  susceptible	
  to	
  cisplatin	
  nephrotoxicity.48-­‐52	
  Tissue	
  expression	
  of	
  OCTs	
  is	
  limited,	
  and	
  they	
   are	
   not	
   expressed	
   on	
   most	
   human	
   cancers,	
   including	
   childhood	
   cancers.51,52	
  Therefore,	
  inhibiting	
  OCT2	
  could	
  selectively	
  rescue	
  the	
  kidney	
  from	
  the	
  toxic	
  effects	
  of	
  cisplatin	
  without	
  interfering	
   with	
   the	
   drug’s	
   antitumor	
   effect.50	
  Patients	
   treated	
   with	
   cisplatin	
   may	
   also	
   be	
   at	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  7	
  higher	
  risk	
  to	
  develop	
  renal	
  cancer	
  later	
  in	
  life,53	
  but	
  it	
  is	
  not	
  clear	
  whether	
  this	
  is	
  related	
  to	
  cisplatin	
  accumulation	
  in	
  the	
  renal	
  tubule	
  cells.	
  Cisplatin	
  pharmacokinetics	
  is	
  difficult	
  to	
  quantify	
  because	
  it	
  is	
  chemically	
  unstable.	
  The	
  parent	
  drug	
   spontaneously	
   forms	
   a	
   reactive	
   aquated	
   intermediate	
   that	
   rapidly	
   reacts	
   with	
   a	
   nearby	
  nucleophilic	
  group.	
  In	
  plasma,	
  the	
  reactive	
  intermediates	
  react	
  with	
  plasma	
  proteins	
  forming	
  a	
  covalent	
  bond,	
  which	
  inactivates	
  the	
  drug.	
  Protein	
  binding	
  increases	
  over	
  time,	
  reflecting	
  the	
  non-­‐reversible	
  nature	
  of	
  the	
  protein	
  binding.	
  The	
  platinated	
  proteins	
  are	
  slowly	
  removed	
  from	
  circulation	
  and	
  degraded,	
  which	
  releases	
  platinum	
  in	
  a	
  form	
  that	
  is	
  no	
  longer	
  active.	
  Studies	
  of	
  cisplatin	
   pharmacokinetics	
   (PK)	
   have	
   measured	
   free	
   (non-­‐protein	
   bound)	
   and	
   total	
   platinum	
  (bound	
  +	
  free)	
  using	
  atomic	
  absorption	
  spectroscopy.	
  The	
  free	
  form	
  of	
  platinum,	
  which	
  includes	
  both	
   active	
   drug	
   species	
   and	
   inactive	
   forms,	
   has	
   a	
   biexponential	
   plasma	
   concentration-­‐time	
  curve	
   with	
   half-­‐lives	
   of	
   20	
   min	
   and	
   >24	
   h	
   in	
   children.54,55	
  The	
   former	
   likely	
   represents	
   the	
  disappearance	
  of	
  the	
  active	
  species	
  of	
  the	
  drug,	
  and	
  the	
  latter,	
  more	
  prolonged	
  half-­‐life	
  likely	
  reflects	
  the	
  disappearance	
  of	
  inactive,	
  non-­‐protein	
  bound	
  forms.	
  Although	
  renal	
  excretion	
  is	
  the	
  primary	
   route	
   of	
   platinum	
   elimination,	
   it	
   accounts	
   for	
   only	
   27%	
   of	
   total	
   clearance,55	
  and	
   a	
  substantial	
   fraction	
   of	
   platinum	
   in	
   urine	
   is	
   inactivated	
   before	
   it	
   is	
   excreted.	
   Therefore,	
   renal	
  excretion	
  is	
  not	
  the	
  major	
  route	
  of	
  elimination	
  for	
  the	
  active	
  species	
  of	
  the	
  drug	
  as	
  evidenced	
  by	
  the	
  fact	
  that	
  cisplatin	
  clearance	
  in	
  an	
  anephric	
  patient	
  was	
  not	
  substantially	
  different	
  than	
  that	
   of	
   patients	
   with	
   normal	
   renal	
   function.56	
  Co-­‐administration	
   of	
   an	
   OCT2	
   inhibitor	
   with	
  cisplatin	
  should	
  not	
  interfere	
  with	
  cisplatin	
  clearance,	
  because	
  cisplatin	
  is	
  not	
  secreted	
  after	
  it	
  is	
  taken	
  up	
  into	
  renal	
  tubular	
  cells	
  (see	
  above)	
  and	
  because	
  renal	
  excretion	
  of	
  the	
  active	
  forms	
  of	
  the	
  drug	
  is	
  not	
  a	
  major	
  route	
  of	
  elimination.	
  1.3.3	
  Biomarkers	
  of	
  Acute	
  Kidney	
  Injury	
  Current	
  clinical	
  laboratory	
  tests	
  of	
  renal	
  function	
  in	
  children	
  with	
  cancer	
  do	
  not	
  detect	
  early,	
  subtle	
  changes	
  in	
  glomerular	
  filtration	
  rate	
  (GFR)	
  or	
  renal	
  tubular	
  function.	
  Limitations	
  of	
  serum	
  creatinine	
  (sCr)	
  as	
  a	
  marker	
  of	
  GFR57	
  include:	
  • Non-­‐renal	
   factors	
   (diet,	
   muscle	
   mass,	
   tubular	
   secretion)	
  can	
  alter	
   the	
   sCr	
   but	
   do	
   not	
  affect	
  GFR,	
  • sCr	
  can	
  be	
  within	
  the	
  normal	
  range	
  with	
  a	
  GFR	
  as	
  low	
  as	
  40	
  mL/min/1.73	
  m2,	
  • sCr	
  is	
  imprecise	
  in	
  small	
  children	
  and	
  infants	
  because	
  it	
  is	
  rounded	
  to	
  the	
  first	
  decimal	
  place,	
  resulting	
  in	
  a	
  significant	
  potential	
  error	
  in	
  estimating	
  creatinine	
  clearance	
  (eCrCL),	
  • a	
  recent	
  change	
  in	
  the	
  method	
  used	
  to	
  quantify	
  sCr	
  has	
  invalidated	
  formulas	
  used	
  for	
  eCrCL.58	
  More	
  sensitive	
  and	
  specific	
  biomarkers	
  to	
  accurately	
  quantify	
  small	
  changes	
  GFR	
  and	
  to	
  rapidly	
  detect	
   renal	
   tubular	
   damage	
   are	
   being	
   developed.	
  These	
   biomarkers	
   may	
   be	
   useful	
   for	
  detecting	
   and	
   monitoring	
   renal	
   toxicity	
   of	
   nephrotoxic	
   anticancer	
   drugs,	
   such	
   as	
   MTX	
   and	
  cisplatin.	
   We	
   plan	
   to	
   use	
   a	
   panel	
   of	
   new	
   biomarkers	
   (described	
   below)	
   in	
   combination	
   with	
  traditional	
   laboratory	
   tests	
   of	
   renal	
   function	
   to	
   assess	
   the	
   impact	
   of	
   altering	
   the	
   schedule	
   of	
  HDMTX	
  and	
  adding	
  pantopazole	
  as	
  a	
  cisplatin	
  rescue	
  agent	
  on	
  nephrotoxicity	
  of	
  these	
  drugs	
  on	
  this	
  trial.	
  These	
  new	
  biomarkers	
  will	
  include:	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  8	
  • Cystatin	
   C	
  is	
   a	
   13kDa	
   cysteine	
   protease	
   inhibitor	
   produced	
   by	
   all	
   nucleated	
   cells.	
   It	
   is	
  freely	
   filtered,	
  reabsorbed	
   and	
   metabolized	
   in	
   proximal	
   tubules	
   but	
   not	
  normally	
  secreted	
   in	
  urine	
   by	
   the	
   kidney.	
   Serum	
   cystatin	
  C	
   is	
   used	
   to	
   estimate	
  GFR	
   and	
   urine	
  cystatin	
  C	
  is	
  a	
  marker	
  of	
  tubular	
  damage.	
  Cystatin	
  C	
  is	
  not	
  influenced	
  by	
  muscle	
  mass,	
  and	
  it	
  has	
  improved	
  temporal	
  discrimination	
  in	
  detection	
  of	
  kidney	
  injury	
  compared	
  to	
  sCr.	
   Cystatin	
  C	
   is	
   measured	
   by	
   a	
   FDA	
   approved	
   nephelometry	
   method	
   in	
   clinical	
  laboratories.59-­‐68	
  CrCl	
  can	
  be	
  estimated	
  from	
  sCr	
  using	
  the	
  Schwartz	
  formula	
  and	
  GFR	
  is	
  calculated	
   from	
  a	
  sCr	
   and	
  Cystatin	
  C	
   based	
   formula	
   developed	
   in	
   the	
   Children	
  with	
  Chronic	
  Kidney	
  Disease	
  Cohort:58	
  	
  CrCL=0.413•[height	
  (cm)]/sCr	
  	
  Chemotherapy	
   induced	
   renal	
   tubular	
   dysfunction	
  manifests	
   as	
   renal	
   wasting	
   of	
   minerals	
   and	
  electrolytes.	
   In	
   current	
   clinical	
   practice,	
  renal	
   tubular	
   dysfunction	
   is	
  diagnosed	
   when	
  serum	
  electrolyte	
  concentrations	
  fall	
  below	
   normal	
  and	
   require	
   oral	
   supplementation.	
  Sensitive	
  biomarkers	
  of	
  renal	
  tubular	
  damage	
  or	
  dysfunction	
  could	
  detect	
  toxicity	
  earlier	
  and	
  contribute	
  to	
  the	
  evaluation	
   of	
   strategies	
   to	
  attenuate	
  nephrotoxicity.	
   New	
   biomarkers	
   of	
   renal	
  tubular	
  damage	
  or	
  dysfunction	
  include:	
  § Kidney	
   Injury	
   Molecule-­‐1	
   (KIM-­‐1)	
  is	
   a	
   50	
  kDa	
   trans-­‐membrane	
   protein	
   expressed	
   on	
  proximal	
   tubule	
   cells.	
   Urine	
   KIM-­‐1	
   is	
   a	
   marker	
   of	
   proximal	
   tubular	
   damage	
   that	
   may	
  discriminate	
  pre-­‐renal	
  azotemia	
  from	
  ischemia.	
  	
  Urine	
  concentrations	
  are	
  not	
  effected	
  by	
  chronic	
  kidney	
  disease.	
  ELISA	
  kits	
  are	
  commercially	
  available	
  for	
  research,	
  and	
  clinical	
  laboratory	
  micro-­‐bead	
  assays	
  are	
  under	
  development.69-­‐73	
  § Neutrophil	
   Gelatinase-­‐Associated	
   Lipocalin	
   (NGAL)	
  is	
   a	
  25	
  kDa	
  protein	
   expressed	
   in	
  intestine	
  lung,	
  liver,	
  and	
  renal	
  tubular	
  epithelial	
  cells.	
  Elevations	
  in	
  plasma	
  NGAL	
  occur	
  promptly	
   after	
   renal	
   ischemic	
   or	
   tissue	
   injury.	
   Plasma	
   and	
   urine	
   NGAL	
   are	
  early	
  predictors	
  of	
  acute	
  kidney	
  injury	
  (AKI)	
  and	
  may	
  discriminate	
  pre-­‐renal	
  from	
  intrinsic	
  AKI.	
  ELISA	
   kits	
   are	
   commercially	
   available	
   for	
   research	
   applications	
   and	
   clinical	
   laboratory	
  assays	
  are	
  available.74-­‐85	
  § N-­‐acetyl-­‐β-­‐D-­‐glucosamidase	
   (NAG)	
  is	
  a	
  130	
  kD	
  enzyme	
  within	
  lysomomes	
  of	
  proximal	
  tubular	
  cells	
  of	
  the	
  kidney.	
  Urinary	
  NAG	
  concentrations	
  are	
  increased	
  during	
  oxidative	
  stress	
   and	
   renal	
   tubular	
   damage	
   including	
   from	
   cisplatin	
  and	
   gentamicin.52,86	
  Urinary	
  NAG	
   increases	
   in	
   the	
   presence	
   of	
  oxidative	
   stress	
   and	
   proximal	
  tubular	
   damage	
  regardless	
  of	
  development	
  of	
  AKI.	
  Prospective	
   systematic	
   evaluation	
   of	
   glomerular	
   and	
   tubular	
   function	
   using	
  these	
  new,	
   more	
  sensitive	
  biomarkers	
  should	
  allow	
  us	
  to	
  detect	
  more	
  subtle	
  changes	
  in	
  GFR	
  and	
  tubular	
  function	
  and	
  assess	
  the	
  impact	
  of	
  the	
  interventions	
  to	
  attenuate	
  HDMTX	
  and	
  cisplatin	
  nephrotoxicity.	
      € GFR=39.1•HgtCrserum      0.5161.8CyC      0.29430BUNserum      0.1691.099[]maleHgt1.4      0.188
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  9	
  The	
  fractional	
  excretion	
  of	
  magnesium	
  will	
  also	
  be	
  monitored	
  during	
  cisplatin	
  administration	
  to	
  assess	
  renal	
  tubular	
  function.	
  FEMg	
  =	
  (100•(Urine	
  Mg	
  •	
  Serum	
  Cr))/(0.7•Serum	
  Mg	
  •	
  Urine	
  Cr).	
  Multiplying	
  serum	
  Mg	
  by	
  0.7	
  accounts	
  for	
  30%	
  protein	
  binding	
  to	
  albumin.	
  1.3.4	
  Ototoxicity	
  Cisplatin	
   causes	
   dose-­‐	
  and	
   schedule-­‐dependent	
   permanent,	
   sensorineural	
   hearing	
   loss	
   by	
  damaging	
   cochlear	
   hair	
   cells.87	
  Initially,	
  osteosarcoma	
  patients	
   experience	
   high	
   frequency	
  hearing	
   loss	
   at	
  4	
   to	
   8	
  kHz	
   at	
  cumulative	
   doses	
   exceeding	
   300	
  mg/m2,	
   but	
   hearing	
   at	
   lower	
  frequencies	
  becomes	
  impaired	
  as	
  the	
  cumulative	
  dose	
  increases,	
  and	
  a	
  substantial	
  fraction	
  of	
  patients	
   are	
   affected.14,88-­‐90	
  Younger	
   patients	
   are	
   at	
   greater	
   risk	
   for	
   hearing	
   loss	
  from	
  cisplatin.91,92	
  With	
  long-­‐term	
  follow-­‐up,	
  there	
  may	
  be	
  worsening	
  or	
  progression	
  of	
  hearing	
  loss	
  at	
  lower	
  frequencies.93	
  Fractionating	
  the	
  cisplatin	
  dose	
  appears	
  to	
  lessen	
  the	
  risk	
  of	
  ototoxicity,88	
  but	
  more	
  effective	
  strategies	
  to	
  prevent	
  damage	
  to	
  the	
  hair	
  cells	
  are	
  needed.	
  Sodium	
  thiosulfate	
  is	
  being	
  tested	
  as	
  a	
  rescue	
  agent	
  in	
  an	
  ongoing	
  COG	
  trial,	
  but	
  thiosulfate	
  is	
  a	
  non-­‐selective	
  rescue	
  agent	
  and	
  can	
  interfere	
   with	
   the	
   anti-­‐tumor	
   effect	
   of	
   cisplatin.	
   Cochlear	
   hair	
   cells	
   also	
   express	
   OCT2,	
   and	
  inhibition	
  of	
  OCT2	
  during	
  cisplatin	
  therapy	
  may	
  selectively	
  block	
  the	
  uptake	
  of	
  cisplatin	
  into	
  hair	
  cells	
  without	
  impacting	
  the	
  drug’s	
  anti-­‐tumor	
  effect.48,50	
  1.3.5	
  Pantoprazole	
  Pantoprazole	
  (Figure	
  5)	
  is	
  a	
  proton	
  pump	
  inhibitor	
  (PPI)	
  that	
  blocks	
  gastric	
  acid	
  secretion	
  by	
  irreversibly	
  binding	
  to	
  the	
  proton	
  pump.94	
  It	
  is	
  indicated	
  for	
  treatment	
  of	
  GERD	
  with	
  erosive	
   esophagitis	
  and	
   hypersecretion	
  associated	
   with	
   Zollinger-­‐Ellison	
   syndrome.	
  Pantoprazole	
   is	
   commercially	
   available	
   in	
   an	
  intravenous	
   formulation	
   that	
   can	
   be	
   administered	
   as	
  an	
  intermittent	
  bolus	
  or	
  continuous	
  infusion.	
  Pantoprazole	
  and	
  other	
  PPIs	
  are	
  potent	
  OCT2	
  inhibitors	
  (Figure	
  6).1	
  The	
  IC50	
  for	
  pantoprazole	
  inhibition	
  of	
  OCT2	
  is	
  2.8	
  mcM	
  and	
  the	
  Cmax	
  of	
  the	
  drug	
  in	
  children	
  after	
  0.8	
  mg/kg	
  (equivalent	
  to	
  40	
  mg	
  in	
  adults)	
  was	
  15	
  mcM	
  and	
  after	
  a	
  dose	
  of	
  1.6	
  mg/kg	
  (equivalent	
  to	
  80	
  mg	
  in	
  adults)	
  was	
  27	
  mcM,3	
  which	
  would	
  inhibit	
  OCT2	
  by	
  >80%.1	
  Cimetidine	
  (histamine	
  H2-­‐receptor	
  antagonist)	
  also	
  inhibits	
  OCT2.	
  In	
  a	
  small	
  study	
  of	
  9	
  patients	
  with	
  testicular	
  cancer	
  treated	
   with	
   cisplatin	
   (20	
   mg/m2/d	
   x	
   5	
   days),	
   cimetidine	
  plus	
   verapamil	
  appeared	
   to	
   prevent	
   cisplatin	
  nephrotoxicity	
  (assessed	
   as	
   change	
   in	
   effective	
   renal	
  plasma	
   flow	
   and	
   GFR)	
  compared	
   to	
   a	
   similar	
   historical	
  control	
   population	
  (n=9)	
  treated	
   with	
   cisplatin	
  alone	
  (Figure	
   7).4	
  Cimetidine	
   does	
   not	
   interfere	
   with	
   the	
  anticancer	
   effect	
   of	
   cisplatin	
  in	
   vitro	
  and	
  in	
   vivo	
  in	
  an	
  osteosarcoma	
   cell	
   line,	
   indicating	
   that	
   uptake	
   of	
   cisplatin	
  
	
  Figure	
  5	
  Structure	
  of	
  pantoprazole.	
  
	
  Figure	
  6	
  Inhibition	
  of	
  OCT2	
  by	
  panto-­‐prazole.1	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  10	
  into	
   tumor	
   cells	
   is	
   not	
   mediated	
   by	
   OCT2	
   in	
   osteosarcoma.95	
  Pretreatment	
   of	
   human	
   tumor	
  cells	
  with	
  a	
  proton	
  pump	
  inhibitor	
  enhanced	
  the	
  cytotoxic	
  effect	
  of	
  multiple	
  anti-­‐cancer	
  drugs	
  including	
  cisplatin,	
  and	
  omeprazole	
  pretreatment	
  in	
  mice	
  harboring	
  human	
  tumor	
  xenografts	
  induced	
  sensitivity	
  of	
  the	
  tumors	
  to	
  cisplatin.96,97	
  The	
  PK	
  and	
  tolerability	
  of	
  single	
  intravenous	
  doses	
  of	
  0.8	
  and	
  1.6	
  mg/kg	
  of	
  pantoprazole	
  have	
  been	
  studied	
  in	
  children.3	
  The	
  Cmax	
  and	
  AUC	
  of	
  IV	
  pantoprazole	
  at	
  0.8	
  and	
  1.6	
  mg/kg	
  in	
  children	
  aged	
  2	
  to	
  16	
  years	
  were	
  similar	
  to	
  these	
  PK	
  parameters	
  in	
  adults	
  at	
  40	
  and	
  80	
  mg	
  (Figure	
  8).	
  The	
  clearance	
  of	
  pantoprazole	
  in	
  children	
  was	
  0.2	
  L/h/kg	
  and	
  the	
  half-­‐life	
  was	
  1.2	
  h.	
  Although	
  the	
  t1/2	
  is	
   short,	
   it	
   pharmacodynamic	
  effect	
   is	
   more	
   long	
   lasting.94	
  PPIs	
   interfere	
   with	
   MTX	
  excretion,98	
  but	
  by	
  20	
  days	
  after	
  the	
  last	
  cisplatin	
  dose	
  when	
   HDMTX	
   is	
   adminis-­‐tered,	
  pantoprazole	
  will	
  be	
  completely	
  cleared.	
  Pantoprazole	
   is	
   primarily	
  metabolized	
   by	
   CYP2C19,	
  which	
   is	
   genetically	
   poly-­‐morphic.	
   CYP2C19	
   activity	
  is	
   absent	
   in	
   3%	
   of	
   whites	
  and	
   20%	
   of	
   Asians,	
   and	
  children	
   with	
   CYP2C19	
  polymorphisms	
   have	
  slower	
   clearance	
   and	
  longer	
  t1/2s.3	
  
	
  Figure	
  7	
  Change	
  in	
  GFR	
  10	
  and	
  21	
  days	
  after	
  100	
  mg/m2	
  cisplatin	
  administered	
  over	
  5	
  days	
  without	
  (left)	
  and	
  with	
  cimetidine	
  and	
  verapamil.	
  	
  
	
  Figure	
  8	
  PK	
  of	
  intravenous	
  pantoprazole	
  in	
  children	
  (2-­‐16	
  yrs)	
  at	
  doses	
  of	
  0.8	
  and	
  1.6	
  mg/kg	
  compared	
  to	
  adults	
  at	
  20,	
  40	
  and	
  80	
  mg.3,4	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  11	
  The	
   single	
   IV	
   doses	
   of	
   pantoprazole	
   (0.8	
   and	
   1.6	
   mg/kg)	
   were	
   well	
   tolerated.	
  Three	
   adverse	
  events	
  occurred	
   in	
   18	
   patients,	
   all	
   of	
   which	
   were	
   mild	
   and	
   judged	
   to	
   be	
   unrelated	
   to	
  pantoprazole.3	
  The	
   most	
   common	
   toxicities	
   associated	
   with	
   PPIs	
   are	
  diarrhea,	
   nausea,	
  headaches,	
  abdominal	
  pain,	
  fatigue	
  and	
  dizziness.94	
  1.3.6	
  Serum	
  biomarkers	
  for	
  osteosarcoma	
  Serum	
  biomarkers	
  for	
  diagnosing	
  osteosarcoma,	
  for	
  monitoring	
  response	
  to	
  treatment,	
  and	
  for	
  detecting	
  disease	
  recurrence	
  would	
  be	
  valuable	
  for	
  the	
  clinical	
  management	
  of	
  the	
  disease	
  and	
  as	
   endpoints	
   for	
   clinical	
   trials.	
  Osteosarcoma	
   is	
   a	
   matrix-­‐producing	
   tumor	
  and	
   radiographic	
  response	
  (tumor	
  shrinkage)	
  to	
  neoadjuvant	
  chemotherapy	
  may	
  not	
  reflect	
  the	
  extent	
  of	
  tumor	
  necrosis,	
  histologically,	
  after	
  neoadjuvant	
  chemotherapy.	
  Elevated	
   serum	
   alkaline	
   phosphatase	
   (AP)	
   is	
   an	
   independent	
   prognostic	
   factor	
   predicting	
   for	
  poor	
   outcome	
   in	
   osteosarcoma,25,99	
  but	
   serum	
   AP	
   may	
   be	
   derived	
   from	
   other	
   organs	
   and	
   is	
  therefore	
  not	
  specific.	
  Bone-­‐specific	
  AP	
  (BSAP),	
  which	
  is	
  the	
  isoform	
  of	
  AP	
  derived	
  from	
  bone,	
  is	
  a	
  more	
  specific	
  measure	
  of	
  osteoblastic	
  activity.100-­‐102	
  BSAP	
  is	
  elevated	
  in	
  patients	
  with	
  OS	
  and	
  is	
   correlated	
   with	
   tumor	
   burden.102,103	
  However,	
   BSAP	
   is	
   also	
   higher	
   in	
   adolescents	
   reflecting	
  periods	
  of	
  bone	
  growth	
  during	
  the	
  adolescent	
  growth	
  spurt.	
  We	
  will	
  investigate	
  the	
  potential	
  role	
   of	
   BSAP	
   as	
   a	
   potential	
   biomarker	
   for	
   OS	
   by	
   measuring	
   serum	
   levels	
   at	
   diagnosis,	
   after	
  neoadjuvant	
  chemotherapy,	
  after	
  surgical	
  resection,	
  and	
  at	
  the	
  end	
  of	
  treatment.	
  1.3.7	
  Study	
  Rationale	
  Current	
  osteosarcoma	
  treatment	
  regimens	
  include	
  drugs	
  that	
  are	
  nephrotoxic	
  and	
  ototoxic,	
  and	
  the	
  damage	
  to	
  kidneys	
  and	
  cochlear	
  hair	
  cells	
  may	
  be	
  irreversible.	
  Preventing	
  these	
  toxicities	
  will	
   improve	
   the	
   outcome	
   in	
   long-­‐term	
   survivors	
   and	
   may	
   also	
   prevent	
   short-­‐term	
   treatment	
  delays	
   and	
   dose	
   reductions	
  that	
   can	
   compromise	
   the	
   efficacy	
   of	
   the	
   treatment	
   regimen	
  and	
  allow	
   for	
   administration	
   of	
   higher	
   cumulative	
   doses	
   of	
   cisplatin.	
   This	
   pilot	
   study	
   evaluates	
  pharmacologically-­‐based	
  approaches	
  to:	
  • prevent	
   the	
   nephrotoxic	
   effect	
   of	
   HDMTX	
   by	
   prolonging	
   the	
   infusion	
   duration	
   and	
  thereby	
  lowering	
  the	
  risk	
  of	
  drug	
  precipitation	
  in	
  renal	
  tubules,	
  and	
  • selectively	
  block	
  the	
  uptake	
  of	
  cisplatin	
  into	
  renal	
  tubular	
  cells	
  and	
  cochlear	
  hair	
  cells	
  by	
  inhibiting	
   the	
   organic	
   cation	
   transporter	
   2	
   with	
   the	
   proton	
   pump	
   inhibitor,	
  pantoprazole.	
  A	
  randomized	
  cross-­‐over	
  design,	
  in	
  which	
  patients	
  serve	
  as	
  their	
  own	
  control,	
  will	
  be	
  used	
  to	
  maximize	
  the	
   potential	
   to	
   detect	
   differences	
  in	
   markers	
   of	
  acute	
  kidney	
   injury	
  (NAG,	
   NGAL,	
  KIM-­‐1,	
  cystatin	
  C)	
  and	
  audiograms	
  resulting	
  from	
  altering	
  the	
  infusion	
  duration	
  of	
  HDMTX	
  and	
  from	
  administering	
  pantoprazole	
  with	
  cisplatin.	
  Two	
  infusion	
   durations	
   of	
   HDMTX	
   will	
   be	
   studied	
  –	
  the	
   standard	
   4	
   h	
  duration	
   and	
  more	
  prolonged	
  12	
  h	
  infusion	
  duration.	
  Leucovorin	
  rescue	
  will	
  commence	
  24	
  h	
  from	
  the	
  start	
  of	
  the	
  infusion.	
  The	
   HDMTX	
   infusions	
   will	
   be	
   divided	
   into	
  2	
  blocks	
   (cycles	
   1	
   &	
   2,	
   cycles	
   3	
   &	
   4,	
  see	
  Figure	
  2),	
  each	
  of	
  which	
  include	
  4	
  HDMTX	
  infusions.	
  The	
  order	
  of	
  infusion	
  duration	
  studied	
  in	
  each	
  block	
  will	
  be	
  randomly	
  determined.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  12	
  Pantoprazole	
   will	
   either	
   be	
   administered	
   with	
  the	
  first	
  two	
  courses	
  of	
  cisplatin	
  during	
  cycles	
  1	
  &	
  2	
  or	
  with	
  the	
  third	
  and	
  fourth	
  courses	
  during	
  cycles	
  3	
  &	
  4,	
  and	
  the	
  order	
  will	
  be	
  randomly	
  determined.	
  Cisplatin	
   is	
   administered	
   as	
   a	
  60	
   mg/m2	
  dose	
   infused	
   over	
  4	
   h	
  daily	
   x	
   2	
   d,	
   and	
  Figure	
  9	
  is	
  a	
  PK	
  simulation	
  showing	
  the	
  amount	
  of	
  active	
  drug	
  in	
  the	
  body	
  (assuming	
  a	
  half-­‐life	
  of	
   20	
   min)	
  and	
   the	
   percent	
   of	
   the	
   total	
   dose	
   cleared.	
   At	
   steady	
   state,	
   7.2	
   mg/m2	
  of	
   active	
  cisplatin	
   is	
   in	
   the	
   body,	
   and	
   by	
   the	
   end	
   of	
   the	
   4	
   h	
   infusion,	
   88%	
   of	
   the	
   total	
   dose	
   has	
   been	
  cleared.	
  Therefore,	
  adequate	
  concentrations	
  to	
  inhibit	
  OCT2	
  should	
  be	
  present	
  for	
  at	
  least	
  4	
  h	
  to	
  prevent	
  cisplatin	
  nephrotoxicity	
  and	
  ototoxicity.	
  Pantoprazole	
  has	
  a	
  short	
  half-­‐life	
  (1.2	
  h),3	
  and	
   when	
   administered	
  at	
   a	
   dose	
   of	
   1.6	
   mg/kg	
  as	
  a	
  standard	
   15	
   min	
   infusion	
   (Figure	
   10),	
  plasma	
  pantoprazole	
   concentration	
  by	
   the	
   end	
   of	
   the	
  4	
   h	
   cisplatin	
   infusion	
   is	
   1.3	
   mcM.	
  By	
  administering	
  the	
  same	
  dose	
  as	
  a	
  0.3	
  mg/kg	
  loading	
  dose	
  infused	
  over	
  15	
  min	
  followed	
  by	
  a	
  4	
  h	
  infusion	
   of	
   the	
   remaining	
   1.3	
   mg/kg,	
   plasma	
   pantoprazole	
   concentration	
   is	
   5.9	
   mcM	
   at	
   4	
   h	
  (Figure	
  10).	
  The	
   primary	
   endpoint	
   to	
   assess	
   nephrotoxicity	
   will	
   be	
   the	
   AKI	
  biomarkers	
   (cystatin	
   C,	
   KIM-­‐1,	
  NGAL,	
  NAG)	
  described	
  in	
  Section	
  1.3.3.	
  This	
  will	
  allow	
  us	
  to	
  assess	
  each	
  dose	
  of	
  HDMTX	
  and	
  each	
   course	
   of	
  cisplatin	
   independently.	
   Standard	
   renal	
   function	
   tests	
   (urinalysis,	
   serum	
  creatinine,	
  creatinine	
  clearance,	
  and	
  fractional	
  excretion	
  of	
  magnesium)	
  will	
  also	
  be	
  monitored.	
  Audiograms	
  will	
  be	
  performed	
  after	
  each	
  course	
  of	
  cisplatin	
  to	
  assess	
  ototoxicity.	
  Radiographic	
  response	
   and	
   histological	
  response	
  in	
   the	
   resected	
   tumor	
   specimen	
  after	
  neoadjuvant	
  chemotherapy	
  will	
  be	
  assessed	
  to	
  ensure	
  changes	
  in	
  HDMTX	
  infusion	
  duration	
  and	
  the	
  addition	
  of	
   pantoprazole	
  to	
   cisplatin	
  do	
   not	
   alter	
   the	
  efficacy	
   of	
   chemotherapy.	
  The	
   toxicity	
   of	
   the	
  regimen	
   will	
   be	
   closely	
   monitored,	
   and	
   we	
   will	
   pilot	
   a	
   disease-­‐specific	
   patient	
   reported	
  outcome	
  survey	
  to	
  assess	
  the	
  impact	
  of	
  tumor-­‐related	
  and	
  drug	
  toxicity-­‐related	
  symptoms.	
  	
  	
  
	
  Figure	
  9	
  Amount	
  of	
  cisplatin	
  in	
   the	
  body	
  (blue)	
  and	
  cumulative	
   percent	
   of	
   the	
   dose	
   cleared	
  (orange)	
  for	
  a	
  60	
  mg/m2	
  dose	
  infused	
  over	
  4	
  h.	
  
	
  Figure	
  10	
  Plasma	
   concentration-­‐time	
   profile	
   of	
  1.6	
   mg/kg	
   pantoprazole	
   infused	
   over	
  15	
  min	
  (blue)3	
  or	
  administered	
  as	
  a	
  0.3	
  mg/kg	
   loading	
   dose	
   over	
   15	
   min	
  followed	
  by	
  1.3	
  mg/kg	
  infused	
  over	
  4	
  h	
  (green).	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  13	
  2.	
  STUDY	
  OBJECTIVES	
  The	
  primary	
  objective	
  is	
   to	
   identify	
   more	
   rational,	
   pharmacologically-­‐based	
   drug	
   delivery	
  approaches	
  to	
  prevent	
  nephrotoxicity	
  from	
  HDMTX	
  and	
  cisplatin	
  and	
  ototoxicity	
  from	
  cisplatin	
  in	
  patients	
  with	
  OS	
  by:	
  • comparing	
  biomarkers	
  of	
  acute	
  kidney	
  injury	
  (KIM-­‐1,	
  NAG,	
  NGAL),	
  glomerular	
  function	
  (cystatin	
  C,	
  creatinine)	
  and	
  plasma	
  and	
  urine	
  MTX	
  concentrations	
  after	
  12	
  g/m2	
  of	
  MTX	
  infused	
  over	
  4	
  and	
  12	
  hours,	
  • comparing	
  biomarkers	
  of	
  acute	
  kidney	
  injury	
  (KIM-­‐1,	
  NAG,	
  NGAL)	
  and	
  glomerular	
  and	
  tubular	
   function	
  (cystatin	
   C,	
   creatinine,	
   FEMg)	
  after	
   cisplatin	
   administered	
   with	
   and	
  without	
  the	
  OCT2	
  inhibitor,	
  pantoprazole,	
  and	
  • comparing	
  hearing	
  loss	
  (audiograms)	
  after	
  cisplatin	
  administered	
  with	
  and	
  without	
  the	
  OCT2	
  inhibitor,	
  pantoprazole.	
  Secondary	
  objectives	
  include:	
  • Comparing	
  the	
  incidence	
  and	
  severity	
  of	
  common	
  toxicities	
  from	
  cisplatin/doxorubicin	
  administered	
  with	
  and	
  without	
  pantoprazole	
  and	
  from	
  HDMTX	
  administered	
  as	
  a	
  4	
  and	
  12	
  h	
  infusion,	
  • comparing	
  radiographic	
  response	
  (log	
  ratio	
  of	
  tumor	
  volumes)	
  and	
  histological	
  response	
  (percent	
  tumor	
  necrosis)	
  to	
  two	
  cycles	
  (10	
  weeks)	
  of	
  neoadjuvant	
  chemotherapy	
  for	
  the	
  two	
  infusion	
  durations	
  of	
  HDMTX	
  and	
  for	
  cisplatin	
  with	
  and	
  without	
  pantoprazole,	
  • correlating	
  urinary	
  biomarkers	
   of	
   AKI	
  and	
   GFR	
   estimated	
   from	
   serum	
  cystatin	
  C	
  to	
  standard	
  measures	
  of	
  renal	
  function	
  (serum	
  creatinine,	
  urinalysis,	
  estimated	
  creatinine	
  clearance,	
  FEMg),	
  • building	
   a	
   tissue	
   microarray	
   from	
   biopsy,	
   primary	
   resection	
   and	
   resected	
   metastatic	
  tumors	
  to	
  evaluate	
  the	
  expression	
  of	
  proteins	
  that	
  are	
  responsible	
  for	
  resistance	
  to	
  the	
  drugs	
  in	
  the	
  MAP	
  regimen	
  and	
  to	
  assess	
  expression	
  of	
  proteins	
  that	
  are	
  targeted	
  by	
  new	
  anticancer	
  drugs	
  under	
  development	
  for	
  childhood	
  cancers,	
  	
  • evaluating	
  serum	
  BSAP	
  as	
  a	
  potential	
  biomarker	
  for	
  OS,	
  • monitoring	
  nutritional	
   status	
   (weight,	
   arm	
   circumference,	
   skin	
   fold	
   thickness,	
   pre-­‐albumin)	
  in	
  patients	
  receiving	
  the	
  MAP	
  chemotherapy	
  regimen,	
  and	
  • piloting	
   an	
   osteosarcoma-­‐specific	
   patient	
   reported	
   outcomes	
  survey	
   to	
   assess	
   the	
  incidence	
  and	
  severity	
  of	
  tumor-­‐related	
  and	
  treatment-­‐related	
  symptoms.	
  3.	
  INVESTIGATIONAL	
  PLAN	
  3.1	
  General	
  Schema	
  of	
  Study	
  Design	
  Patients	
   with	
   previously	
   untreated	
   osteosarcoma	
   will	
   receive	
   6	
   cycles	
   of	
   the	
   standard	
   MAP	
  (Methotrexate,	
  Adriamycin	
  [doxorubicin],	
  cisPlatin)	
  chemotherapy	
  regimen.	
  The	
  first	
  two	
  cycles	
  will	
   be	
   administered	
   neoadjuvantly	
   followed	
   by	
   surgical	
   resection	
   of	
   the	
   primary	
   tumor	
  if	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  14	
  feasible,	
   and	
   then	
   2	
   additional	
   cycles	
   of	
   MAP	
   followed	
   by	
   2	
   cycles	
   of	
  MA	
  (Figure	
   2).	
  A	
  randomized,	
  2	
  x	
  2	
  factorial,	
  crossover	
  design	
  (see	
  Study	
  Diagram)	
  will	
  be	
  used	
  to:	
  • study	
  the	
  effect	
  of	
  prolonging	
  the	
  methotrexate	
  infusion	
  duration	
  from	
  4	
  h	
  to	
  12	
  h	
  on	
  nephrotoxicity	
  as	
  measured	
  by	
  biomarkers	
  of	
  acute	
  renal	
  injury	
  and	
  • study	
  the	
   effect	
  of	
   the	
   OCT2	
  inhibitor,	
   pantoprazole,	
   on	
   cisplatin	
   nephrotoxicity	
  as	
  measured	
  by	
  biomarkers	
  of	
  acute	
  renal	
  injury	
  and	
  on	
  ototoxicity	
  as	
  assessed	
  on	
  serial	
  audiograms.	
  Each	
   patient	
   will	
   serve	
   as	
   his/her	
   own	
   control,	
   and	
   24	
   evaluable	
   patients	
   will	
   be	
   studied.	
  Randomization	
   to	
  one	
   of	
  4	
  treatment	
   arms	
  (see	
  Study	
   Diagram)	
   will	
   be	
   performed	
   after	
  enrollment	
  onto	
   the	
   trial	
   and	
   prior	
   to	
   the	
   start	
   of	
   neoadjuvant	
   chemotherapy.	
  The	
   use	
   of	
  sensitive,	
   short-­‐term	
   biomarkers	
   as	
   endpoints	
   to	
   assess	
   the	
   effect	
   of	
   these	
   interventions,	
  continuous	
   (rather	
   than	
   categorical)	
   endpoints	
   analyzed	
   by	
  dose,	
  course	
  or	
   treatment	
   cycle	
  rather	
   than	
   by	
   patient,	
   and	
   a	
   cross-­‐over	
   design	
   that	
   allows	
   patients	
   to	
   serve	
   as	
   their	
   own	
  controls	
  will	
  minimize	
  the	
  number	
  of	
  subjects	
  and	
  time	
  required	
  to	
  complete	
  this	
  pilot	
  study,	
  increase	
  the	
  statistical	
  power,	
  and	
  maximize	
  the	
  amount	
  of	
  data	
  collected.	
  3.1.1	
  Screening,	
  Diagnosis,	
  and	
  Staging	
  Patients	
  with	
  osteosarcoma	
  typically	
  present	
  to	
  the	
  orthopedic	
  or	
  oncology	
  clinical	
  service	
  with	
  a	
   history	
   of	
  pain	
   and	
   swelling	
   at	
   the	
   primary	
   tumor	
   site	
   and	
   radiographic	
   evidence	
   of	
   a	
  destructive	
  bone	
  lesion.	
  The	
  standard	
  of	
  care	
  at	
  CHOP	
  is	
  to	
  perform	
  an	
  open	
  biopsy	
  to	
  ensure	
  that	
  an	
  adequate	
  amount	
  of	
  viable	
  tumor	
  tissue	
  is	
  obtained	
  to	
  make	
  a	
  diagnosis.	
  Histological	
  diagnosis	
  is	
   based	
   on	
   morphology	
   and	
   the	
   presence	
   of	
   osteoid	
  (unmineralized	
   bone	
  matrix).	
  There	
  are	
  no	
  specific	
  immunohistochemical	
  stains	
  that	
  can	
  be	
  used	
  to	
  confirm	
  the	
  diagnosis	
  of	
  osteosarcoma.	
  The	
   standard	
   radiographic	
  staging	
  for	
   osteosarcoma	
   to	
  assess	
   tumor	
   extent	
   in	
   the	
   involved	
  bone	
   and	
  to	
   document	
   the	
  presence	
   of	
   overt	
   metastatic	
   disease	
  in	
   the	
   lungs	
   or	
   skeleton	
  includes:	
  • AP	
  and	
  lateral	
  radiographic	
  of	
  the	
  entire	
  involved	
  bone	
  • MRI	
  with	
  contrast	
  of	
  the	
  entire	
  involved	
  bone,	
  including	
  joints	
  proximal	
  and	
  distal	
  to	
  the	
  tumor	
  (e.g.,	
  for	
  a	
  distal	
  femoral	
  tumor,	
  the	
  scan	
  should	
  include	
  the	
  entire	
  femur	
  with	
  the	
  hip	
  and	
  knee	
  joints)	
  • Chest	
  CT	
  scan	
  • 99mTc-­‐MDP	
  Bone	
  scan	
  OR	
  18FDG	
  PET	
  scan	
  Other	
  standard	
  clinical	
  and	
  laboratory	
  test	
  performed	
  prior	
  to	
  initiation	
  of	
  treatment	
  in	
  patients	
  with	
  osteosarcoma	
  include:	
  • History	
   and	
   physical	
   examination,	
   including	
   measurement	
   of	
   the	
   primary	
   tumor	
  (circumference	
  for	
  limb	
  tumors)	
  and	
  performance	
  status,	
  • CBC	
   with	
   differential,	
   comprehensive	
   mineral	
   panel,	
   calcium,	
   phosphate,	
   magnesium,	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  15	
  urinalysis,	
  12-­‐24	
  h	
  urine	
  collection	
  for	
  creatinine	
  clearance,	
  urine	
  pregnancy	
  test,	
  • Echocardiogram	
   with	
   quantitation	
   of	
   left	
   ventricular	
   shortening	
   fraction	
   prior	
   to	
  administration	
  of	
  doxorubicin,	
  and	
  • Audiogram	
  to	
  document	
  baseline	
  hearing	
  prior	
  to	
  administration	
  of	
  cisplatin.	
  These	
  procedures	
  are	
  standard	
  of	
  care	
  for	
  patients	
  with	
  osteosarcoma	
  and	
  can	
  be	
  performed	
  prior	
  to	
  informed	
  consent	
  and	
  enrollment	
  on	
  this	
  clinical	
  trial.	
  Results	
  of	
  these	
  studies	
  will	
  be	
  used	
   as	
   baseline	
   values	
   and	
  entered	
   into	
   the	
   clinical	
   trial	
   database	
   after	
   patients	
   have	
  consented	
  and	
  enrolled	
  onto	
  the	
  trial.	
  3.1.2	
  Baseline	
  (Pretreatment)	
  Research	
  Studies	
  See	
  Section	
  4.1	
  for	
  research	
  sample	
  collection,	
  processing,	
  and	
  storage	
  instructions.	
  • Urinary	
  AKI	
  Markers	
  (NAG,	
  NGAL,	
  KIM-­‐1)	
  	
  • Plasma	
  and	
  urine	
  magnesium	
  and	
  creatinine	
  for	
  FEMg.	
  • Serum	
  cystatin	
  C	
  • Serum	
  bone-­‐specific	
  alkaline	
  phosphatase	
  (BSAP)	
  • Plasma	
  pre-­‐albumin	
  • Patient-­‐reported	
  outcomes	
  survey	
  • Upper	
   arm	
  (mid-­‐way	
   between	
   the	
  shoulder	
   [acromion]	
   and	
   elbow	
   [humeral	
  lateral	
  condyle])	
  circumference	
  with	
  elbow	
  extended	
  and	
  triceps	
  skin	
  fold	
  thickness	
  1	
  cm	
  above	
  site	
   circumference	
   was	
   measured	
  in	
   arm	
   NOT	
   involved	
   with	
   tumor.	
   These	
  measurements	
   are	
   performed	
   to	
   estimate	
  nutritional	
   status,	
  muscle	
   mass,	
  and	
  creatinine	
  production.	
  3.1.3	
  Treatment	
  with	
  MAP	
  Regimen	
  All	
   patients	
   will	
   receive	
   6	
   cycles	
   of	
   the	
  3-­‐drug	
  MAP	
   chemotherapy	
   regimen	
  (Methotrexate,	
  Adriamycin	
   [doxorubicin]	
  and	
  cisPlatin)	
  that	
  is	
   shown	
   in	
   Figure	
   2.	
  Cycles	
   1	
   &	
   2	
   will	
   be	
  administered	
   neoadjuvantly	
  (before	
   resection	
   of	
   the	
   primary	
   tumor).	
   After	
   recovery	
   from	
  surgery,	
  patients	
  will	
  resume	
  treatment	
  with	
  2	
  cycles	
  of	
  MAP	
  followed	
  by	
  2	
  cycles	
  of	
  MA	
  (no	
  cisplatin).	
  Treatment	
  arm	
  specific	
  treatment	
  delivery	
  maps	
  (TDM)	
  will	
  be	
  generated	
  for	
  each	
  patient	
  after	
  randomization	
  and	
  placed	
  in	
  the	
  clinic	
  chart	
  to	
  serve	
  as	
  a	
  guide.	
  Appendix	
  1	
  shows	
  an	
  example	
  of	
  a	
  TDM.	
  Standard	
   treatments:	
  Cycles	
   1-­‐4	
   of	
   MAP	
   are	
   5	
   weeks	
  (35	
   days)	
  in	
   duration.	
   Cisplatin	
   and	
  doxorubicin	
  are	
  administered	
  on	
  days	
  1	
  &	
  2	
  and	
  HDMTX	
  +	
  leucovorin	
  rescue	
  is	
  infused	
  on	
  days	
  22	
  &	
  29.	
  cisplatin	
  is	
  not	
  administered	
  in	
  Cycles	
  5	
  &	
  6	
  and	
  the	
  duration	
  of	
  Cycles	
  5	
  &	
  6	
  is	
  4	
  weeks	
  (28	
   days).	
  During	
  cycles	
   5	
   &	
   6,	
  doxorubicin	
   is	
   administered	
   on	
   days	
   1	
   &	
   2	
   and	
   HDMTX	
  +	
  leucovorin	
   rescue	
  is	
   infused	
   on	
   days	
   15	
   &	
   22.	
   Supportive	
   care/rescue	
   agents	
  that	
   are	
  administered	
   with	
   MAP	
   to	
   alleviate	
   toxicity	
   include	
   antiemetics	
   (see	
   CHOP	
   Cancer	
   Center	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  16	
  antiemetic	
  guidelines),	
  dexrazoxane	
  as	
  a	
  cardioprotectant,	
  pegfilgrastim	
  to	
  facilitate	
  neutrophil	
  recovery	
  after	
  doxorubicin,	
   and	
   leucovorin	
   as	
   a	
   HDMTX	
   rescue	
   agent.	
   Intravenous	
   fluid	
  hydration	
   is	
  administered	
   with	
   cisplatin	
   and	
   HDMTX	
   to	
   prevent	
   nephrotoxicity,	
  and	
  urine	
  alkalinization	
  is	
  used	
  to	
  increase	
  the	
  solubility	
  of	
  MTX	
  in	
  urine.	
  Research	
  Interventions:	
  Pantoprazole	
   will	
   be	
   administered	
   intravenously	
   with	
   cisplatin	
   on	
   2	
  consecutive	
   treatment	
   cycles	
   (either	
   Cycles	
   1	
   &	
  2	
   or	
   Cycles	
   3	
   &	
   4),	
   and	
   the	
   order	
   of	
  pantoprazole	
  administration	
  will	
  be	
  determined	
  by	
  randomization	
  (see	
  Study	
  Diagram).	
  Patients	
  will	
  receive	
  HDMTX	
  as	
  4	
  and	
  12	
  h	
  infusions	
  on	
  2	
  consecutive	
  treatment	
  cycles	
  (Cycles	
  1	
  &	
  2	
  or	
  Cycles	
  3	
  &	
  4),	
  and	
  the	
  order	
  of	
  the	
  infusion	
  durations	
  will	
  be	
  determined	
  by	
  randomization.	
  Drug	
   doses,	
   schedules,	
   and	
   administration	
   routes:	
  for	
   the	
   chemotherapy	
   and	
   supportive	
  care/rescue	
  medications	
  are	
  listed	
  below:	
  • Dexrazoxane	
  375	
   mg/m2/dose	
   IV	
   over	
   15	
   min	
   immediately	
   prior	
   to	
   the	
  doxorubicin	
  doses	
  on	
  days	
  1	
  &	
  2	
  (total	
  dose	
  750	
  mg/m2/cycle)	
  of	
  treatment	
  cycles	
  1-­‐6;	
  • DOXOrubicin	
  37.5	
   mg/m2/dose	
   IV	
   over	
   15	
   min	
   on	
   days	
   1	
   &	
   2	
   (total	
   dose	
   75	
  mg/m2/cycle)	
  of	
  treatment	
  cycles	
  1-­‐6	
  (total	
  cumulative	
  dose	
  450	
  mg/m2);	
  • Pantoprazole	
  0.3	
  mg/kg	
  IV	
  over	
  15	
  min	
  immediately	
  prior	
  to	
  cisplatin	
  as	
  a	
  loading	
  dose	
  on	
  days	
  1	
  &	
  2	
  followed	
  by	
  1.3	
  mg/kg	
  IV	
  infused	
  over	
  4	
  h	
  concurrent	
  with	
  the	
  4	
  h	
  cisplatin	
  infusion	
  on	
  days	
  1	
  &	
  2	
  of	
  treatment	
  Cycles	
  1	
  &	
  2	
  (Treatment	
  Arms	
  1,	
  3)	
  OR	
  Cycles	
  3	
  &	
  4	
  (Treatment	
  Arms	
  2,	
  4);	
  • CISplatin	
  60	
  mg/m2/dose	
  infused	
  IV	
  over	
  4	
  h	
  on	
  days	
  1	
  &	
  2	
  (total	
  dose	
  120	
  mg/m2/cycle)	
  of	
  treatment	
  cycles	
  1-­‐4;	
  • Pegfilgrastim	
  0.1	
   mg/kg	
  (6	
   mg	
  for	
   patients	
   weighing	
   ≥45	
   kg)	
   SC	
  on	
   day	
   3	
  or	
   4	
  of	
  treatment	
  cycles	
  1-­‐6;	
  • Methotrexate	
  12	
  g/m2	
  (maximum	
  dose	
  20	
  g)	
  infused	
  IV	
  over	
  4	
  OR	
  12	
  h	
  on	
  days	
  22	
  &	
  29	
  of	
  Cycles	
  1-­‐4	
  and	
  on	
  days	
  15	
  and	
  22	
  of	
  Cycles	
  5	
  &	
  6	
  (HDMTX	
  infusion	
  duration	
  on	
  Cycles	
  5	
  &	
  6	
  based	
  on	
  patient	
  tolerance	
  on	
  cycles	
  1-­‐4);	
  • Leucovorin	
  15	
  mg/m2	
  IV	
  or	
  PO	
  every	
  6	
  h	
  until	
  serum	
  MTX	
  <0.1	
  mcM	
  on	
  days	
  23	
  and	
  30	
  of	
   cycles	
   1-­‐4	
   and	
   days	
   16	
   &	
   23	
   of	
   cycles	
   5	
   &	
   6,	
  starting	
   24	
   h	
  after	
  the	
   start	
   of	
   the	
  HDMTX	
  infusion.	
  Intravenous	
   fluid	
   hydration	
   guidelines:	
  Intravenous	
   fluid	
  hydration	
   should	
   be	
   administered	
  prior	
  to,	
  during	
  and	
  after	
  cisplatin	
  and	
  HDMTX.	
  In	
  addition,	
  the	
  urine	
  should	
  be	
  alkalinized	
  to	
  a	
  pH	
  of	
  ≥7	
  for	
  HDMTX	
  until	
  serum	
  MTX	
  <1	
  mcM	
  by	
  including	
  sodium	
  bicarbonate	
  or	
  equivalent	
  base	
  in	
  the	
  IV	
  fluids.	
  Cisplatin:	
  • Prior	
  to	
   the	
   first	
   dose	
   of	
   cisplatin	
   on	
  day	
   1	
   of	
   the	
   cycle,	
  infuse	
   a	
  normal	
   saline	
  (0.9%	
  NaCl)	
  fluid	
  bolus	
  of	
  750	
  mL/m2	
  over	
  1	
  h.	
  • Cisplatin	
  is	
  diluted	
  in	
  0.9%	
  NaCl	
  to	
  a	
  final	
  cisplatin	
  concentration	
  of	
  100	
  mg/L.	
  Therefore,	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  17	
  patients	
  will	
  receive	
  150	
  mL/m2/h	
  of	
  this	
  solution	
  over	
  the	
  4	
  hour	
  drug	
  infusion.	
  • After	
  the	
  cisplatin	
  infusion	
  is	
  completed,	
  infuse	
  100	
  mL/m2/h	
  D5	
  0.45%	
  NaCl	
  +	
  20	
  mEq/L	
  KCl	
  until	
  at	
  least	
  12	
  h	
  after	
  the	
  second	
  cisplatin	
  infusion	
  is	
  completed	
  and	
  the	
  patient	
  is	
  tolerating	
  PO	
  fluids.	
  • Monitor	
  Input	
  and	
  Output,	
  at	
  3hr	
  or	
  6hr	
  after	
  start	
  of	
  cisplatin	
  	
  o If	
  urine	
  Output	
  >	
  total	
  Input	
  by	
  100	
  mL/m2/hr	
  over	
  the	
  previous	
  3	
  hr,	
  consider	
  0.9%	
  NaCl	
  bolus	
  (10-­‐15	
  cc/kg)	
  o If	
  total	
  Input	
  >	
  urine	
  Output	
  by	
  100	
  mL/m2/hr	
  over	
  the	
  previous	
  3	
  hr,	
  consider	
  furosemide	
  (0.5	
  mg/kg,	
  MAX	
  dose	
  20	
  mg)	
  to	
  promote	
  urine	
  output.104,105	
  HDMTX:	
  • Prior	
   to	
   the	
   start	
   of	
   a	
   HDMTX	
   infusion,	
   infuse	
  D5	
  0.22%	
   NaCl	
   with	
  40	
   mEq/L	
   NaHCO3	
  (sodium	
  biocarbonate)	
  or	
  equivalent	
  base	
  as	
  a	
  fluid	
  bolus	
  of	
  750	
  mL/m2	
  over	
  1	
  h.	
  • Continue	
  hydration	
  with	
  D5	
  0.22%	
  NaCl	
  with	
  40	
  mEq/L	
  NaHCO3	
  (sodium	
  bicarbonate)	
  or	
  equivalent	
  base	
  at	
  100	
  mL/m2/h	
  until	
  serum	
  MTX	
  <1	
  mcM	
  and	
  PO	
  fluids	
  are	
  tolerated.	
  Acetate	
  can	
  be	
  substituted	
  if	
  bicarbonate	
  is	
  not	
  available	
  at	
  a	
  1:1	
  dose	
  conversion.	
  • If	
   urine	
   pH	
   <7	
   administer	
   0.5	
   mEq/kg	
   NaHCO3	
  IV.	
   Recheck	
   urine	
   pH	
  ≥30	
   min	
   after	
  NaHCO3	
  bolus	
   is	
   complete.	
  Repeat	
   NaHCO3	
  bolus	
   until	
   urine	
   pH	
  ≥7	
   and	
   consider	
  increasing	
  dose	
  of	
  bicarbonate	
  in	
  maintenance	
  fluids	
  if	
  urine	
  pH	
  consistently	
  <7.	
  • Once	
   urine	
   pH	
   ≥7	
   start	
   HDMTX	
   infusion.	
  Continue	
  to	
  check	
  urine	
  pH	
  every	
  8	
  hours	
  and	
  administer	
   0.5	
   mEq/kg	
   NHCO3	
  IV	
   if	
  urine	
  pH	
  <7,	
  until	
  serum	
  MTX	
  <1	
  mcM.	
  • HDMTX	
   solution	
  (25	
   mg/mL)	
  is	
   piggy-­‐backed	
   into	
   the	
   hydration	
   fluids	
  and	
  infused	
  over	
  4	
  OR	
  12	
  h	
  depending	
  on	
  the	
  treatment	
   arm	
   and	
   cycle	
   (see	
   Study	
  Diagram).	
  Leucovorin	
  dosing	
  guidelines	
  including	
   guide-­‐lines	
  for	
  delayed	
  MTX	
  excretion:	
  	
  • The	
   dose	
   and	
   duration	
   of	
   leucovorin	
   rescue	
  are	
  determined	
   by	
   the	
   plasma	
   MTX	
  concentration.	
  Leucovorin	
  rescue	
  should	
  start	
  no	
   later	
   than	
   24	
   h	
   after	
   the	
  start	
  of	
   the	
  HDMTX	
   infusion	
   and	
   continue	
   until	
   the	
  plasma	
  MTX	
  concentration	
  is	
  <0.1	
  mcM.	
  • Leucovorin	
  15	
   mg/m2	
  IV	
   or	
   PO	
   every	
   6	
   h	
  starting	
   24	
   h	
  after	
  the	
   start	
   of	
   the	
   HDMTX	
  
	
  Figure	
  11:	
  	
  Concentration	
  time	
  curves	
  for	
  MTX	
  (12	
  g/m2)	
  infusions	
  over	
  4	
  and	
  12	
  h	
  generated	
  by	
  fitting	
  a	
  2-­‐compartment	
  pharmacokinetic	
  model	
  to	
  the	
  mean	
  plasma	
  MTX	
  concentrations	
  from	
  1,045	
  infusions	
  of	
  12	
  g/m2	
  over	
  4	
  h.5	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  18	
  infusion	
  on	
  days	
  23	
  and	
  30	
  of	
  cycles	
  1-­‐4	
  and	
  days	
  16	
  &	
  23	
   of	
   cycles	
   5	
   &	
   6	
   and	
   administered	
   until	
   serum	
   MTX	
  <0.1	
  mcM.	
  • Serum	
  MTX	
  levels	
  will	
  vary	
  based	
  on	
  the	
  duration	
  of	
  the	
  HDMTX	
   infusion	
  (Figure	
   11).	
  Table	
  3	
  lists	
   the	
   expected	
  plasma	
   MTX	
   concentrations	
   at	
   various	
   times	
   after	
   a	
   4	
  and	
  12	
  h	
  infusion.	
  Please	
   contact	
  the	
   PI	
   or	
   study	
   Co-­‐investigators	
  at	
   any	
   time	
  for	
  questions	
   or	
  concerns	
  about	
  MTX	
  levels.	
  • If	
  a	
  patient	
  experiences	
  MTX	
  nephrotoxicity	
  and	
  delayed	
  MTX	
   clearance,	
   the	
   leucovorin	
   dose	
   or	
   schedule	
  may	
  need	
  adjustment	
  based	
   on	
  plasma	
  MTX	
  concentration,	
  or	
  the	
  patient	
  may	
  require	
  glucarpidase	
  to	
  lower	
  plasma	
  MTX	
  concentrations.	
  The	
  study	
  PI	
  or	
  a	
  co-­‐Investigator	
  should	
  be	
  contacted	
  immediately	
  if	
  the	
  plasma	
  MTX	
  concentration	
  is	
  >100	
  mcM	
  at	
  hour	
  24,	
  >50	
  mcM	
  at	
  hour	
  28-­‐40,	
  or	
  >10	
  mcM	
  at	
  hour	
  48	
  or	
  later.	
  Leucovorin	
  should	
  be	
  escalated	
  to	
  15	
  mg/m2	
  IV	
  or	
  PO	
  every	
  3	
  h	
  if	
  the	
  plasma	
  MTX	
  concentration	
  is	
  >2-­‐fold	
   higher	
   than	
   expected	
   (Table	
   3)	
   AND	
   >1	
  mcM.	
   The	
   every	
   6	
   h	
   schedule	
   can	
   be	
  resumed	
  when	
  the	
  plasma	
  MTX	
  concentration	
  is	
  <1	
  mcM.	
  3.1.4	
  Criteria	
  for	
  Starting	
  Treatment	
  CISplatin/DOXOrubicin	
  (Cycle	
  1-­‐4)	
  or	
  DOXOrubicin	
  alone	
  (Cycle	
  5&6):	
  Delay	
  treatment	
  until	
  the	
  following	
  conditions	
  are	
  met:	
  • ANC	
  >750/mcL	
  and	
  platelet	
  count	
  >75,000/mcL	
  • Oral	
  mucositis	
  grade	
  <2	
  • Hyperbilirubinemia	
  (total)	
  grade	
  <3	
  and	
  ALT/AST	
  elevation	
  grade	
  <4	
  • Normal	
   serum	
   creatinine	
   for	
   age	
   and	
   gender	
  (see	
   Table	
   in	
   eligibility	
   criteria)	
  OR	
  creatinine	
   clearance	
   >70	
   mL/min/1.73	
   m2	
  (Cycles	
   1-­‐4	
  only).	
   If	
   renal	
   function	
   does	
   not	
  recover	
  after	
  a	
  one	
  week	
  delay,	
  administer	
  doxorubicin	
  alone.	
  • Adequate	
   wound	
   healing	
   (determined	
   by	
   the	
   surgeon)	
   after	
   resection	
   of	
   the	
   primary	
  tumor	
  (prior	
  to	
  Cycle	
  3)	
  or	
  after	
  resection	
  of	
  pulmonary	
  metastases.	
  HDMTX:	
  Delay	
  treatment	
  until	
  the	
  following	
  conditions	
  are	
  met:	
  • ANC	
  >250/mcL	
  and	
  platelet	
  count	
  >50,000/mcL	
  • Oral	
  mucositis	
  grade	
  <2	
  • Hyperbilirubinemia	
  grade	
  <3	
  and	
  ALT/AST	
  elevation	
  grade	
  <4	
  • Normal	
  serum	
  creatinine	
  for	
  age	
  &	
  gender	
  OR	
  creatinine	
  clearance	
  >70	
  mL/min/1.73	
  m2	
  
Table	
  3.	
  Expected	
  MTX	
  levels	
  by	
  infusion	
  duration.	
  (EOI,	
  end	
  of	
  infusion)	
  	
  Plasma	
  MTX	
  [mcM]	
  Sample	
  time	
  (h)	
  4	
  h	
  Infusion	
  12	
  h	
  Infusion	
  EOI	
  1200	
  600	
  24	
  15	
  40	
  36	
  3	
  5	
  48	
  1	
  2	
  60	
  0.5	
  1	
  72	
  0.3	
  0.4	
  96	
  <0.1	
  <0.1	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  19	
  3.1.5	
  Dose	
  Modifications	
  Modification	
   of	
   the	
   doses	
   of	
   cisplatin,	
   doxorubicin,	
   and	
   HDMTX	
   is	
   required	
   if	
   toxicity	
   for	
   the	
  drugs	
  exceeds	
  the	
  thresholds	
  listed	
  in	
  the	
  Tables	
  below	
  on	
  a	
  prior	
  treatment	
  cycle.	
  The	
  percent	
  of	
  full	
   protocol	
  prescribed	
  dose	
  should	
   be	
   recorded	
   on	
   the	
   TDM	
   in	
   the	
   column	
   labeled	
   “%	
  Dose”.	
  If	
  the	
  dose	
  is	
  reduced	
  by	
  25%,	
  then	
  the	
  %	
  Dose	
  should	
  be	
  recorded	
  as	
  75%	
  (75%	
  of	
  the	
  full	
  dose).	
  Cisplatin:	
  Toxicity	
  Severity	
  Modification	
  Ototoxicity	
  >30	
  dB	
  threshold	
  at	
  2	
  kHz	
  Discontinue	
  cisplatin	
  Nephrotoxicity	
  Serum	
  creatinine	
  >ULN	
  for	
  age	
  and	
  gender	
  OR	
  creatinine	
  clearance	
  <70	
  mL/min/1.73	
  m2	
  Hold	
  cisplatin	
  until	
  criterion	
  in	
  Section	
  3.1.4	
  is	
  met	
  Neuropathy*	
  Grade	
  >2	
  motor	
  or	
  sensory	
  neuropathy	
  Hold	
  cisplatin	
  until	
  resolved	
  to	
  grade	
  ≤2	
  *	
  See	
  Appendix	
  2	
  for	
  toxicity	
  grading	
  scale	
  Doxorubicin:	
  Toxicity	
  Severity	
  Modification	
  Myelosuppression	
  Planned	
  day	
  22	
  HDMTX	
  is	
  delayed	
  by	
  >10d	
  (cycle	
  day	
  >32)	
  due	
  to	
  ANC	
  <250/mcL	
  or	
  platelet	
  count	
  <50,000/mcL	
  Reduce	
  doxorubicin	
  dose	
  by	
  20%	
  Cardiotoxicity	
  SF	
  <27%	
  (confirmed	
  with	
  repeat	
  Echocadiogram	
  1	
  week	
  later)	
  Hold	
  doxorubicin	
  until	
  recovery	
  to	
  SF	
  >28%	
  Mucositis	
  Grade	
  4	
  related	
  to	
  doxorubicin	
  Reduce	
  doxorubicin	
  dose	
  by	
  20%	
  HDMTX:	
  Toxicity	
  Severity	
  Modification	
  Nephrotoxicity	
  Serum	
   creatinine	
   >ULN	
   for	
   age	
   and	
  gender	
   OR	
   creatinine	
   clearance	
   <70	
  mL/min/1.73	
  m2	
  Hold	
  HDMTX.	
  Omit	
  dose	
  if	
  renal	
  function	
  has	
  not	
  recovered	
  after	
  a	
  7-­‐day	
  delay	
  Mucositis	
  Grade	
  4	
  related	
  to	
  HDMTX	
  Reduce	
  HDMTX	
  by	
  50%	
  3.1.6	
  Local	
  Control	
  of	
  Primary	
  Tumor	
  Complete	
  resection	
  of	
  the	
  primary	
  tumor	
  is	
  the	
  optimal	
  form	
  of	
  local	
  therapy	
  and	
  is	
  performed	
  after	
   two	
   5-­‐week	
   cycles	
   of	
   neoadjuvant	
   MAP	
   chemotherapy	
  (11	
   weeks	
   after	
   the	
   start	
   of	
  therapy).	
  A	
  limb	
  salvage	
  procedure	
  is	
  indicated	
  if	
  the	
  neurovascular	
  bundle	
  is	
  not	
  extensively	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  20	
  involved,	
  the	
  tumor	
  can	
  be	
  resected	
  en	
  bloc	
  with	
  tumor-­‐free	
  margins,	
  and	
  reconstruction	
  with	
  an	
  endoprosthesis	
  to	
  replace	
  the	
  involved	
  bone	
  and	
  joint	
  is	
  feasible.	
  If	
  a	
  limb	
  salvage	
  procedure	
  is	
  not	
  indicated,	
  an	
  amputation	
  of	
  the	
  involved	
  portion	
  of	
  the	
  limb	
  will	
  be	
  performed.	
  Radiation	
  therapy	
  is	
  reserved	
  for	
  patients	
  who	
  have	
  unresectable	
  primary	
  tumors	
  (e.g.,	
  spine	
  tumors).	
  The	
  timing	
  of	
  radiation	
  therapy	
  will	
  be	
  based	
  on	
  symptoms,	
  such	
  as	
  pain,	
  response	
  to	
  neoadjuvant	
   chemotherapy,	
   and	
   ability	
   to	
   deliver	
  full	
   dose	
   intensity	
   of	
   the	
   chemotherapy	
  regimen.	
  Radiation	
   is	
   less	
   effective	
   than	
   surgery	
   but	
   can	
   achieve	
   local	
   control	
   in	
   some	
  patients.106,107	
  3.1.7	
  Management	
  of	
  Metastatic	
  Tumors	
  Complete	
  resection	
  of	
  overt	
  pulmonary	
  metastases	
  that	
  are	
  present	
  at	
  diagnosis	
  can	
  enhance	
  survival	
  chances.11,108	
  Median	
  sternotomy	
  or	
  bilateral	
  thoracotomies	
  with	
  manual	
  palpation	
  of	
  both	
  lungs	
  is	
  recommended	
  even	
  in	
  patients	
  with	
  unilateral	
  pulmonary	
  metastases	
  on	
  CT	
  scan.	
  Timing	
  of	
  resection	
  of	
  metastatic	
  disease	
  is	
  left	
  to	
  the	
  clinical	
  judgment	
  of	
  the	
  oncologist	
  and	
  surgeons.	
  3.2	
  Randomization	
  Patients	
   will	
   be	
   randomized	
   to	
   one	
   of	
  4	
  treatment	
   arms	
   (see	
   Study	
   Diagram),	
  which	
   will	
  determine	
   the	
   order	
   in	
   which	
   they	
   receive	
   pantoprazole	
   with	
   cisplatin	
   (Cycles	
   1&2	
   vs.	
   Cycles	
  3&4)	
  and	
  the	
  order	
  in	
  which	
  they	
  will	
  receive	
  HDMTX	
  as	
  a	
  4	
  or	
  12	
  h	
  infusion	
  (Cycles	
  1&2	
  vs.	
  Cycles	
  3&4).	
  A	
  block	
  randomization	
  procedure	
  will	
  be	
  used	
  so	
  that	
  3	
  of	
  the	
  first	
  12	
  subjects	
  will	
  be	
  randomly	
  assigned	
  to	
  each	
  of	
  the	
  4	
  treatment	
  arms	
  (three	
  patient	
  per	
  arm)	
  and	
  3	
  of	
  subjects	
  13	
  to	
  24	
  will	
  be	
  randomly	
  assigned	
  to	
  each	
  of	
  the	
  4	
  arms	
  (six	
  patients	
  per	
  arm	
  when	
  enrollment	
  is	
  completed).	
  Subjects	
  who	
  are	
  unable	
  to	
  complete	
  4	
  cycles	
  of	
  therapy	
  may	
  be	
  replaced,	
  and	
  the	
  new	
  subject	
  will	
  be	
  placed	
  on	
  the	
  same	
  treatment	
  arm	
  as	
  the	
  subject	
  being	
  replaced.	
  3.3	
  Study	
  Duration,	
  Enrollment	
  and	
  Number	
  of	
  Sites	
  3.3.1	
  Duration	
  of	
  Study	
  The	
   duration	
   of	
   study	
   participation	
   will	
   be	
   approximately	
   8	
   months.	
   The	
   screening	
   process	
  including	
   biopsy	
   of	
   the	
   primary	
   tumor	
   for	
   diagnosis	
   will	
   take	
   up	
   to	
   2	
   weeks.	
   The	
   first	
   4	
  treatment	
  cycles	
  are	
  5	
  weeks	
  each	
  (total,	
  20	
  weeks)	
  and	
  cycles	
  5	
  and	
  6	
  are	
  4	
  weeks	
  each	
  (total,	
  8	
   weeks).	
   The	
   time	
   for	
   recovery	
   from	
   surgery	
   to	
   resect	
   the	
   primary	
   tumor	
   after	
   Cycle	
   2	
   is	
  usually	
   1-­‐2	
   weeks.	
   Endpoints	
   for	
   this	
   trial	
   are	
   measured	
   during	
   therapy	
   and	
   at	
   the	
   end	
   of	
  therapy	
  visit	
  after	
  the	
  last	
  HDMTX	
  infusion.	
  3.3.2	
  Number	
  of	
  Subjects	
  and	
  Number	
  of	
  Study	
  Sites	
  This	
  pilot	
  study	
  will	
  be	
  conducted	
  at	
  CHOP.	
  We	
  plan	
  to	
  study	
  24	
  subjects.	
  Patients	
  who	
  do	
  not	
  complete	
  4	
  cycles	
   of	
  treatment	
  for	
   any	
   reason	
  may	
   be	
   replaced.	
   We	
   may	
   enroll	
   up	
   to	
   28	
  subjects	
  in	
  order	
  to	
  have	
  24	
  fully	
  evaluable	
  subjects.	
  Based	
  on	
  the	
  number	
  of	
  children	
  with	
  OS	
  seen	
  at	
  CHOP	
  annually,	
  we	
  expect	
  accrual	
  to	
  be	
  complete	
  in	
  2	
  to	
  3	
  years.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  21	
  3.4	
  Study	
  Population	
  3.4.1	
  Study	
  Enrollment/Registration	
  Subjects	
  are	
  enrolled	
  on	
  study	
  after	
  fulfilling	
  the	
  eligibility	
  criteria	
  listed	
  below.	
  Treatment	
  arm	
  will	
  be	
  assigned	
  by	
  the	
  Study	
  PI	
  based	
  on	
  a	
  spreadsheet	
  provided	
  by	
  the	
  Study	
  Biostatistician.	
  Demographic	
  information,	
  results	
  of	
  screening	
  and	
  baseline	
  studies,	
  tumor	
  site(s)	
  and	
  histology,	
  and	
   treatment	
   arm	
   will	
   be	
   entered	
   into	
   OnCore	
   CRM.	
  Patients	
   must	
   be	
   enrolled	
   and	
  randomized	
  prior	
  to	
  starting	
  neoadjuvant	
  chemotherapy.	
  3.4.2	
  Inclusion	
  Criteria	
  • Age:	
  <30	
  years	
  of	
  age	
  • Diagnosis:	
  histological	
  diagnosis	
  of	
  high-­‐grade	
  osteosarcoma	
  (Section	
  3.1.1)	
  • Site:	
  Extremity	
   or	
   central	
   axis	
   (including	
   craniofacial)	
   primary	
   tumor;	
   localized	
   or	
  metastatic	
  • Prior	
  therapy:	
  No	
  prior	
  chemotherapy	
  or	
  radiation	
  therapy	
  for	
  osteosarcoma.	
  Subjects	
  who	
  develop	
  osteosarcoma	
  as	
  a	
  second	
  cancer	
  are	
  eligible	
  if	
  they	
  have	
  not	
  previously	
  received	
  cisplatin,	
  doxorubicin	
  or	
  other	
  anthracyclines,	
  or	
  MTX	
  • Kidney	
  function:	
  Serum	
  creatinine	
  at	
  or	
  below	
  the	
  upper	
  limit	
  of	
  normal	
  (ULN)	
  for	
  age	
  and	
  gender:	
  Age	
  Maximum	
  Serum	
  Creatinine	
  (mg/dL)	
  	
  Male	
  Female	
  1	
  mo	
  to	
  <	
  6	
  months	
  0.4	
  0.4	
  6	
  mo	
  to	
  <	
  1	
  year	
  0.5	
  0.5	
  1	
  year	
  to	
  	
  <	
  2	
  years	
  0.6	
  0.6	
  2	
  to	
  <	
  6	
  years	
  0.8	
  0.8	
  6	
  to	
  <	
  10	
  years	
  1	
  1	
  10	
  to	
  <	
  13	
  years	
  1.2	
  1.2	
  13	
  to	
  <	
  16	
  years	
  1.5	
  1.4	
  ≥	
  16	
  years	
  1.7	
  1.4	
  Derived	
   for	
   Schwartz	
   et	
   a.	
  J	
   Peds	
   106:522,	
   1985	
   utilizing	
  child	
  length	
  and	
  stature	
  data	
  published	
  by	
  the	
  CDC	
  	
  • Cardiac	
  function:	
  Shortening	
  fraction	
  on	
  echocardiogram	
  >28%	
  • Hearing:	
  Hearing	
  level	
  threshold	
  ≤25	
  dB	
  at	
  all	
  frequencies	
  in	
  both	
  ears	
  to	
  be	
  evaluable	
  for	
  evaluation	
  of	
  pantoprazole’s	
  effect	
  on	
  cisplatin	
  ototoxicity.	
  Patients	
  with	
  hearing	
  loss	
  can	
  be	
  enrolled	
  but	
  will	
  not	
  be	
  evaluable	
  for	
  ototoxicity	
  objective.	
  • Hematological	
   function:	
  Absolute	
   neutrophil	
  count	
   >1,000/mcL	
   and	
   platelet	
   count	
  >100,000/mcL	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  22	
  3.4.3	
  Exclusion	
  Criteria	
  • Receiving	
  H2	
  antagonists	
  (cimetidine,	
  ranitidine,	
  famotidine,	
  nizatidine)	
  or	
  proton	
  pump	
  inhibitors	
   (lansoprazole,	
   omeprazole,	
   pantoprazole,	
   esomeprazole,	
   raberprazole,	
  dexlansoprazole)	
   AND	
   unable	
   to	
   hold	
   the	
   drug	
   for	
   24	
   h	
   prior	
   to	
   and	
   24	
   h	
   after	
   each	
  cisplatin	
  course	
  on	
  cycles	
  1-­‐4.	
  • Inability	
  to	
  tolerate	
  a	
  PPI	
  • Pregnant	
  or	
  breastfeeding	
  • Unable	
  to	
  cooperate	
  with	
  research	
  procedures	
  4.	
  RESEARCH	
  PROCEDURES	
  Refer	
   to	
   Treatment	
   arm	
   specific	
  TDMs	
   for	
   schedule	
   of	
   drug	
   administration	
   and	
  Schedule	
   of	
  Study	
  Procedures	
  for	
  timing	
  of	
  standard	
  of	
  care	
  and	
  research	
  procedures.	
  4.1	
  Research	
  Studies	
  during	
  Treatment	
  See	
  Schedule	
  of	
  Study	
  Procedures	
  table	
  for	
  timing	
  of	
  standard	
  of	
  care	
  and	
  research	
  procedures.	
  Test	
  Specimen	
  Tube	
  Volume	
  Collection	
  Processing	
  Storage	
  Lab/Assay	
  KIM-­‐1	
  Spot	
  urine	
  Urine	
  container	
  >5	
  mL	
  Prior	
  to	
  cisplatin	
  D1,	
  EOI	
  D2,	
  D7;	
  prior	
  to	
  each	
  HDMTX	
  &	
  24	
  after	
  the	
  start	
  of	
  infusion;	
  pre-­‐op;	
  C5D1	
  Centrifuge	
  -­‐70°C	
  CTSU	
  Core	
  NGAL	
  NAG	
  Cystatin	
  C	
  Serum	
  Gold	
  top	
  SST-­‐clot	
  activator	
  3	
  mL	
  Prior	
  to	
  cisplatin	
  and	
  HDMTX;	
  D7;	
  pre-­‐op;	
  C5D1;	
  post-­‐inf	
  IF	
  sCr	
  ≥50%	
  above	
  baseline	
  	
  Centrifuge	
  -­‐70°C	
  UPenn	
  Core	
  Mg,	
  Cr	
  Plasma	
  Light	
  green	
  top	
  0.5	
  mL	
  Prior	
  to	
  cisplatin	
  D1,	
  D2	
  &	
  D7;	
  C5D1	
  Send	
  to	
  Clinical	
  Lab	
  Room	
  temp	
  Clinical	
  Lab	
  Mg,	
  Cr	
  Spot	
  urine	
  Urine	
  container	
  >2	
  mL	
  Prior	
  to	
  cisplatin	
  D1,	
  D2	
  &	
  D7;	
  C5D1	
  Send	
  to	
  Clinical	
  Lab	
  Room	
  temp	
  Clinical	
  Lab	
  BSAP	
  Serum	
  Red	
  top	
  2	
  mL	
  Baseline,	
  pre-­‐op,	
  C3D1	
  &	
  EOT	
  Clot,	
  centrifuge,	
  separate	
  serum	
  -­‐70°	
  C	
  CTSU	
  Core	
  Pre-­‐albumin	
  Plasma	
  Light	
  green	
  top	
  1	
  mL	
  Baseline,	
  D1	
  C2-­‐6,	
  Pre-­‐op,	
  EOT	
  Send	
  to	
  Clinical	
  Lab	
  Room	
  temp	
  Clinical	
  Lab	
  MTX	
  Urine	
  Conical	
  tube	
  	
  1	
  mL	
  EOI	
  of	
  each	
  HDMTX	
  C1-­‐4	
  Pipette	
  1	
  mL	
  urine	
  into	
  conical	
  tube	
  w/	
  9	
  mL	
  buffer	
  -­‐70°	
  C	
  PK	
  Core	
  HPLC/MS/MS	
  Abbreviations:	
  EOI,	
  end	
  of	
  infusion;	
  Mg,	
  magnesium;	
  Cr,	
  creatinine;	
  BSAP,	
  bone-­‐specific	
  alkaline	
  phosphatase;	
  inf,	
  infusion;	
  EOT,	
  end	
  of	
  therapy;	
  MTX,	
  methotrexate	
  concentration	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  23	
  4.2	
  Post-­‐Therapy	
  Follow-­‐up	
  Periodic	
   follow-­‐up	
   and	
   restaging	
   is	
   standard	
   of	
   care	
   for	
   patients	
   who	
   have	
   completed	
  treatment.	
  Guidelines	
  for	
  following	
  patients	
  after	
  completion	
  of	
  treatment	
  are	
  provided	
  in	
  the	
  table	
  below:	
  	
  Months	
  Post-­‐Treatment	
  Procedure	
  3	
  6	
  9	
  12	
  15	
  18	
  21	
  24	
  30	
  36	
  42	
  48	
  54	
  60	
  History,	
  physical,	
  PS	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  CBC,	
  CMP,	
  Mg,	
  PO4	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  	
  	
  	
  	
  	
  	
  Chest	
  CT	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  X	
  	
  	
  	
  	
  	
  	
  MRI	
  of	
  primary1	
  X	
  X	
  	
  X	
  	
  X	
  	
  X	
  	
  	
  	
  	
  	
  	
  Chest	
  X-­‐ray	
  	
  	
  	
  	
  	
  	
  	
  	
  X	
  X	
  X	
  X	
  X	
  X	
  X-­‐ray	
  of	
  primary	
  	
  	
  	
  	
  	
  	
  	
  	
  X	
  X	
  X	
  X	
  X	
  X	
  Bone	
  or	
  PET	
  scan2	
  	
  X	
  	
  X	
  	
  X	
  	
  X	
  	
  	
  	
  	
  	
  	
  Audiogram	
  	
  	
  	
  X	
  	
  	
  	
  X	
  	
  	
  	
  	
  	
  X	
  Echocardiogram	
  	
  	
  	
  X	
  	
  	
  	
  X	
  	
  X	
  	
  X	
  	
  X	
  BSAP3	
  Draw	
  sample	
  if	
  subject	
  has	
  evidence	
  of	
  tumor	
  recurrence	
  Arm	
  circum/Skin	
  fold3	
  X	
  X	
  	
  X	
  	
  	
  	
  X	
  	
  X	
  	
  X	
  	
  X	
  1	
  Substitute	
  CT	
  scan	
  if	
  metal	
  in	
  endoprothesis	
  does	
  not	
  allow	
  for	
  MRI	
  to	
  be	
  performed	
  2	
  Only	
  if	
  positive	
  for	
  metastatic	
  disease	
  at	
  baseline	
  3	
  Research	
  procedure	
  4.3	
  Concomitant	
  Medications	
  H2-­‐antagonists	
  (cimetidine,	
   ranitidine,	
   famotidine,	
   nizatidine)	
   and	
  proton	
   pump	
   inhibitors	
  (lansoprazole,	
  omeprazole,	
  pantoprazole,	
  esomeprazole,	
  raberprazole,	
  dexlansoprazole)	
  should	
  NOT	
   be	
   administered	
   for	
  24	
  h	
   prior	
   to	
   and	
   24	
   h	
   after	
   cisplatin	
   on	
   Cycles	
   1-­‐4.	
   Patients	
   will	
  receive	
  pantoprazole	
  with	
  cisplatin	
  on	
  Cycles	
  1&2	
  OR	
  Cycles	
  3&4.	
  Probenecid,	
  NSAIDS,	
  sulfonamides	
  (including	
  co-­‐trimoxazole),	
  and	
  penicillins	
  should	
  NOT	
  be	
  administered	
  concurrently	
  with	
  HDMTX.	
  These	
  drugs	
  can	
  interfere	
  with	
  the	
  secretion	
  of	
  MTX	
  by	
  the	
  renal	
  tubule.	
  Patients	
  should	
  receive	
  co-­‐trimoxazole	
  2.5	
  mg/kg/dose	
  twice	
  daily	
  on	
  2	
  consecutive	
  days	
  per	
  week	
   to	
   prevent	
   pneumocystis	
   pneumonia.	
   Co-­‐trimoxazole	
   should	
   NOT	
   be	
   administered	
  concurrently	
  with	
  HDMTX.	
  Antiemetics	
  should	
   be	
   administered	
  prior	
   to	
   and	
   as	
   needed	
   during	
   and	
   after	
   chemotherapy	
  according	
  to	
  the	
  CHOP	
  Antiemetic	
  guidelines	
  available	
  on	
  the	
  Cancer	
  Center	
  Website.	
  4.4	
  Subject	
  Completion/Withdrawal	
  Subjects	
  will	
  be	
  followed	
  (Section	
  4.2)	
  until:	
  • Five	
  years	
  after	
  completing	
  treatment	
  • Relapse	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  24	
  • Death	
  from	
  any	
  cause	
  Subjects	
   may	
   voluntarily	
   withdraw	
   from	
   this	
   study	
   at	
   any	
   time	
   but	
   should	
   complete	
   the	
  standard	
  of	
  care	
  chemotherapy	
  regimen	
  and	
  resection	
  of	
  their	
  primary	
  and	
  metastatic	
  tumor	
  as	
  described	
  in	
  this	
  protocol.	
  5.	
  STUDY	
  ENDPOINTS	
  AND	
  EVALUATIONS	
  The	
  timing	
  of	
  study	
  endpoints,	
  as	
  well	
  as	
  standard	
  of	
  care	
  procedures,	
  is	
  shown	
  in	
  the	
  Schedule	
  of	
  Study	
  Procedures.	
  5.1	
  Primary	
  Endpoints	
  • Urinary	
   biomarkers	
   of	
   acute	
   kidney	
   injury	
   (KIM-­‐1,	
   NAG,	
   NGAL)	
  after	
  each	
  course	
   of	
  cisplatin	
  (days	
   2	
   and	
   7)	
  and	
  each	
  HDMTX	
   infusion	
  (24	
   h	
   and	
   day	
   7)	
  on	
   cycles	
   1-­‐4	
  compared	
  to	
  baseline	
  (pre-­‐infusion)	
  values	
  • Serum	
   cystatin-­‐C	
   and	
   creatinine	
  prior	
   to	
   each	
  course	
  of	
   cisplatin	
   and	
  each	
  HDMTX	
  infusion	
   on	
   cycles	
   1-­‐4	
  and	
   post-­‐infusion	
  cystatin-­‐C	
  and	
   BMP	
  if	
   serum	
   creatinine	
  increases	
  by	
  ≥50%	
  compared	
  to	
  pre-­‐infusion	
  baseline	
  value	
  • FEMg	
  (simultaneous	
  serum	
  and	
  spot	
  urine	
  for	
  Mg	
  and	
  creatinine)	
  prior	
  to	
  the	
  start	
  of	
  the	
  cisplatin	
  infusions	
  on	
  days	
  1&2	
  and	
  day	
  7	
  of	
  cycles	
  1-­‐4	
  • Plasma	
  and	
  urine	
  MTX	
  concentrations	
  at	
  the	
  end	
  of	
  each	
  HDMTX	
  infusion	
  on	
  cycles	
  1-­‐4	
  • Audiograms	
  prior	
  to	
  cycles	
  1-­‐4	
  and	
  at	
  the	
  end	
  of	
  therapy.	
  5.2	
  Secondary	
  Endpoints	
  • The	
  incidence	
  and	
  severity	
  (CTCAE	
  v.4	
  grade)	
  of	
  safety	
  events	
  listed	
  in	
  Section	
  5.4,	
  • Response	
   of	
   the	
   primary	
   tumor	
   to	
   the	
   first	
   2	
   treatment	
   cycles	
   will	
   be	
   assessed	
   by	
  quantifying	
   the	
   change	
   in	
   tumor	
   volume	
   on	
   MRI	
   after	
   treatment	
  relative	
  to	
   the	
   pre-­‐treatment	
  tumor	
   volume	
  using	
   the	
   log	
   ratio	
   method	
  [log(Vt/V0),	
   where	
   Vt	
  is	
   tumor	
  volume	
   post-­‐treatment	
   and	
   V0	
  is	
   tumor	
   volume	
   at	
   baseline]109	
  and	
   quantifying	
   the	
  percent	
  tumor	
  necrosis	
  in	
  the	
  resected	
  tumor	
  specimens	
  histologically,	
  • The	
  new	
  biomarkers	
  of	
  AKI	
  (KIM-­‐1,	
  NAG,	
  NGAL)	
  and	
  GFR	
  (cystatin	
  C)	
  will	
  be	
  correlated	
  with	
  the	
  current	
  standard	
  clinical	
  laboratory	
  methods	
  of	
  assessing	
  renal	
  function	
  with	
  serum	
  creatinine,	
  estimated	
  creatinine	
  clearance,	
  urinalysis	
  and	
  FEMg,	
  • A	
   tissue	
   microarray	
   will	
   be	
   constructed	
   from	
   the	
   paraffin	
   blocks	
   containing	
   the	
   initial	
  biopsy	
   specimen,	
   the	
   resected	
   primary	
   tumor	
   and	
   resected	
   metastatic	
   lesion	
   (if	
  available)	
  in	
  the	
  Pathology	
  Core	
  Laboratory.	
  A	
  slide	
  cut	
  from	
  the	
  top	
  of	
  the	
  block	
  will	
  be	
  used	
   to	
   identify	
   areas	
   of	
   viable	
   tumor,	
   which	
   will	
   then	
   be	
   marked	
   on	
   the	
   block.	
   IHC	
  staining	
  will	
  be	
  performed	
  for	
  proteins	
  responsible	
  for	
  resistance	
  to	
  MAP	
  agents	
  and	
  for	
  protein	
  targets	
  of	
  new	
  agents	
  under	
  development,	
  • Serum	
  bone	
  specific	
  alkaline	
  phosphatase	
  will	
  be	
  measured	
  at	
  baseline,	
  pre-­‐	
  and	
  post-­‐op,	
  end	
  of	
  treatment	
  and	
  at	
  the	
  time	
  of	
  relapse	
  and	
  correlated	
  with	
  tumor	
  volume,	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  25	
  • An	
  osteosarcoma-­‐specific	
  patient	
  reported	
  outcome	
  survey	
  (Appendix	
  3)	
  developed	
  for	
  this	
  study	
  will	
  be	
  administered	
  prior	
  to	
  each	
  treatment	
  cycle,	
  prior	
  to	
  surgery	
  and	
  at	
  the	
  end	
  of	
  therapy,	
  • Weight,	
  arm	
  circumference	
  (muscle	
  mass),	
  skin	
  fold	
  thickness	
  (body	
  fat),	
  pre-­‐albumin,	
  and	
   use	
   of	
   supplemental	
   feedings	
   via	
   NG	
   tube	
   or	
   G-­‐tube	
   will	
   be	
   used	
   to	
   assess	
   the	
  impact	
  of	
  treatment	
  on	
  nutritional	
  status	
  over	
  the	
  course	
  of	
  therapy.	
  5.3	
  Efficacy	
  Evaluations	
  • The	
  effect	
  of	
  prolonging	
  the	
  duration	
  of	
  the	
  HDMTX	
  infusion	
  to	
  12	
  h	
  will	
  be	
  assessed	
  by	
  comparing	
  urinary	
  biomarkers	
   of	
   AKI	
   and	
   serum	
  cystatin	
   C	
   and	
  creatinine	
  measured	
  prior	
  to,	
  24	
  h	
  and	
  7	
  days	
  after	
  the	
  start	
  of	
  each	
  HDMTX	
  infusion	
  (n=8).	
  All	
  subjects	
  will	
  receive	
  four	
  HDMTX	
  infusion	
  durations	
  of	
  4	
  h	
  and	
  four	
  HDMTX	
  infusion	
  durations	
  of	
  12	
  h	
  in	
  this	
  crossover	
  design,	
  and	
  subjects	
  will	
  serve	
  as	
  their	
  controls.	
  Measurement	
  of	
  the	
  urine	
  MTX	
  concentration	
  at	
  the	
  end	
  of	
  the	
  infusion	
  will	
  be	
  used	
  to	
  determine	
  whether	
  urinary	
  MTX	
  concentrations	
  exceed	
  the	
  solubility	
  limit	
  for	
  each	
  HDMTX	
  infusion.	
  • The	
  effect	
  of	
  IV	
  pantoprazole	
  on	
  cisplatin	
  nephrotoxicity	
  will	
  be	
  assessed	
  by	
  comparing	
  urinary	
  biomarkers	
  of	
  AKI,	
  FEMg	
  and	
  serum	
  cystatin	
  C	
  and	
  creatinine	
  measured	
  prior	
  to,	
  at	
  the	
  end	
  of	
  the	
  day	
  2	
  infusion,	
  and	
  on	
  day	
  7	
  each	
  cisplatin	
  course	
  (n=4).	
  All	
  subjects	
  will	
   receive	
   cisplatin	
   with	
   and	
   without	
   pantoprazole	
   in	
   this	
   crossover	
   design,	
   and	
  subjects	
  will,	
  therefore,	
  serve	
  as	
  their	
  controls.	
  • The	
   effect	
   of	
   IV	
   pantoprazole	
   on	
   cisplatin	
   ototoxicity	
   will	
   be	
   assessed	
   by	
   comparing	
  audiograms	
   performed	
   prior	
   to	
   each	
   cisplatin	
   infusion	
  and	
   at	
   the	
   end	
   of	
   therapy.	
   All	
  subjects	
   will	
   receive	
   cisplatin	
   with	
   and	
   without	
   pantoprazole	
   in	
   this	
   crossover	
   design,	
  and	
  subjects	
  will,	
  therefore,	
  serve	
  as	
  their	
  own	
  controls.	
  • Event-­‐free	
  and	
  overall	
  survival	
  will	
  be	
  monitored	
  but	
  are	
  not	
  scientific	
  objectives	
  on	
  this	
  trial.	
  An	
  event	
  is	
  defined	
  as	
  tumor	
  progression,	
  relapse	
  or	
  death	
  from	
  any	
  cause.	
  5.4	
  Safety	
  Evaluations	
  • More	
  than	
  90%	
  of	
  patients	
  receiving	
  MAP	
  chemotherapy	
  will	
  experience	
  severe	
  (CTCAE	
  grade	
  3	
  or	
  4)	
  acute	
  toxicity.	
  The	
  most	
  common	
  acute	
  toxicities	
  are	
  nausea	
  and	
  vomiting,	
  neutropenia,	
   thrombocytopenia,	
   fever/infection,	
  oral	
  mucositis,	
   and	
   hepatotoxicity	
  (elevated	
   serum	
   transaminases	
  and	
   bilirubin).14,16,23	
  Neutropenic	
   fever	
   or	
   infection	
  necessitates	
  hospital	
  admission	
  and	
  empirical	
  antibiotics.	
  • The	
  following	
  adverse	
  events	
  will	
  be	
  tracked	
  by	
  treatment	
  cycle:	
  o Nadir	
  neutrophil	
  count	
  and	
  duration	
  of	
  severe	
  (ANC	
  <500/mcL)	
  neutropenia	
  o Nadir	
  platelet	
  count	
  and	
  number	
  of	
  platelet	
  transfusions	
  o Hospital	
  admissions/days	
  for	
  neutropenia	
  with	
  fever	
  or	
  infection	
  o Highest	
  value	
  for	
  serum	
  ALT	
  and	
  total	
  bilirubin	
  o Grade	
  3	
  or	
  4	
  mucositis	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  26	
  o Treatment	
   delays	
   or	
   missed	
   chemotherapy	
   doses	
   to	
   allow	
   for	
   recovery	
   from	
  toxicity	
  o Dose	
  modifications	
  for	
  toxicity	
  o Deaths	
  attributed	
  to	
  chemotherapy	
  toxicity	
  • After	
   the	
   first	
   12	
   patients	
   have	
   completed	
   therapy,	
   the	
   incidence	
   and	
   severity	
   of	
   the	
  events	
   listed	
   above	
   as	
   well	
   as	
   the	
   nephrotoxicity	
   and	
   ototoxicity	
   endpoints	
   will	
   be	
  assessed	
  by	
  Cycle	
  according	
  to	
  HDMTX	
  infusion	
  duration	
  (4	
  h	
  vs.	
  12	
  h)	
  and	
  according	
  to	
  whether	
   or	
   not	
   IV	
   pantoprazole	
   was	
   administered	
   with	
   cisplatin	
   to	
   ensure	
   that	
   the	
  experimental	
  dosing	
  methods	
  are	
  not	
  associated	
  with	
  excessive	
  toxicity.	
  • After	
   the	
   first	
   12	
   patients	
   have	
   undergone	
   resection	
   of	
   their	
   primary	
   tumor,	
   the	
  radiographic	
  response	
  (log	
  ratio)	
  and	
  histologic	
  response	
  (%	
  necrosis)	
  will	
  be	
  assessed	
  according	
  to	
  HDMTX	
  infusion	
  duration	
  (4	
  h	
  vs.	
  12	
  h)	
  during	
  Cycles	
  1	
  &	
  2	
  and	
  according	
  to	
  whether	
  or	
  not	
  IV	
  pantoprazole	
  was	
  administered	
  with	
  cisplatin	
  during	
  Cycles	
  1	
  &	
  2	
  to	
  ensure	
   that	
   the	
   anti-­‐tumor	
   effect	
   of	
   the	
   MAP	
   chemotherapy	
   regimen	
   is	
   not	
  compromised	
  by	
  the	
  experimental	
  dosing	
  methods.	
  	
  6.	
  STATISTICAL	
  CONSIDERATIONS	
  This	
   is	
   a	
   pilot	
   study	
   to	
   evaluate	
   pharmacologically-­‐based	
   dosing	
   approaches	
   to	
   prevent	
   the	
  nephrotoxic	
   effects	
   of	
   HDMTX	
   and	
   cisplatin	
   and	
   ototoxic	
   effect	
   of	
   cisplatin	
   in	
   children,	
  adolescents	
   and	
   young	
   adults	
   with	
   osteosarcoma	
   treated	
   with	
   the	
  standard	
  MAP	
  chemotherapy	
  regimen.	
  Acute	
  biomarkers	
  of	
  AKI	
  (KIM-­‐1,	
  NAG,	
  NGAL)	
  and	
  renal	
  function	
  tests	
  (creatinine,	
  cystatin	
  C,	
  FEMg)	
  will	
  be	
  used	
  to	
  assess	
  the	
  incidence	
  and	
  severity	
  of	
  nephrotoxicity	
  after	
  each	
  course	
  of	
  cisplatin	
  (with	
  and	
  without	
  pantoprazole)	
  and	
  HDMTX	
  (infused	
  over	
  4	
  and	
  12	
  h),	
  and	
  audiograms	
  will	
  be	
  used	
  to	
  measure	
  hearing	
  loss	
  prior	
  to	
  cycles	
  1-­‐4	
  and	
  at	
  the	
  end	
  of	
  therapy.	
  A	
  2	
  x	
  2	
  factorial,	
  randomized	
  crossover	
  design	
  will	
  allow	
  patients	
  to	
  serve	
  as	
  their	
  own	
  control.	
  Nephrotoxicity	
   data	
  will	
   be	
   analyzed	
   by	
  course	
  for	
   cisplatin	
   and	
  by	
   dose	
   for	
  HDMTX,	
   and	
  ototoxicity	
   data	
  will	
   be	
   analyzed	
   by	
   treatment	
   cycle.	
  All	
   endpoints	
   will	
   be	
   analyzed	
   as	
  continuous	
  variables.	
  6.1	
  Statistical	
  Analysis	
  Plan	
  6.1.1	
  Primary	
  Endpoints	
  • Urinary	
   KIM-­‐1,	
   NAG	
   and	
   NGAL	
  will	
   be	
   normalized	
   to	
   the	
   urinary	
   creatinine	
  concentration	
  measured	
   in	
  the	
   same	
   urine	
   specimen	
  and	
   expressed	
  as	
   ng/mg	
   Cr.	
  The	
  end	
  of	
  infusion	
  and	
  7-­‐day	
  post	
  values	
  for	
  each	
  biomarker	
  will	
  be	
  analyzed	
  by	
  course	
  for	
  cisplatin	
  with	
  vs.	
  without	
  pantoprazole	
  and	
  by	
  dose	
  for	
  HDMTX	
  administered	
  as	
  a	
  4	
  h	
  vs.	
  12	
  h	
  infusion.	
  • GFR	
  will	
  be	
  estimated	
  from	
  serum	
  creatinine	
  and	
  from	
  the	
  cystatin	
  C	
  (see	
  Section	
  1.3.3)	
  prior	
  to	
  each	
  course	
  of	
  cisplatin	
  and	
  each	
  dose	
  of	
  HDMTX	
  and	
  7-­‐days	
  post	
  treatment.	
  A	
  decrease	
  in	
   the	
   GFR	
  will	
   reflect	
  toxicity	
   from	
   the	
   immediately	
   preceding	
   course	
   of	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  27	
  cisplatin	
  or	
  dose	
  of	
  HDMTX.	
  Change	
  in	
  GFR	
  will	
  be	
  analyzed	
  by	
  course	
  for	
  cisplatin	
  with	
  vs.	
  without	
  pantoprazole	
  and	
  by	
  dose	
  for	
  HDMTX	
  administered	
  as	
  a	
  4	
  h	
  vs.	
  12	
  h	
  infusion.	
  • Change	
  in	
  FEMg	
  from	
  pre-­‐dose	
  1	
  (day	
  1	
  of	
  cycles	
  1-­‐4)	
  of	
  cisplatin	
  to	
  pre-­‐dose	
  2	
  (day	
  2	
  of	
  cycles	
   1-­‐4)	
  of	
   cisplatin	
  and	
   day	
   7	
  will	
   be	
   measured	
   for	
   each	
  cycle	
   containing	
  cisplatin	
  (n=4).	
  Change	
   in	
   FEMg	
   will	
   be	
   analyzed	
   by	
  course	
  for	
   cisplatin	
   with	
   vs.	
   without	
  pantoprazole	
  to	
  assess	
  renal	
  tubular	
  toxicity.	
  • The	
  urinary	
  MTX	
  concentration	
  at	
  the	
  end	
  of	
  each	
  HDMTX	
  infusion	
  on	
  cycles	
  1-­‐4	
  will	
  be	
  tabulated	
  for	
  the	
  4	
  and	
  12	
  h	
  infusion	
  durations	
  and	
  compared	
  to	
  the	
  MTX	
  solubility	
  limit	
  for	
  the	
  urine	
  pH	
  to	
  determine	
  whether	
  the	
  solubility	
  limit	
  was	
  exceeded.	
  End	
  infusion	
  urine	
  MTX	
  concentration	
  will	
  also	
  be	
  correlated	
  with	
  simultaneous	
  serum	
  concentration	
  and	
   with	
   the	
   severity	
   of	
   renal	
   toxicity	
   as	
   measured	
   by	
   AKI	
   biomarkers	
   and	
   serum	
  creatinine	
  and	
  serum	
  cystatin	
  C.	
  • An	
  audiogram	
  will	
  be	
  performed	
  prior	
  to	
  Cycles	
  1,	
  2,	
  3	
  and	
  4	
  and	
  at	
  the	
  end	
  of	
  therapy	
  (after	
  cycle	
  6).	
  The	
  average	
  hearing	
  level	
  (HL)	
  threshold	
  in	
  dB	
  over	
  the	
  frequency	
  range	
  of	
   4,000-­‐8,000	
   Hz	
   will	
   be	
   derived	
   separately	
   for	
   each	
   ear	
  from	
   each	
   audiogram.	
  The	
  increase	
  in	
  the	
  average	
  HL	
  threshold	
  in	
  dB	
  from	
  the	
  pre-­‐cycle	
  1	
  to	
  pre-­‐cycle	
  2,	
  from	
  pre-­‐cycle	
  2	
  to	
  pre-­‐cycle	
  3,	
  from	
  pre-­‐cycle	
  3	
  to	
  pre-­‐cycle	
  4,	
  and	
  from	
  pre-­‐cycle	
  4	
  to	
  end	
  of	
  therapy	
  audiograms	
  will	
  be	
  derived	
  and	
  this	
  increase	
  in	
  HL	
  threshold	
  will	
  be	
  compared	
  for	
  cisplatin	
  with	
  vs.	
  without	
  pantoprazole.	
  For	
  each	
  primary	
  endpoint,	
  we	
  will	
  construct	
  separate	
  models	
  for	
  comparison	
  of	
  cisplatin	
  with	
   vs.	
   without	
   pantoprazole	
   and	
   for	
   comparison	
   of	
  the	
   4	
   vs.	
   12	
   h	
  infusion	
  durations	
   of	
  HDMTX.	
   Linear	
   mixed	
   effects	
   model	
   will	
   be	
   used	
   for	
   this	
   crossover	
   design,	
   including	
   all	
  repeated	
  measures	
  as	
  the	
  outcome,	
  order	
  type	
  and	
  period	
  number	
  as	
  the	
  fixed	
  effects,	
  and	
  a	
  subject	
  level	
  random	
  intercept	
  to	
  account	
  for	
  within-­‐subject	
  correlation	
  (or	
  unstructured	
  correlation	
   matrix	
   for	
   the	
   repeated	
   measures	
   if	
   needed).	
   Appropriate	
   contrasts	
   will	
   be	
  constructed	
  to	
  test	
  for	
  treatment	
  effect.	
  For	
  nephrotoxicity	
  outcomes	
  using	
  AKI	
  biomarkers,	
  little	
  carryover	
  effect	
  is	
  expected.	
  For	
  ototoxicity	
  outcomes,	
  carryover	
  effect	
  is	
  possible,	
  but	
  unlikely	
  to	
  be	
  differential	
  between	
  comparison	
  arms	
  because	
  we	
  randomized	
  the	
  order	
  of	
  treatment.	
  Nevertheless,	
  we	
  will	
  conduct	
  a	
  statistical	
  test	
  for	
  differential	
  carryover	
  effect,	
  acknowledging	
   limited	
   power	
   with	
   this	
   test.	
  If	
   differential	
   carryover	
  is	
   present	
  in	
   the	
  analysis	
  we	
  will	
  only	
  use	
  the	
  data	
  from	
  cycle	
  1.	
  6.1.2	
  Secondary	
  Endpoints	
  • Common	
  grade	
   ≥2	
  toxicities	
  from	
   cisplatin	
  +	
   doxorubicin	
  (other	
   than	
  cisplatin	
  nephrotoxicity	
   and	
   ototoxicity),	
  including	
  myelosuppression,	
   mucositis,	
   nausea	
   and	
  vomiting	
   leading	
   to	
   dehydration	
   requiring	
   IV	
   fluid	
   hydration,	
  peripheral	
   neuropathy,	
  cardiac	
  dysfunction,	
  and	
  treatment	
  delays	
  due	
  to	
  toxicity	
  will	
  be	
  collected	
  and	
  graded	
  according	
   to	
   CTCAE	
   v.4.	
   Similarly,	
   HDMTX-­‐related	
  grade	
   ≥2	
  toxicities	
   (other	
   than	
  nephrotoxicity),	
   including	
   myelosuppression,	
   mucositis,	
   dermatitis,	
  hepatotoxicity	
   and	
  neurotoxicity	
  will	
  be	
   collected	
   and	
   graded.	
   The	
   incidence	
   and	
   severity	
   (grade)	
   of	
  toxicities	
   will	
   be	
   tabulated	
   and	
   compared	
   by	
   treatment	
   arm	
   (with	
   vs.	
   without	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  28	
  pantoprazole	
  for	
  cisplatin	
  +	
  doxorubicin	
  and	
  by	
  infusion	
  duration	
  for	
  HDMTX).	
  • Response	
  to	
   2	
   cycles	
   of	
   neoadjuvant	
   chemotherapy	
   will	
   be	
   assessed	
   radiographically	
  and	
  histologically.	
  o The	
   volume	
   of	
   the	
   tumor	
   on	
   MRI	
   will	
   be	
   measured	
   pretreatment	
   and	
   pre-­‐operatively	
  (post-­‐cycle	
  2).	
  The	
  log	
  ratio	
  (Section	
  5.2)	
  of	
  the	
  two	
  measurements	
  will	
  be	
  derived	
  and	
  compared	
  using	
  a	
  non-­‐parametric	
  analysis	
  for	
  cisplatin	
  with	
  (patients	
  on	
  treatment	
  arms	
  1	
  and	
  3)	
  vs.	
  without	
  (patients	
  on	
  treatment	
  arms	
  2	
  and	
  4)	
  pantoprazole	
  and	
  for	
  HDMTX	
  administered	
  as	
  a	
  4	
  h	
  infusion	
  (treatment	
  arms	
  1	
  and	
  2)	
  vs.	
  a	
  12	
  h	
  infusion	
  (treatment	
  arms	
  3	
  and	
  4).	
  o The	
   tumor	
   specimen	
   that	
   is	
   removed	
   after	
   2	
   cycles	
   of	
   neoadjuvant	
  chemotherapy	
  will	
  be	
  evaluated	
  histologically	
  and	
  the	
  percent	
  of	
  the	
  tumor	
  that	
  is	
   necrotic	
   will	
   be	
   estimated	
   from	
   review	
   of	
   multiple	
   sections.	
   The	
   percent	
  necrosis	
   will	
   be	
   compared	
  using	
   a	
   non-­‐parametric	
   analysis	
   for	
   cisplatin	
   with	
  (patients	
  on	
  treatment	
  arms	
  1	
  and	
  3)	
  vs.	
  without	
  (patients	
  on	
  treatment	
  arms	
  2	
  and	
  4)	
  pantoprazole	
  and	
  for	
  HDMTX	
  administered	
  as	
  a	
  4	
  h	
  infusion	
  (treatment	
  arms	
  1	
  and	
  2)	
  vs.	
  a	
  12	
  h	
  infusion	
  (treatment	
  arms	
  3	
  and	
  4.).	
  • GFR	
  estimated	
   from	
   serum	
   creatinine	
   using	
   the	
   modified	
   Schwartz	
   formula	
   will	
   be	
  correlated	
  with	
  GFR	
  estimated	
  from	
  serum	
  cystatin	
  C	
  (Section	
  1.3.3,	
  the	
  equation	
  also	
  includes	
   serum	
   creatinine	
   and	
   BUN).	
  The	
   presence	
   and	
   amount	
   (normalized	
   to	
  creatinine	
   concentration)	
   of	
   biomarkers	
   of	
   AKI	
   in	
   urine	
   will	
   be	
   correlated	
   with	
  proteinuria,	
  serum	
  creatinine,	
  and	
  change	
  in	
  FEMg.	
  • BSAP	
  levels	
   will	
   be	
   correlated	
   with	
   tumor	
   volume	
   and	
   presence	
   or	
   absence	
   of	
  metastatic	
  disease	
  at	
  diagnosis.	
  BSAP	
  after	
  2	
  cycles	
  of	
  neoadjuvant	
  chemotherapy	
  will	
  be	
  correlated	
  with	
  tumor	
  volume	
  and	
  percent	
  tumor	
  necrosis	
  post-­‐cycle	
  2.	
  BSAP	
  drawn	
  post-­‐operatively,	
  at	
  the	
  end	
  of	
  therapy	
  and	
  at	
  the	
  time	
  of	
  relapse	
  will	
  be	
  correlated	
  with	
  disease	
  status.	
  • An	
   osteosarcoma-­‐specific	
  Patient	
   Reported	
   Outcome	
   survey	
  will	
   be	
  used	
  to	
   assess	
  disease-­‐related	
  and	
  treatment-­‐related	
  symptoms	
  and	
  tested	
  in	
  the	
  patients	
  enrolled	
  on	
  this	
   trial.	
   The	
   patient	
   reported	
   outcomes	
   will	
   be	
   compared	
   to	
   toxicity	
   data	
   collected	
  from	
  the	
  medical	
  record	
  and	
  to	
  physician	
  assessments	
  of	
  patient	
  status	
  (performance	
  score).	
  6.2	
  Sample	
  Size	
  and	
  Power	
  The	
   primary	
   endpoints	
   are	
   sensitive	
   urinary	
   biomarkers	
   of	
   AKI	
   and	
   audiograms,	
   and	
  all	
  endpoints	
  are	
  continuous	
  variables.	
  The	
  study	
  is	
  designed	
  to	
  detect	
  a	
  signal	
  sufficient	
  to	
  justify	
  a	
  randomized	
  trial	
  that	
  would	
  be	
  conducted	
  in	
  a	
  cooperative	
  group	
  setting.	
  Twenty-­‐four	
  patients	
  will	
  be	
  enrolled	
  and	
  data	
  will	
  be	
  analyzed	
  by	
  dose	
  or	
  treatment	
  cycle	
  with	
  patients	
  serving	
  as	
  their	
  own	
  control.	
  Over	
  the	
  past	
  5	
  years	
  57	
  newly	
  diagnosed	
  patients	
  with	
  osteosarcoma	
   were	
   seen	
   and	
   treated	
   at	
   CHOP.	
   This	
   is	
   an	
   average	
   of	
   11.5	
   patients	
   per	
   year,	
  indicating	
  that	
  we	
  can	
  complete	
  accrual	
  to	
  this	
  study	
  in	
  about	
  two	
  years.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  29	
  • For	
   the	
   analyses	
   of	
   nephrotoxicity	
   using	
   biomarker	
   endpoints	
   of	
   AKI	
   (Urinary	
   KIM-­‐1,	
  NAG	
  and	
  NGAL),	
  data	
  will	
  be	
  the	
  analyzed	
  by	
  course	
  or	
  by	
  dose.	
  Each	
  patient	
  will	
  have	
  2	
  courses	
  of	
   cisplatin	
   with	
   pantoprazole	
   and	
  2	
  courses	
  without	
   pantoprazole.	
  A	
   power	
  calculation	
   was	
   conducted	
   under	
   the	
   framework	
   of	
   a	
   multivariate	
   general	
   linear	
  hypothesis	
   for	
   general	
   linear	
   models,	
   using	
   the	
   Wilks	
   Lambda	
  test	
   with	
   a	
   significance	
  level	
  of	
  0.05.110,111	
  Because	
  the	
  comparison	
  will	
  be	
  within	
  subject,	
  a	
  larger	
  within-­‐subject	
  correlation	
   will	
   provide	
   greater	
   power	
   for	
   the	
   test.	
   Based	
   on	
   the	
   most	
   conservative	
  assumption	
   that	
   all	
   repeated	
   measures	
   are	
   independent,	
   we	
   will	
   have	
   80%	
   power	
   to	
  detect	
   a	
  0.60SD	
   difference	
   for	
   with	
   vs.	
   without	
   pantoprazole.	
   Assuming	
   a	
   moderate	
  correlation	
   of	
   0.5,	
   we	
   will	
   have	
   80%	
   power	
   to	
   detect	
   a	
   smaller	
   difference	
   of	
   0.42SD.	
  Variability	
   (SD)	
   for	
   these	
   biomarkers	
   in	
   children	
   with	
   AKI	
   are	
   not	
   available,	
   but	
   in	
   a	
  healthy	
  adult	
  population,112	
  the	
  mean	
  value	
  of	
  KIM-­‐1	
  was	
  0.228	
  with	
  a	
  SD	
  of	
  0.094,	
  so	
  assuming	
   a	
   similar	
   mean	
   and	
   SD	
   for	
   pediatric	
   patients,	
   we	
  will	
   have	
   80%	
   power	
   to	
  detect	
   a	
   0.056	
  difference	
   (about	
  25%	
   decrease)	
   in	
   the	
   mean	
   KIM-­‐1	
   value	
   with	
  pantoprazole,	
   assuming	
   independence	
   among	
   repeated	
   measures.	
   We	
   will	
   have	
   80%	
  power	
   to	
   detect	
   a	
   difference	
   of	
   0.039	
  (about	
   17%	
  decrease)	
   if	
   the	
   correlation	
  is	
  moderate	
  (e.g.	
  0.5).	
  	
  • For	
  comparison	
  of	
  HDMTX	
  infusion	
  durations,	
  each	
  patient	
  will	
  have	
  4	
  doses	
  with	
  4	
  h	
  infusion	
  duration	
  and	
  4	
  doses	
  with	
  12	
  h	
  infusion	
  duration.	
  Using	
  the	
  Wilks	
  Lambda	
  test	
  with	
  a	
  significance	
  level	
  of	
  0.05	
  under	
  the	
  framework	
  of	
  general	
  linear	
  models,	
  with	
  24	
  subjects	
  of	
  8	
  repeated	
  measures	
  (4	
  measures	
  with	
  4	
  h	
  duration	
  and	
  4	
  measures	
  with	
  12	
  h	
  duration),	
  we	
  will	
  have	
  80%	
  power	
  to	
  detect	
  a	
  0.42SD	
  difference	
  assuming	
  a	
  within-­‐subject	
  correlation	
  of	
  0,	
  and	
  will	
  detect	
  a	
  0.30SD	
  difference	
  assuming	
  a	
  correlation	
  of	
  0.5.	
  • For	
   the	
   analyses	
   of	
   ototoxicity	
   data	
   (hearing	
   level	
   thresholds	
   from	
   4	
   to	
   8	
   kHz	
   in	
   dB),	
  treatment	
   cycle	
   will	
   be	
   the	
   analysis	
   unit.	
   Each	
   patient	
   will	
   have	
   2	
   cycles	
   with	
  pantoprazole	
   and	
   2	
   cycles	
   without	
   pantoprazole.	
  Using	
   the	
   Wilks	
   Lambda	
  test	
   with	
   a	
  significance	
  level	
  of	
  0.05	
  under	
  the	
  framework	
  of	
  general	
  linear	
  models,	
  with	
  24	
  subjects	
  of	
   4	
   repeated	
   measures	
   (2	
   measures	
   with	
   and	
   2	
   measures	
   without	
   pantoprazole),	
   we	
  will	
  have	
  80%	
  power	
  to	
  detect	
  a	
  0.60SD	
  difference	
  assuming	
  a	
  within-­‐subject	
  correlation	
  of	
   0,	
   and	
   will	
   detect	
   a	
   0.42SD	
   difference	
   assuming	
   a	
   correlation	
   of	
   0.5.	
   	
   Moreover,	
   if	
  differential	
  carryover	
  is	
  present,	
  we	
  will	
  only	
  use	
  the	
  data	
  from	
  the	
  first	
  two	
  cycles,	
  so	
  that	
   the	
   comparison	
   will	
   be	
   between	
   subjects,	
   with	
   12	
   subjects	
   in	
   each	
   comparison	
  group.	
  We	
  will	
  then	
  have	
  80%	
  power	
  to	
  detect	
  a	
  1.2SD	
  difference,	
  based	
  on	
  a	
  two-­‐sided,	
  two-­‐sample	
  t	
  test	
  with	
  a	
  significance	
  level	
  of	
  0.05.	
  6.3	
  Interim	
  Analysis	
  The	
  sample	
  size	
  in	
  this	
  pilot	
  study	
  is	
  too	
  small	
  to	
  derive	
  a	
  statistically	
  valid	
  stopping	
  rule	
  with	
  sufficient	
   sensitivity.	
   However,	
   after	
   the	
   first	
   12	
   patients	
   have	
   completed	
   treatment,	
   the	
  investigators	
   will	
   evaluate	
   the	
   following	
   parameters	
  to	
   determine	
   whether	
   pantoprazole	
   or	
  prolonging	
  the	
  HDMTX	
  infusion	
  affect	
  toxicity	
  or	
  anti-­‐tumor	
  response	
  to	
  MAP:	
  • The	
   incidence	
   and	
   severity	
   (CTCAE	
   grade)	
  of	
   toxicities	
   will	
  be	
  compared	
  for	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  30	
  cisplatin/doxorubicin	
  with	
  vs.	
  without	
  pantoprazole	
  and	
  for	
  HDMTX	
  infused	
  over	
  4	
  h	
  vs.	
  12	
  h	
  within	
  and	
  across	
  patients.	
  • Radiographic	
  response	
  (log	
  ratio)	
  and	
  histological	
  response	
  (%	
  tumor	
  necrosis)	
  following	
  2	
   cycles	
   of	
   neoadjuvant	
   chemotherapy	
  will	
   be	
   compared	
   in	
   patients	
   who	
   received	
  pantoprazole	
   vs.	
   patients	
   who	
   did	
   not	
   receive	
   pantoprazole	
   and	
   in	
   patients	
   who	
  received	
  HDMTX	
  over	
  4	
  h	
  vs.	
  12	
  h.	
  If	
  the	
  toxicity	
  from	
   MAP	
  is	
   clinically	
   significantly	
   worse	
   when	
   cisplatin	
   is	
   administered	
   with	
  pantoprazole	
  or	
  when	
  HDMTX	
  is	
  infused	
  over	
  12	
  h	
  OR	
  if	
  radiographic	
  or	
  histological	
  response	
  to	
  neoadjuvant	
  chemotherapy	
  is	
  clinically	
  significantly	
  less	
  in	
  patients	
  receiving	
  pantoprazole	
  or	
  a	
  prolonged	
   HDMTX	
   infusion,	
  then	
   the	
   intervention	
   found	
   to	
   have	
   the	
   worse	
   outcome	
   will	
   be	
  discontinued.	
  7.	
  STUDY	
  MEDICATIONS	
  All	
  medications	
  prescribed	
  in	
  this	
  protocol	
  are	
  commercially	
  available.	
  The	
  MAP	
  chemotherapy	
  regimen,	
   which	
   includes	
   cisplatin,	
   doxorubicin	
   and	
   methotrexate,	
   is	
   the	
   standard	
   of	
   care	
   for	
  osteosarcoma,	
  and	
  the	
  doses,	
  routes	
  of	
  administration	
  and	
  schedules	
  are	
  also	
  standard,	
  except	
  for	
  the	
  alternative	
  infusion	
  duration	
  for	
  HDMTX.	
  Intravenous	
  pantoprazole	
  is	
  being	
  studied	
  to	
  determine	
   whether	
   co-­‐administration	
   with	
   cisplatin	
   can	
   selectively	
   prevent	
   cisplatin	
  nephrotoxicity	
  and	
  ototoxicity.	
  7.1	
  Intravenous	
  Pantoprazole	
  (PROTONIX	
  I.V.)	
  • IUPAC	
   Name:	
   (RS)-­‐6-­‐(Difluoromethoxy)-­‐2-­‐[(3,4-­‐dimethoxypyridin-­‐2-­‐yl)methylsulfinyl]-­‐1H-­‐benzo[d]imidazole	
  • Molecular	
  formula	
  &	
  weight:	
  C16H15F2N3O4S	
  -­‐	
  383.4	
  g/mol	
  (Fig	
  5,	
  chemical	
  structure)	
  • Manufacturer:	
  Pfizer	
  Injectables	
  (Distributed	
  by	
  Wyeth	
  Pharmaceuticals	
  Inc.)	
  • Drug	
  supply:	
  purchased	
  from	
  commercial	
  sources	
  • Indications:	
  gastroesophageal	
  reflux	
  associated	
  with	
  a	
  history	
  of	
  erosive	
  esophagitis	
  and	
  pathological	
  hypersecretory	
  conditions	
  (e.g.,	
  Zollinger-­‐Ellison	
  syndrome)	
  • Dosage	
   forms	
   and	
   strength:	
  supplied	
   in	
   a	
   vial	
   containing	
   40	
   mg	
   of	
   pantoprazole	
   as	
   a	
  freeze	
  dried	
  powder	
  • Storage	
   and	
   Handling:	
  store	
   vials	
   at	
   20-­‐25°C	
   (USP	
   controlled	
   room	
   temperature);	
  excursions	
  permitted	
  to	
  15-­‐30°C.	
  • Dosing	
   (Section	
   3.1.3):	
   0.3	
  mg/kg	
   IV	
   over	
   15	
   min	
   immediately	
   prior	
   to	
   each	
   dose	
   of	
  cisplatin	
  as	
  a	
  loading	
  dose	
  followed	
  by	
  1.3	
  mg/kg	
  IV	
  infused	
  over	
  4	
  h	
  concurrent	
  with	
  each	
   4	
   h	
   cisplatin	
   infusion	
   on	
   either	
   Cycles	
   1	
   &	
   2	
   OR	
   Cycles	
   3	
   &	
   4	
   depending	
   on	
   the	
  treatment	
   arm.	
   See	
   Section	
   1.3.8	
   for	
   the	
   rationale	
   for	
   pantoprazole	
   administration	
  schedule.	
  • Compatibility:	
  the	
   compatibility	
   of	
   the	
   cisplatin	
   and	
   pantoprazole	
   drugs	
   solutions	
  was	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  31	
  tested	
  at	
   UPenn	
   by	
   Dr.	
   Suzanne	
   Wehrli,	
   and	
  at	
   the	
   concentrations	
   used	
   for	
   drug	
  administration,	
   there	
   was	
   no	
   evidence	
   of	
   an	
   interaction	
  –	
  indicating	
   that	
  the	
  pantoprazole	
  solution	
  can	
  be	
  infused	
  into	
  the	
  same	
  intravenous	
  tubing	
  through	
  which	
  the	
  cisplatin	
  is	
  being	
  infused.	
  • Clinical	
   pharmacology:	
  see	
   Section	
   1.3.5	
   for	
   pediatric	
   pharmacokinetic	
   data	
   and	
  tolerability	
  of	
  single	
  doses	
  in	
  children	
  • Adverse	
  reactions:	
  reactions	
  reported	
  in	
  clinical	
  trials	
  in	
  adults	
  (n=1473)	
  with	
  GERD	
  at	
  a	
  frequency	
  >2%	
  included	
  headache	
  (12%),	
  diarrhea	
  (8.8%),	
  nausea	
  (7%),	
  abdominal	
  pain	
  (6.2%),	
  vomiting	
  (4.3%),	
  flatulence	
  (3.9%),	
  dizziness	
  (3%),	
  arthralgia	
  (2.8%).	
  The	
  use	
  of	
  PPIs	
  is	
  associated	
  with	
  a	
  moderately	
  increased	
  risk	
  of	
  C.	
  difficile	
  colitis.113,114	
  • Drug	
   accountability:	
  a	
  separate	
  drug	
  supply	
  will	
  be	
  purchased	
  for	
  this	
  study	
  using	
  the	
  research	
  funds,	
  and	
  NCI	
  DARFs	
  will	
  be	
  used	
  to	
  track	
  drug	
  supply.	
  • IND	
   status:	
  this	
   pilot	
   study	
   will	
   evaluate	
   pantoprazole	
   for	
   a	
   non-­‐approved	
   indication.	
  The	
  use	
  of	
  pantoprazole	
  in	
  this	
  study	
  meets	
  the	
  five	
  criteria	
  for	
  IND	
  exempt	
  status:	
  o The	
   study	
   is	
  not	
   intended	
   to	
   support	
   FDA	
   approval	
   of	
   a	
   new	
   indication	
   or	
   a	
  significant	
  change	
  in	
  the	
  product	
  labeling	
  o The	
  study	
  is	
  not	
  intended	
  to	
  support	
  a	
  significant	
  change	
  in	
  the	
  advertising	
  for	
  the	
  product	
  o The	
  investigation	
  does	
  not	
  involve	
  a	
  route	
  of	
  administration	
  or	
  dosage	
  level	
  or	
  use	
  in	
  a	
  patient	
  population	
  or	
  other	
  factor	
  that	
  significantly	
  increases	
  the	
  risk	
  (or	
  decreases	
   the	
   acceptability	
   of	
   the	
   risks)	
   associated	
   with	
   the	
   use	
   of	
   the	
   drug	
  product	
  o The	
  study	
  is	
  conducted	
  in	
  compliance	
  with	
  institutional	
  review	
  board	
  (IRB)	
  and	
  informed	
  consent	
  regulations	
  set	
  forth	
  in	
  21	
  CFR	
  parts	
  56	
  and	
  50	
  o The	
  study	
  is	
  conducted	
  in	
  compliance	
  with	
  §	
  312.7	
  (promotion	
  and	
  charging	
  for	
  investigational	
  drugs)	
  8.	
  SAFETY	
  MANAGEMENT	
  Patients	
   with	
   osteosarcoma	
  that	
   will	
  be	
   treated	
   with	
   surgery	
   (or	
   radiation	
   if	
   surgery	
   is	
   not	
  feasible)	
  and	
  a	
  standard	
  3-­‐drug	
  MAP	
  chemotherapy	
  will	
  be	
  enrolled	
  on	
  this	
  pilot	
  trial	
  to	
  assess	
  two	
   interventions	
   designed	
   to	
   reduce	
   the	
   nephrotoxicity	
   and	
   ototoxicity	
  from	
   cisplatin	
   and	
  HDMTX.	
  The	
   primary	
   endpoints	
   on	
   this	
   trial	
   will	
   monitor	
   the	
   incidence	
   and	
   severity	
   of	
   these	
  known	
   toxicities.	
  Secondary	
   endpoints	
   include	
   monitoring	
   the	
   overall	
   toxicity	
   of	
   the	
   regimen	
  and	
  response	
  to	
  neoadjuvant	
  chemotherapy	
  to	
  determine	
  whether	
  the	
  interventions	
  increase	
  the	
  incidence	
  or	
  severity	
  of	
  the	
  other	
  expected	
  toxicities	
  of	
  the	
  regimen	
  or	
  alter	
  the	
  response	
  to	
  neoadjuvant	
  treatment.	
  Toxicities	
  of	
  the	
  regimen	
  will	
  be	
  categorized	
  and	
  graded	
  according	
  to	
  the	
  standard	
  NCI	
  CTCAE	
  v.4	
  toxicity	
  criteria.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  32	
  8.1	
  Clinical	
  adverse	
  events	
  In	
  addition	
  to	
  nephrotoxicity	
  and	
  ototoxicity,	
  the	
  MAP	
  chemotherapy	
  regimen	
  is	
  expected	
  to	
  cause	
   substantial	
   toxicity	
   in	
   all	
   patients	
   undergoing	
   treatment	
   for	
   osteosarcoma,	
   including	
  myelosuppression,	
  febrile	
  neutropenia	
  and	
  infection,	
  nausea	
  and	
  vomiting,	
  mucositis,	
  anorexia,	
  weight	
  loss,	
  fatigue,	
  hepatotoxicity,	
  and	
  neurotoxicity.	
  Clinical	
  adverse	
  events	
  (AEs)	
  related	
  to	
  the	
  research	
  interventions,	
  which	
  are	
  administration	
  of	
  pantoprazole	
  with	
  cisplatin	
  and	
  prolonging	
  the	
  infusion	
  duration	
  of	
  HDMTX,	
  will	
  be	
  monitored	
  throughout	
  this	
  study.	
  	
  8.2	
  Adverse	
  Event	
  Reporting	
  SAEs	
  will	
  be	
  promptly	
  reported	
  to	
  the	
  IRB	
  in	
  accordance	
  with	
  CHOP	
  IRB	
  policies.	
  AEs	
  that	
  are	
  not	
   serious	
   but	
   that	
   might	
   involve	
   risks	
   to	
   subjects	
   will	
   be	
   summarized	
   in	
   narrative	
   or	
   other	
  format	
  and	
  submitted	
  to	
  the	
  IRB	
  at	
  the	
  time	
  of	
  continuing	
  review.	
  8.3	
  Definition	
  of	
  an	
  Adverse	
  Event	
  An	
   adverse	
   event	
   is	
   any	
   untoward	
   medical	
   occurrence	
   in	
   a	
   subject	
   who	
   has	
   received	
   an	
  intervention	
  (drug,	
  biologic,	
  or	
  other	
  intervention).	
  The	
  occurrence	
  does	
  not	
  necessarily	
  have	
  to	
  have	
   a	
   causal	
   relationship	
   with	
   the	
   treatment.	
  An	
   AE	
   can	
   therefore	
   be	
   any	
   unfavorable	
   or	
  unintended	
  sign	
  (including	
  an	
  abnormal	
  laboratory	
  finding,	
  for	
  example),	
  symptom,	
  or	
  disease	
  temporally	
  associated	
  with	
  the	
  use	
  of	
  a	
  medicinal	
  product,	
  whether	
  or	
  not	
  considered	
  related	
  to	
  the	
  medicinal	
  product.	
  AEs	
  (including	
  SAEs)	
  that	
  are	
  grade	
  ≥2	
  in	
  severity	
  and	
  related	
  to	
  the	
  treatment	
  will	
  be	
  collected	
  in	
  an	
   eCRF	
  in	
   OnCore	
  including	
  CTCAE	
   category,	
  grade,	
  date	
   of	
   onset,	
   duration,	
  attribution	
  (causality),	
  and	
  outcome	
  of	
  the	
  event	
  (resolution).	
  8.4	
  Definition	
  of	
  a	
  Serious	
  Adverse	
  Event	
  (SAE)	
  An	
  SAE	
  is	
  any	
  adverse	
  drug	
  experience	
  occurring	
  at	
  any	
  dose	
  that	
  results	
  in	
  any	
  of	
  the	
  following	
  outcomes:	
  	
  • death,	
  • a	
  life-­‐threatening	
  event	
  (at	
  risk	
  of	
  death	
  at	
  the	
  time	
  of	
  the	
  event),	
  	
  • requires	
  inpatient	
  hospitalization	
  or	
  prolongation	
  of	
  existing	
  hospitalization,	
  • a	
  persistent	
  or	
  significant	
  disability/incapacity,	
  or	
  • a	
  congenital	
  anomaly/birth	
  defect	
  in	
  the	
  offspring	
  of	
  a	
  subject.	
  	
  	
  Important	
   medical	
   events	
   that	
   may	
   not	
   result	
   in	
   death,	
   be	
   life-­‐threatening,	
   or	
   require	
  hospitalization	
  may	
  be	
  considered	
  a	
  serious	
  adverse	
  drug	
  event	
  when,	
  based	
  upon	
  appropriate	
  medical	
   judgment,	
   they	
   may	
   jeopardize	
   the	
   subject	
   and	
   may	
   require	
   medical	
   or	
   surgical	
  intervention	
  to	
  prevent	
  one	
  of	
  the	
  outcomes	
  listed	
  in	
  this	
  definition.	
  A	
  distinction	
  should	
  be	
  drawn	
  between	
  serious	
  and	
  severe	
  AEs.	
  A	
  severe	
  AE	
  is	
  a	
  major	
  event	
  of	
  its	
  type.	
  A	
  severe	
  AE	
  does	
  not	
  necessarily	
  need	
  to	
  be	
  considered	
  serious.	
  For	
  example,	
  nausea	
  that	
  persists	
  for	
  several	
  hours	
  may	
  be	
  considered	
  severe	
  nausea,	
  but	
  would	
  not	
  be	
  an	
  SAE.	
  On	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  33	
  the	
  other	
  hand,	
  a	
  stroke	
  that	
  results	
  in	
  only	
  a	
  limited	
  degree	
  of	
  disability	
  may	
  be	
  considered	
  a	
  mild	
  stroke,	
  but	
  would	
  be	
  an	
  SAE.	
  	
  8.4.1	
  Relationship	
  of	
  SAE	
  to	
  study	
  drug	
  or	
  other	
  intervention	
  or	
  procedure	
  The	
  relationship	
  of	
  each	
  SAE	
  to	
  the	
  study	
  intervention	
  will	
  be	
  characterized	
  using	
  one	
  of	
  the	
  following	
   terms	
   in	
   accordance	
   with	
   CHOP	
   IRB	
   Guidelines:	
   definitely,	
   probably,	
   possibly,	
  unlikely	
  or	
  unrelated.	
  	
  8.4.2	
  IRB/IEC	
  Notification	
  of	
  SAEs	
  The	
  IRB	
  will	
  be	
  promptly	
  notified	
  of	
  all	
  on-­‐site	
  AEs	
  that	
  are	
  (1)	
  serious,	
  (2)	
  unexpected	
  and	
  (3)	
   related	
   to	
   the	
   research	
   procedures.	
   Other	
  unanticipated	
   problems	
   involving	
   risk	
   to	
  subjects	
   or	
   others	
  will	
   also	
   be	
   reported	
   promptly	
  using	
   the	
   CHOP	
   Internal	
   SAE	
   reporting	
  form	
  and	
  in	
  accordance	
  with	
  the	
  following	
  timeline.	
  	
  Type	
  of	
  Internal	
  Adverse	
  Event	
  Initial	
  Notification	
  (Phone,	
  Email,	
  Fax)	
  Written	
  Report	
  Internal	
  (on-­‐site)	
  SAEs	
  	
  Death	
  or	
  Life	
  Threatening	
  	
  24	
  hours	
  Within	
  2	
  calendar	
  days	
  Internal	
  (on-­‐site)	
  SAEs	
  	
  All	
  other	
  SAEs	
  7	
  days	
  Within	
  7	
  business	
  days	
  Unanticipated	
  Problems	
  Related	
  to	
  Research	
  7	
  days	
  	
  Within	
  7	
  business	
  days	
  All	
  other	
  AEs	
  N/A	
  Summary	
   of	
   AEs	
   Reported	
   at	
  Time	
  of	
  Continuing	
  Review	
  8.4.3	
  Follow-­‐up	
  report	
  If	
  an	
  SAE	
  has	
  not	
  resolved	
  at	
  the	
  time	
  of	
  the	
  initial	
  report,	
  a	
  follow-­‐up	
  report	
  including	
  all	
  relevant	
  new	
   or	
   reassessed	
   information	
   (e.g.,	
   concomitant	
   medication,	
   medical	
   history)	
  should	
  be	
  submitted	
  to	
  the	
  IRB.	
  All	
  SAE	
  should	
  be	
  followed	
  until	
  either	
  resolved	
  or	
  stable.	
  	
  9.	
  STUDY	
  ADMINISTRATION	
  9.1	
  Data	
  collection	
  and	
  management	
  9.1.1	
  Confidentiality	
  Demographic	
   data	
   including	
   each	
   patient’s	
   name,	
   MRN,	
   DOB,	
   and	
   a	
   unique	
   patient	
   study	
  number	
   is	
   entered	
   and	
   stored	
   in	
   Oncore	
  CRM	
  (Forte	
   Research),	
   the	
   CCCR’s	
   clinical	
   trial	
  management	
   system.	
   Data	
   regarding	
   markers	
   of	
   Acute	
   Kidney	
   Injury	
   (Cystatin-­‐C,	
   KIM-­‐1,	
  NGAL,	
   NAG)	
   will	
   be	
   collected	
   using	
   secure	
  OnCore	
  electronic	
   case	
   report	
  forms	
  (eCRFs).	
  Results	
   of	
   standard	
   renal	
   function	
   tests,	
   audiograms,	
   bone-­‐specific	
   alkaline	
   phosphatase	
  assays,	
  nutritional	
  assessments,	
  and	
  response	
  assessments	
  (radiographic	
  and	
  histologic)	
  as	
  well	
  as	
  toxicity	
  data	
  will	
  also	
  be	
  entered	
  into	
  Oncore	
  eCRFs.	
  Patient	
  related	
  outcomes	
  forms	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  34	
  completed	
  by	
  a	
  parent	
  will	
  be	
  stored	
  in	
  a	
  locked	
  file	
  cabinet	
  in	
  the	
  CTRB.	
  These	
  forms	
  will	
  have	
  patient	
  identifiers	
  (name,	
  DOB,	
  MRN).	
  9.1.2	
  Security	
  OnCore	
   is	
  maintained	
  on	
   a	
  Research	
   IS	
  server	
   that	
   is	
  password	
   protected	
   and	
   backed	
   up	
  frequently.	
  File	
  cabinets	
  in	
  CTRB	
  with	
  paper	
  forms	
  will	
  be	
  kept	
  locked.	
  9.1.3	
  Anonymization,	
  de-­‐identification,	
  or	
  destruction	
  The	
  PHI	
  in	
  OnCore	
  will	
  be	
  kept	
  indefinitely.	
  	
  9.2	
  Confidentiality	
  All	
  data	
  and	
  records	
  generated	
  during	
  this	
  study	
  will	
  be	
  kept	
  confidential	
  in	
  accordance	
  with	
  CHOP	
   Institutional	
   policies	
   and	
   HIPAA	
   on	
   subject	
   privacy	
   and	
   the	
   Investigator	
   and	
   other	
   site	
  personnel	
  will	
  not	
  use	
  the	
  data	
  and	
  records	
  for	
  any	
  purpose	
  other	
  than	
  conducting	
  the	
  study.	
  Records	
   with	
   identifiers	
   will	
   be	
   retained	
  indefinitely	
  in	
   a	
   secure,	
   password	
   protected	
  commercial	
  clinical	
  trial	
  management	
  system	
  (OnCore).	
  	
  Safeguards	
   to	
   maintain	
   subject	
   confidentiality	
   are	
   described	
   under	
   Data	
  Collection	
   and	
  Management	
  (Section	
  9.1).	
  9.3	
  Regulatory	
  and	
  ethical	
  considerations	
  9.3.1	
  Data	
  safety	
  and	
  monitoring	
  plan	
  The	
  research	
  team	
  led	
  by	
  the	
  protocol	
  PI	
  will	
  monitor	
  adverse	
  events	
  related	
  to	
  the	
  protocol	
  therapy	
  in	
  real	
  time.	
  The	
  progress	
  of	
  every	
  patient	
  actively	
  receiving	
  treatment	
  on	
  this	
  study	
  will	
  be	
  discussed	
  weekly	
  in	
  the	
  Solid	
  Tumor	
  Team	
  Meeting.	
  An	
  interim	
  analysis	
  to	
  assess	
  the	
  safety	
   of	
   the	
   interventions	
   will	
   be	
   performed	
   after	
   the	
   first	
   12	
   patients	
   have	
   completed	
  therapy.	
  9.3.2	
  Risk	
  assessment	
  There	
  is	
  risk	
  associated	
  with	
  the	
  addition	
  of	
  pantoprazole	
  to	
  cisplatin	
  therapy,	
  however	
  PPIs	
  are	
  widely	
  used	
  in	
  pediatric	
  medicine	
  and	
  there	
  is	
  substantial	
  experience	
  with	
  the	
  toxicities	
  associated	
  with	
  these	
  agents	
  (Section	
  7.1,	
  Adverse	
  Events).	
  Single	
  IV	
  doses	
  of	
  pantoprazole	
  are	
  very	
  well	
  tolerated	
  in	
  children.	
  An	
  association	
  between	
  the	
  use	
  of	
  PPIs	
  and	
  C.	
  difficile	
  colitis	
  was	
  recently	
  reported,	
  but	
  the	
  use	
  of	
  pantoprazole	
  in	
  this	
  study	
  is	
  limited	
  to	
  4	
  doses.	
  The	
   use	
   of	
   cisplatin	
   and	
   pantoprazole	
   together	
   has	
   not	
   been	
   studied	
   in	
   children.	
   As	
  described	
   in	
   the	
   background,	
   we	
   do	
   not	
   expect	
   pantoprazole	
   to	
   alter	
   the	
  excretion	
   of	
  cisplatin.	
  PPIs	
  are	
  frequently	
  administered	
  chronically	
  to	
  patients	
  receiving	
  chemotherapy	
  for	
   symptoms	
   of	
   reflux.	
   The	
   risk	
   associated	
   with	
   administration	
   of	
   pantoprazole	
   with	
  cisplatin	
  must	
  be	
  considered	
  greater	
  than	
  minimal.	
  	
  Prolonging	
   the	
   infusion	
   duration	
   may	
   alter	
   the	
   toxicity	
  profile	
  of	
  HDMTX	
   because	
   the	
  pharmacologic	
   effect	
   of	
   MTX	
   is	
   determined	
   by	
   the	
   duration	
   of	
   exposure	
   to	
   the	
   drug.	
  Leucovorin	
   rescue	
   will	
   start	
   24	
   h	
   after	
   the	
   start	
   of	
   the	
   HDMTX	
   infusion	
   for	
  both	
  infusion	
  durations.	
   The	
   PK	
   simulations	
   (Figure	
   4)	
   show	
   that	
   plasma	
   concentrations	
   at	
   later	
   time	
  points	
   are	
   similar	
   for	
   the	
  two	
  infusion	
   durations.	
  There	
   is	
  considerable	
   experience	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  35	
  demonstrating	
  tolerability	
  of	
  HDMTX	
  in	
  children	
  with	
  leukemia	
  treated	
  with	
  higher	
  doses	
  of	
  MTX	
   (e.g.,	
   33	
   g/m2)	
   administered	
   as	
   prolonged	
   infusions	
   with	
   leucovorin	
   rescue.	
  Administration	
   of	
  12	
   g/m2	
  HDMTX	
  infused	
   over	
   12	
   h	
  instead	
   of	
  4	
   h	
  must	
   be	
   considered	
  greater	
  than	
  minimal	
  risk.	
  9.3.3	
  Potential	
  benefits	
  of	
  trial	
  participation	
  The	
   crossover	
   design	
   ensures	
   all	
   patients	
   will	
   receive	
   pantoprazole	
   and	
   the	
   prolonged	
  infusions	
   of	
   HDMTX.	
  Therefore,	
   all	
   patients	
   have	
  the	
   potential	
   for	
  direct	
   benefit	
   from	
  participation	
  in	
  this	
  study.	
  	
  Pantoprazole	
  may	
  mitigate	
  the	
  nephrotoxicity	
  and	
  hearing	
  loss	
  associated	
  with	
  cisplatin	
  exposure.	
  Prolonged	
  administration	
  of	
  methotrexate	
  may	
  decrease	
  the	
  risk	
  of	
  acute	
  kidney	
  injury	
  in	
  patients	
  receiving	
  this	
  agent.	
  In	
  addition	
  results	
  from	
  this	
  study	
   could	
   benefit	
   future	
   patients	
  with	
   osteosarcoma	
  and	
   other	
   cancers	
   treated	
   with	
  cisplatin	
   and	
   HDMTX	
  if	
  these	
  more	
   rational	
   dosing	
   methods	
  and	
  sensitive	
  biomarkers	
   of	
  toxicity	
  and	
  response	
  prove	
  to	
  be	
  better.	
  	
  9.3.4	
  Risk-­‐benefit	
  assessment	
  This	
   study	
   is	
  associated	
   with	
   greater	
   than	
   minimal	
   risk,	
   however	
   there	
   is	
   the	
  prospect	
   of	
  direct	
  benefit	
  to	
  the	
  subjects.	
  The	
  results	
  of	
  this	
  study	
  may	
  provide	
  pilot	
  data	
  for	
  a	
  larger	
  definitive	
  clinical	
  trial.	
  There	
  is	
  the	
  potential	
  that	
  such	
  a	
  study	
  may	
  result	
  in	
  adoption	
  of	
  new	
  and	
  safer	
   dosing	
   administration	
   schedules	
  and	
   modifications	
   of	
   supportive	
   care	
  recommendations	
  for	
  children	
  receiving	
  methotrexate	
  and	
  cisplatin	
  for	
  osteosarcoma	
  and	
  other	
   cancer	
   types.	
   As	
   a	
   result,	
  this	
  study	
   and	
   a	
   potential	
   successor	
   study	
  may	
   benefit	
  children	
  who	
  receive	
  these	
  agents	
  in	
  the	
  future.	
  9.4	
  Recruitment	
  strategy	
  Potential	
  subjects	
  are	
  identified	
  from	
  the	
  list	
  of	
  children	
  undergoing	
  evaluation	
  of	
  a	
  suspected	
  primary	
  bone	
  tumor.	
  Investigators	
  will	
  ask	
  each	
  potential	
  subject’s	
  primary	
  physician	
  at	
  CHOP	
  whether	
  the	
  subject	
  is	
  appropriate	
  for	
  this	
  study,	
  and,	
  if	
  so,	
  the	
  PI	
  or	
  a	
  Co-­‐I	
  will	
  meet	
  with	
  the	
  family	
  after	
  the	
  diagnosis	
  of	
  osteosarcoma	
  is	
  confirmed	
  but	
  prior	
  to	
  the	
  initiation	
  of	
  therapy.	
  The	
   PI	
   or	
   a	
   Co-­‐I	
   will	
  discuss	
   the	
   study	
  and	
   obtain	
   informed	
   consent	
   if	
  a	
   potential	
   subject	
   is	
  willing	
  to	
  participate.	
  	
  9.5	
  Informed	
  consent/assent	
  The	
  protocol	
  PI	
  or	
  a	
  co-­‐investigator	
  will	
  discuss	
  participation	
  in	
  the	
  study	
  with	
  each	
  potential	
  subject	
  or	
  the	
  parents	
  or	
  legal	
  guardian	
  of	
  each	
  potential	
  subject.	
  Written	
  informed	
  consent	
  will	
  be	
  obtained.	
  The	
  discussion	
  will	
  take	
  place	
  in	
  a	
  private	
  room	
  in	
  the	
  Oncology	
  clinic	
  or	
  in	
  the	
  patient’s	
  room	
  on	
  the	
  inpatient	
  unit.	
  	
  The	
  family	
  (and	
  patient)	
  are	
  allowed	
  time	
  to	
  ask	
  questions	
  and	
   to	
   read	
   the	
   informed	
   consent	
   form	
   before	
   signing.	
  Participation	
   in	
   this	
   study	
   is	
   entirely	
  voluntary	
  and	
  has	
  no	
  influence	
  on	
  whether	
  the	
  potential	
  subject	
  will	
  receive	
  clinical	
  treatment	
  for	
   osteosarcoma	
   at	
   CHOP.	
  The	
   consent	
   process	
  will	
   be	
  documented	
   in	
   a	
   brief	
   note	
   in	
   the	
  subject’s	
   medical	
   record	
   and	
   by	
   the	
   signed	
   informed	
   consent	
   document.	
  Assent	
   will	
   be	
  obtained	
  in	
  the	
  presence	
  of	
  the	
  potential	
  minor	
  subject’s	
  parents/guardian	
  when	
  appropriate	
  based	
   on	
   the	
   age	
   and	
   level	
   of	
   maturity	
   and	
   understanding	
   of	
   the	
   subject.	
   Assent	
   will	
   be	
  documented	
  on	
  the	
  consent	
  form.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  36	
  9.6	
  Payments	
  to	
  subjects/families	
  Subjects	
  and	
  families	
  will	
  not	
  receive	
  payments	
  for	
  participation	
  in	
  this	
  trial.	
  10.	
  	
  PUBLICATION	
  This	
   is	
   a	
   single	
   Institution	
   pilot	
   study	
  and	
   measurement	
   of	
   the	
   endpoints	
   for	
   the	
   primary	
  objectives	
  will	
  be	
  completed	
  when	
  the	
  treatment	
  is	
  completed.	
  The	
  team	
  of	
  CHOP	
  Investigators	
  plan	
  to	
  publish	
  the	
  results	
  separately	
  for	
  the	
  effect	
  of	
  prolonging	
  the	
  HDMTX	
  infusion	
  duration	
  on	
   MTX	
   nephrotoxicity	
   and	
   the	
   effect	
   of	
   IV	
   pantoprazole	
   on	
   cisplatin	
   nephrotoxicity	
   and	
  ototoxicity.	
  11.	
  REFERENCES	
  1.	
  Nies	
  AT,	
  Hofmann	
  U,	
  Resch	
  C,	
  Schaeffeler	
  E,	
  Rius	
  M,	
  Schwab	
  M.	
  Proton	
  pump	
  inhibitors	
  inhibit	
  metformin	
  uptake	
  by	
  organic	
  cation	
  transporters	
  (OCTs).	
  PloS	
  one	
  2011;6:e22163.	
  2.	
  Anninga	
  JK,	
  Gelderblom	
  H,	
  Fiocco	
  M,	
  et	
  al.	
  Chemotherapeutic	
  adjuvant	
  treatment	
  for	
  osteosarcoma:	
  where	
  do	
  we	
  stand?	
  European	
  journal	
  of	
  cancer	
  2011;47:2431-­‐45.	
  3.	
  Kearns	
  GL,	
  Blumer	
  J,	
  Schexnayder	
  S,	
  et	
  al.	
  Single-­‐dose	
  pharmacokinetics	
  of	
  oral	
  and	
  intravenous	
  pantoprazole	
  in	
  children	
  and	
  adolescents.	
  Journal	
  of	
  clinical	
  pharmacology	
  2008;48:1356-­‐65.	
  4.	
  Sleijfer	
  DT,	
  Offerman	
  JJ,	
  Mulder	
  NH,	
  et	
  al.	
  The	
  protective	
  potential	
  of	
  the	
  combination	
  of	
  verapamil	
  and	
  cimetidine	
  on	
  cisplatin-­‐induced	
  nephrotoxicity	
  in	
  man.	
  Cancer	
  1987;60:2823-­‐8.	
  5.	
  Graf	
  N,	
  Winkler	
  K,	
  Betlemovic	
  M,	
  Fuchs	
  N,	
  Bode	
  U.	
  Methotrexate	
  pharmacokinetics	
  and	
  prognosis	
  in	
  osteosarcoma.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  1994;12:1443-­‐51.	
  6.	
  Jacobs	
  SA,	
  Stoller	
  RG,	
  Chabner	
  BA,	
  Johns	
  DG.	
  7-­‐Hydroxymethotrexate	
  as	
  a	
  urinary	
  metabolite	
  in	
  human	
  subjects	
  and	
  rhesus	
  monkeys	
  receiving	
  high	
  dose	
  methotrexate.	
  The	
  Journal	
  of	
  clinical	
  investigation	
  1976;57:534-­‐8.	
  7.	
  Link	
  MP,	
  Goorin	
  AM,	
  Miser	
  AW,	
  et	
  al.	
  The	
  effect	
  of	
  adjuvant	
  chemotherapy	
  on	
  relapse-­‐free	
  survival	
  in	
  patients	
  with	
  osteosarcoma	
  of	
  the	
  extremity.	
  The	
  New	
  England	
  journal	
  of	
  medicine	
  1986;314:1600-­‐6.	
  8.	
  Magnani	
  C,	
  Pastore	
  G,	
  Coebergh	
  JW,	
  Viscomi	
  S,	
  Spix	
  C,	
  Steliarova-­‐Foucher	
  E.	
  Trends	
  in	
  survival	
  after	
  childhood	
  cancer	
  in	
  Europe,	
  1978-­‐1997:	
  report	
  from	
  the	
  Automated	
  Childhood	
  Cancer	
  Information	
  System	
  project	
  (ACCIS).	
  European	
  journal	
  of	
  cancer	
  2006;42:1981-­‐2005.	
  9.	
  Stiller	
  CA,	
  Passmore	
  SJ,	
  Kroll	
  ME,	
  Brownbill	
  PA,	
  Wallis	
  JC,	
  Craft	
  AW.	
  Patterns	
  of	
  care	
  and	
  survival	
  for	
  patients	
  aged	
  under	
  40	
  years	
  with	
  bone	
  sarcoma	
  in	
  Britain,	
  1980-­‐1994.	
  British	
  journal	
  of	
  cancer	
  2006;94:22-­‐9.	
  10.	
  Smith	
  MA,	
  Seibel	
  NL,	
  Altekruse	
  SF,	
  et	
  al.	
  Outcomes	
  for	
  children	
  and	
  adolescents	
  with	
  cancer:	
  challenges	
  for	
  the	
  twenty-­‐first	
  century.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2010;28:2625-­‐34.	
  11.	
  Kager	
  L,	
  Zoubek	
  A,	
  Potschger	
  U,	
  et	
  al.	
  Primary	
  metastatic	
  osteosarcoma:	
  presentation	
  and	
  outcome	
  of	
  patients	
  treated	
  on	
  neoadjuvant	
  Cooperative	
  Osteosarcoma	
  Study	
  Group	
  protocols.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2003;21:2011-­‐8.	
  12.	
  Chou	
  AJ,	
  Kleinerman	
  ES,	
  Krailo	
  MD,	
  et	
  al.	
  Addition	
  of	
  muramyl	
  tripeptide	
  to	
  chemotherapy	
  for	
  patients	
  with	
  newly	
  diagnosed	
  metastatic	
  osteosarcoma:	
  a	
  report	
  from	
  the	
  Children's	
  Oncology	
  Group.	
  Cancer	
  2009;115:5339-­‐48.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  37	
  13.	
  Meyers	
  PA,	
  Heller	
  G,	
  Healey	
  JH,	
  et	
  al.	
  Osteogenic	
  sarcoma	
  with	
  clinically	
  detectable	
  metastasis	
  at	
  initial	
  presentation.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  1993;11:449-­‐53.	
  14.	
  Ferrari	
  S,	
  Smeland	
  S,	
  Mercuri	
  M,	
  et	
  al.	
  Neoadjuvant	
  chemotherapy	
  with	
  high-­‐dose	
  Ifosfamide,	
  high-­‐dose	
  methotrexate,	
  cisplatin,	
  and	
  doxorubicin	
  for	
  patients	
  with	
  localized	
  osteosarcoma	
  of	
  the	
  extremity:	
  a	
  joint	
  study	
  by	
  the	
  Italian	
  and	
  Scandinavian	
  Sarcoma	
  Groups.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2005;23:8845-­‐52.	
  15.	
  Goorin	
  AM,	
  Schwartzentruber	
  DJ,	
  Devidas	
  M,	
  et	
  al.	
  Presurgical	
  chemotherapy	
  compared	
  with	
  immediate	
  surgery	
  and	
  adjuvant	
  chemotherapy	
  for	
  nonmetastatic	
  osteosarcoma:	
  Pediatric	
  Oncology	
  Group	
  Study	
  POG-­‐8651.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2003;21:1574-­‐80.	
  16.	
  Lewis	
  IJ,	
  Nooij	
  MA,	
  Whelan	
  J,	
  et	
  al.	
  Improvement	
  in	
  histologic	
  response	
  but	
  not	
  survival	
  in	
  osteosarcoma	
  patients	
  treated	
  with	
  intensified	
  chemotherapy:	
  a	
  randomized	
  phase	
  III	
  trial	
  of	
  the	
  European	
  Osteosarcoma	
  Intergroup.	
  J	
  Natl	
  Cancer	
  Inst	
  2007;99:112-­‐28.	
  17.	
  Souhami	
  RL,	
  Craft	
  AW,	
  Van	
  der	
  Eijken	
  JW,	
  et	
  al.	
  Randomised	
  trial	
  of	
  two	
  regimens	
  of	
  chemotherapy	
  in	
  operable	
  osteosarcoma:	
  a	
  study	
  of	
  the	
  European	
  Osteosarcoma	
  Intergroup.	
  Lancet	
  1997;350:911-­‐7.	
  18.	
  Gurney	
  JG,	
  Swenson	
  AR,	
  Bulterys	
  M.	
  Malignant	
  Bone	
  Tumors.	
  In:	
  Ries	
  LAG,	
  Smith	
  MA,	
  Gurney	
  JG,	
  et	
  al.,	
  eds.	
  Cancer	
  Incidence	
  and	
  Survival:	
  United	
  States	
  SEER	
  Program	
  1975-­‐1995,	
  National	
  Cancer	
  Institute,	
  SEER	
  Program.	
  Bethesda,	
  MD:	
  NIH	
  Pub.	
  No.	
  99-­‐4649;	
  1999:99-­‐110.	
  19.	
  Bielack	
  SS,	
  Kempf-­‐Bielack	
  B,	
  Delling	
  G,	
  et	
  al.	
  Prognostic	
  factors	
  in	
  high-­‐grade	
  osteosarcoma	
  of	
  the	
  extremities	
  or	
  trunk:	
  an	
  analysis	
  of	
  1,702	
  patients	
  treated	
  on	
  neoadjuvant	
  cooperative	
  osteosarcoma	
  study	
  group	
  protocols.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2002;20:776-­‐90.	
  20.	
  Ritter	
  J,	
  Bielack	
  SS.	
  Osteosarcoma.	
  Annals	
  of	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  European	
  Society	
  for	
  Medical	
  Oncology	
  /	
  ESMO	
  2010;21	
  Suppl	
  7:vii320-­‐5.	
  21.	
  Davis	
  AM,	
  Bell	
  RS,	
  Goodwin	
  PJ.	
  Prognostic	
  factors	
  in	
  osteosarcoma:	
  a	
  critical	
  review.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  1994;12:423-­‐31.	
  22.	
  Eilber	
  F,	
  Giuliano	
  A,	
  Eckardt	
  J,	
  Patterson	
  K,	
  Moseley	
  S,	
  Goodnight	
  J.	
  Adjuvant	
  chemotherapy	
  for	
  osteosarcoma:	
  a	
  randomized	
  prospective	
  trial.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  1987;5:21-­‐6.	
  23.	
  Meyers	
  PA,	
  Schwartz	
  CL,	
  Krailo	
  M,	
  et	
  al.	
  Osteosarcoma:	
  a	
  randomized,	
  prospective	
  trial	
  of	
  the	
  addition	
  of	
  ifosfamide	
  and/or	
  muramyl	
  tripeptide	
  to	
  cisplatin,	
  doxorubicin,	
  and	
  high-­‐dose	
  methotrexate.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2005;23:2004-­‐11.	
  24.	
  Meyers	
  PA,	
  Schwartz	
  CL,	
  Krailo	
  MD,	
  et	
  al.	
  Osteosarcoma:	
  the	
  addition	
  of	
  muramyl	
  tripeptide	
  to	
  chemotherapy	
  improves	
  overall	
  survival-­‐-­‐a	
  report	
  from	
  the	
  Children's	
  Oncology	
  Group.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2008;26:633-­‐8.	
  25.	
  Ferrari	
  S,	
  Ruggieri	
  P,	
  Cefalo	
  G,	
  et	
  al.	
  Neoadjuvant	
  Chemotherapy	
  With	
  Methotrexate,	
  Cisplatin,	
  and	
  Doxorubicin	
  With	
  or	
  Without	
  Ifosfamide	
  in	
  Nonmetastatic	
  Osteosarcoma	
  of	
  the	
  Extremity:	
  An	
  Italian	
  Sarcoma	
  Group	
  Trial	
  ISG/OS-­‐1.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2012.	
  26.	
  Janeway	
  KA,	
  Grier	
  HE.	
  Sequelae	
  of	
  osteosarcoma	
  medical	
  therapy:	
  a	
  review	
  of	
  rare	
  acute	
  toxicities	
  and	
  late	
  effects.	
  The	
  lancet	
  oncology	
  2010;11:670-­‐8.	
  27.	
  Ferrari	
  S,	
  Pieretti	
  F,	
  Verri	
  E,	
  et	
  al.	
  Prospective	
  evaluation	
  of	
  renal	
  function	
  in	
  pediatric	
  and	
  adult	
  patients	
  treated	
  with	
  high-­‐dose	
  ifosfamide,	
  cisplatin	
  and	
  high-­‐dose	
  methotrexate.	
  Anti-­‐cancer	
  drugs	
  2005;16:733-­‐8.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  38	
  28.	
  Treon	
  SP,	
  Chabner	
  BA.	
  Concepts	
  in	
  use	
  of	
  high-­‐dose	
  methotrexate	
  therapy.	
  Clinical	
  chemistry	
  1996;42:1322-­‐9.	
  29.	
  Mikkelsen	
  TS,	
  Sparreboom	
  A,	
  Cheng	
  C,	
  et	
  al.	
  Shortening	
  infusion	
  time	
  for	
  high-­‐dose	
  methotrexate	
  alters	
  antileukemic	
  effects:	
  a	
  randomized	
  prospective	
  clinical	
  trial.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2011;29:1771-­‐8.	
  30.	
  Bleyer	
  WA.	
  The	
  clinical	
  pharmacology	
  of	
  methotrexate:	
  new	
  applications	
  of	
  an	
  old	
  drug.	
  Cancer	
  1978;41:36-­‐51.	
  31.	
  Widemann	
  BC,	
  Adamson	
  PC.	
  Understanding	
  and	
  managing	
  methotrexate	
  nephrotoxicity.	
  The	
  oncologist	
  2006;11:694-­‐703.	
  32.	
  Widemann	
  BC,	
  Balis	
  FM,	
  Kempf-­‐Bielack	
  B,	
  et	
  al.	
  High-­‐dose	
  methotrexate-­‐induced	
  nephrotoxicity	
  in	
  patients	
  with	
  osteosarcoma.	
  Cancer	
  2004;100:2222-­‐32.	
  33.	
  Fox	
  RM.	
  Methotrexate	
  nephrotoxicity.	
  Clinical	
  and	
  experimental	
  pharmacology	
  &	
  physiology	
  1979:43-­‐5.	
  34.	
  Ferrari	
  S,	
  Palmerini	
  E,	
  Staals	
  E,	
  et	
  al.	
  Sex-­‐	
  and	
  age-­‐related	
  chemotherapy	
  toxicity	
  in	
  patients	
  with	
  non-­‐metastatic	
  osteosarcoma.	
  Journal	
  of	
  chemotherapy	
  2009;21:205-­‐10.	
  35.	
  Hempel	
  L,	
  Misselwitz	
  J,	
  Fleck	
  C,	
  et	
  al.	
  Influence	
  of	
  high-­‐dose	
  methotrexate	
  therapy	
  (HD-­‐MTX)	
  on	
  glomerular	
  and	
  tubular	
  kidney	
  function.	
  Medical	
  and	
  pediatric	
  oncology	
  2003;40:348-­‐54.	
  36.	
  Delepine	
  N,	
  Delepine	
  G,	
  Cornille	
  H,	
  Brion	
  F,	
  Arnaud	
  P,	
  Desbois	
  JC.	
  Dose	
  escalation	
  with	
  pharmacokinetics	
  monitoring	
  in	
  methotrexate	
  chemotherapy	
  of	
  osteosarcoma.	
  Anticancer	
  research	
  1995;15:489-­‐94.	
  37.	
  Ferrari	
  S,	
  Sassoli	
  V,	
  Orlandi	
  M,	
  et	
  al.	
  Serum	
  methotrexate	
  (MTX)	
  concentrations	
  and	
  prognosis	
  in	
  patients	
  with	
  osteosarcoma	
  of	
  the	
  extremities	
  treated	
  with	
  a	
  multidrug	
  neoadjuvant	
  regimen.	
  Journal	
  of	
  chemotherapy	
  1993;5:135-­‐41.	
  38.	
  Bacci	
  G,	
  Loro	
  L,	
  Longhi	
  A,	
  et	
  al.	
  No	
  correlation	
  between	
  methotrexate	
  serum	
  level	
  and	
  histologic	
  response	
  in	
  the	
  pre-­‐operative	
  treatment	
  of	
  extremity	
  osteosarcoma.	
  Anti-­‐cancer	
  drugs	
  2006;17:411-­‐5.	
  39.	
  Leung	
  S,	
  Marshall	
  GM,	
  al	
  Mahr	
  M,	
  Tobias	
  V,	
  Lee	
  DB,	
  Hughes	
  DO.	
  Prognostic	
  significance	
  of	
  chemotherapy	
  dosage	
  characteristics	
  in	
  children	
  with	
  osteogenic	
  sarcoma.	
  Medical	
  and	
  pediatric	
  oncology	
  1997;28:179-­‐82.	
  40.	
  Zelcer	
  S,	
  Kellick	
  M,	
  Wexler	
  LH,	
  et	
  al.	
  Methotrexate	
  levels	
  and	
  outcome	
  in	
  osteosarcoma.	
  Pediatric	
  blood	
  &	
  cancer	
  2005;44:638-­‐42.	
  41.	
  Crews	
  KR,	
  Liu	
  T,	
  Rodriguez-­‐Galindo	
  C,	
  et	
  al.	
  High-­‐dose	
  methotrexate	
  pharmacokinetics	
  and	
  outcome	
  of	
  children	
  and	
  young	
  adults	
  with	
  osteosarcoma.	
  Cancer	
  2004;100:1724-­‐33.	
  42.	
  Krailo	
  M,	
  Ertel	
  I,	
  Makley	
  J,	
  et	
  al.	
  A	
  randomized	
  study	
  comparing	
  high-­‐dose	
  methotrexate	
  with	
  moderate-­‐dose	
  methotrexate	
  as	
  components	
  of	
  adjuvant	
  chemotherapy	
  in	
  childhood	
  nonmetastatic	
  osteosarcoma:	
  a	
  report	
  from	
  the	
  Childrens	
  Cancer	
  Study	
  Group.	
  Medical	
  and	
  pediatric	
  oncology	
  1987;15:69-­‐77.	
  43.	
  Wang	
  D,	
  Lippard	
  SJ.	
  Cellular	
  processing	
  of	
  platinum	
  anticancer	
  drugs.	
  Nature	
  reviews	
  Drug	
  discovery	
  2005;4:307-­‐20.	
  44.	
  Pabla	
  N,	
  Dong	
  Z.	
  Cisplatin	
  nephrotoxicity:	
  mechanisms	
  and	
  renoprotective	
  strategies.	
  Kidney	
  international	
  2008;73:994-­‐1007.	
  45.	
  Skinner	
  R,	
  Pearson	
  AD,	
  English	
  MW,	
  et	
  al.	
  Cisplatin	
  dose	
  rate	
  as	
  a	
  risk	
  factor	
  for	
  nephrotoxicity	
  in	
  children.	
  British	
  journal	
  of	
  cancer	
  1998;77:1677-­‐82.	
  46.	
  Womer	
  RB,	
  Pritchard	
  J,	
  Barratt	
  TM.	
  Renal	
  toxicity	
  of	
  cisplatin	
  in	
  children.	
  The	
  Journal	
  of	
  pediatrics	
  1985;106:659-­‐63.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  39	
  47.	
  Launay-­‐Vacher	
  V,	
  Rey	
  JB,	
  Isnard-­‐Bagnis	
  C,	
  Deray	
  G,	
  Daouphars	
  M.	
  Prevention	
  of	
  cisplatin	
  nephrotoxicity:	
  state	
  of	
  the	
  art	
  and	
  recommendations	
  from	
  the	
  European	
  Society	
  of	
  Clinical	
  Pharmacy	
  Special	
  Interest	
  Group	
  on	
  Cancer	
  Care.	
  Cancer	
  chemotherapy	
  and	
  pharmacology	
  2008;61:903-­‐9.	
  48.	
  Ciarimboli	
  G.	
  Role	
  of	
  organic	
  cation	
  transporters	
  in	
  drug-­‐induced	
  toxicity.	
  Expert	
  opinion	
  on	
  drug	
  metabolism	
  &	
  toxicology	
  2011;7:159-­‐74.	
  49.	
  Yokoo	
  S,	
  Yonezawa	
  A,	
  Masuda	
  S,	
  Fukatsu	
  A,	
  Katsura	
  T,	
  Inui	
  K.	
  Differential	
  contribution	
  of	
  organic	
  cation	
  transporters,	
  OCT2	
  and	
  MATE1,	
  in	
  platinum	
  agent-­‐induced	
  nephrotoxicity.	
  Biochemical	
  pharmacology	
  2007;74:477-­‐87.	
  50.	
  Ciarimboli	
  G,	
  Deuster	
  D,	
  Knief	
  A,	
  et	
  al.	
  Organic	
  cation	
  transporter	
  2	
  mediates	
  cisplatin-­‐induced	
  oto-­‐	
  and	
  nephrotoxicity	
  and	
  is	
  a	
  target	
  for	
  protective	
  interventions.	
  The	
  American	
  journal	
  of	
  pathology	
  2010;176:1169-­‐80.	
  51.	
  Filipski	
  KK,	
  Mathijssen	
  RH,	
  Mikkelsen	
  TS,	
  Schinkel	
  AH,	
  Sparreboom	
  A.	
  Contribution	
  of	
  organic	
  cation	
  transporter	
  2	
  (OCT2)	
  to	
  cisplatin-­‐induced	
  nephrotoxicity.	
  Clinical	
  pharmacology	
  and	
  therapeutics	
  2009;86:396-­‐402.	
  52.	
  Franke	
  RM,	
  Kosloske	
  AM,	
  Lancaster	
  CS,	
  et	
  al.	
  Influence	
  of	
  Oct1/Oct2-­‐deficiency	
  on	
  cisplatin-­‐induced	
  changes	
  in	
  urinary	
  N-­‐acetyl-­‐beta-­‐D-­‐glucosaminidase.	
  Clinical	
  cancer	
  research	
  :	
  an	
  official	
  journal	
  of	
  the	
  American	
  Association	
  for	
  Cancer	
  Research	
  2010;16:4198-­‐206.	
  53.	
  Wilson	
  CL,	
  Ness	
  KK,	
  Neglia	
  JP,	
  et	
  al.	
  Renal	
  carcinoma	
  following	
  therapy	
  for	
  cancer	
  in	
  childhood:	
  A	
  report	
  from	
  the	
  Childhood	
  Cancer	
  Survivor	
  Study	
  (Abstr#9528).	
  In:	
  American	
  Society	
  of	
  Clinical	
  Oncology;	
  2012;	
  Chicago.	
  IL;	
  2012.	
  p.	
  613a.	
  54.	
  Erdlenbruch	
  B,	
  Nier	
  M,	
  Kern	
  W,	
  Hiddemann	
  W,	
  Pekrun	
  A,	
  Lakomek	
  M.	
  Pharmacokinetics	
  of	
  cisplatin	
  and	
  relation	
  to	
  nephrotoxicity	
  in	
  paediatric	
  patients.	
  European	
  journal	
  of	
  clinical	
  pharmacology	
  2001;57:393-­‐402.	
  55.	
  Peng	
  B,	
  English	
  MW,	
  Boddy	
  AV,	
  et	
  al.	
  Cisplatin	
  pharmacokinetics	
  in	
  children	
  with	
  cancer.	
  European	
  journal	
  of	
  cancer	
  1997;33:1823-­‐8.	
  56.	
  Ribrag	
  V,	
  Droz	
  JP,	
  Morizet	
  J,	
  Leclercq	
  B,	
  Gouyette	
  A,	
  Chabot	
  GG.	
  Test	
  dose-­‐guided	
  administration	
  of	
  cisplatin	
  in	
  an	
  anephric	
  patient:	
  a	
  case	
  report.	
  Annals	
  of	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  European	
  Society	
  for	
  Medical	
  Oncology	
  /	
  ESMO	
  1993;4:679-­‐82.	
  57.	
  Stevens	
  LA,	
  Coresh	
  J,	
  Greene	
  T,	
  Levey	
  AS.	
  Assessing	
  kidney	
  function-­‐-­‐measured	
  and	
  estimated	
  glomerular	
  filtration	
  rate.	
  The	
  New	
  England	
  journal	
  of	
  medicine	
  2006;354:2473-­‐83.	
  58.	
  Schwartz	
  GJ,	
  Munoz	
  A,	
  Schneider	
  MF,	
  et	
  al.	
  New	
  equations	
  to	
  estimate	
  GFR	
  in	
  children	
  with	
  CKD.	
  Journal	
  of	
  the	
  American	
  Society	
  of	
  Nephrology	
  :	
  JASN	
  2009;20:629-­‐37.	
  59.	
  Conti	
  M,	
  Moutereau	
  S,	
  Zater	
  M,	
  et	
  al.	
  Urinary	
  cystatin	
  C	
  as	
  a	
  specific	
  marker	
  of	
  tubular	
  dysfunction.	
  Clinical	
  chemistry	
  and	
  laboratory	
  medicine	
  :	
  CCLM	
  /	
  FESCC	
  2006;44:288-­‐91.	
  60.	
  Cordeiro	
  VF,	
  Pinheiro	
  DC,	
  Silva	
  GB,	
  Jr.,	
  et	
  al.	
  Comparative	
  study	
  of	
  cystatin	
  C	
  and	
  serum	
  creatinine	
  in	
  the	
  estimative	
  of	
  glomerular	
  filtration	
  rate	
  in	
  children.	
  Clinica	
  chimica	
  acta;	
  international	
  journal	
  of	
  clinical	
  chemistry	
  2008;391:46-­‐50.	
  61.	
  Dharnidharka	
  VR,	
  Kwon	
  C,	
  Stevens	
  G.	
  Serum	
  cystatin	
  C	
  is	
  superior	
  to	
  serum	
  creatinine	
  as	
  a	
  marker	
  of	
  kidney	
  function:	
  a	
  meta-­‐analysis.	
  American	
  journal	
  of	
  kidney	
  diseases	
  :	
  the	
  official	
  journal	
  of	
  the	
  National	
  Kidney	
  Foundation	
  2002;40:221-­‐6.	
  62.	
  Gronroos	
  MH,	
  Jahnukainen	
  T,	
  Irjala	
  K,	
  et	
  al.	
  Comparison	
  of	
  glomerular	
  function	
  tests	
  in	
  children	
  with	
  cancer.	
  Pediatric	
  nephrology	
  2008;23:797-­‐803.	
  63.	
  Grubb	
  AO.	
  Cystatin	
  C-­‐-­‐properties	
  and	
  use	
  as	
  diagnostic	
  marker.	
  Advances	
  in	
  clinical	
  chemistry	
  2000;35:63-­‐99.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  40	
  64.	
  Herget-­‐Rosenthal	
  S,	
  Feldkamp	
  T,	
  Volbracht	
  L,	
  Kribben	
  A.	
  Measurement	
  of	
  urinary	
  cystatin	
  C	
  by	
  particle-­‐enhanced	
  nephelometric	
  immunoassay:	
  precision,	
  interferences,	
  stability	
  and	
  reference	
  range.	
  Annals	
  of	
  clinical	
  biochemistry	
  2004;41:111-­‐8.	
  65.	
  Herget-­‐Rosenthal	
  S,	
  Marggraf	
  G,	
  Husing	
  J,	
  et	
  al.	
  Early	
  detection	
  of	
  acute	
  renal	
  failure	
  by	
  serum	
  cystatin	
  C.	
  Kidney	
  international	
  2004;66:1115-­‐22.	
  66.	
  Roos	
  JF,	
  Doust	
  J,	
  Tett	
  SE,	
  Kirkpatrick	
  CM.	
  Diagnostic	
  accuracy	
  of	
  cystatin	
  C	
  compared	
  to	
  serum	
  creatinine	
  for	
  the	
  estimation	
  of	
  renal	
  dysfunction	
  in	
  adults	
  and	
  children-­‐-­‐a	
  meta-­‐analysis.	
  Clinical	
  biochemistry	
  2007;40:383-­‐91.	
  67.	
  Westhuyzen	
  J.	
  Cystatin	
  C:	
  a	
  promising	
  marker	
  and	
  predictor	
  of	
  impaired	
  renal	
  function.	
  Annals	
  of	
  clinical	
  and	
  laboratory	
  science	
  2006;36:387-­‐94.	
  68.	
  Zaffanello	
  M,	
  Franchini	
  M,	
  Fanos	
  V.	
  Is	
  serum	
  Cystatin-­‐C	
  a	
  suitable	
  marker	
  of	
  renal	
  function	
  in	
  children?	
  Annals	
  of	
  clinical	
  and	
  laboratory	
  science	
  2007;37:233-­‐40.	
  69.	
  Du	
  Y,	
  Zappitelli	
  M,	
  Mian	
  A,	
  et	
  al.	
  Urinary	
  biomarkers	
  to	
  detect	
  acute	
  kidney	
  injury	
  in	
  the	
  pediatric	
  emergency	
  center.	
  Pediatric	
  nephrology	
  2011;26:267-­‐74.	
  70.	
  Han	
  WK,	
  Bailly	
  V,	
  Abichandani	
  R,	
  Thadhani	
  R,	
  Bonventre	
  JV.	
  Kidney	
  Injury	
  Molecule-­‐1	
  (KIM-­‐1):	
  a	
  novel	
  biomarker	
  for	
  human	
  renal	
  proximal	
  tubule	
  injury.	
  Kidney	
  international	
  2002;62:237-­‐44.	
  71.	
  Han	
  WK,	
  Wagener	
  G,	
  Zhu	
  Y,	
  Wang	
  S,	
  Lee	
  HT.	
  Urinary	
  biomarkers	
  in	
  the	
  early	
  detection	
  of	
  acute	
  kidney	
  injury	
  after	
  cardiac	
  surgery.	
  Clinical	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Nephrology	
  :	
  CJASN	
  2009;4:873-­‐82.	
  72.	
  Koyner	
  JL,	
  Vaidya	
  VS,	
  Bennett	
  MR,	
  et	
  al.	
  Urinary	
  biomarkers	
  in	
  the	
  clinical	
  prognosis	
  and	
  early	
  detection	
  of	
  acute	
  kidney	
  injury.	
  Clinical	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Nephrology	
  :	
  CJASN	
  2010;5:2154-­‐65.	
  73.	
  Liangos	
  O,	
  Perianayagam	
  MC,	
  Vaidya	
  VS,	
  et	
  al.	
  Urinary	
  N-­‐acetyl-­‐beta-­‐(D)-­‐glucosaminidase	
  activity	
  and	
  kidney	
  injury	
  molecule-­‐1	
  level	
  are	
  associated	
  with	
  adverse	
  outcomes	
  in	
  acute	
  renal	
  failure.	
  Journal	
  of	
  the	
  American	
  Society	
  of	
  Nephrology	
  :	
  JASN	
  2007;18:904-­‐12.	
  74.	
  de	
  Geus	
  HR,	
  Bakker	
  J,	
  Lesaffre	
  EM,	
  le	
  Noble	
  JL.	
  Neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  at	
  ICU	
  admission	
  predicts	
  for	
  acute	
  kidney	
  injury	
  in	
  adult	
  patients.	
  American	
  journal	
  of	
  respiratory	
  and	
  critical	
  care	
  medicine	
  2011;183:907-­‐14.	
  75.	
  Dent	
  CL,	
  Ma	
  Q,	
  Dastrala	
  S,	
  et	
  al.	
  Plasma	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  predicts	
  acute	
  kidney	
  injury,	
  morbidity	
  and	
  mortality	
  after	
  pediatric	
  cardiac	
  surgery:	
  a	
  prospective	
  uncontrolled	
  cohort	
  study.	
  Critical	
  care	
  2007;11:R127.	
  76.	
  Haase	
  M,	
  Bellomo	
  R,	
  Devarajan	
  P,	
  Schlattmann	
  P,	
  Haase-­‐Fielitz	
  A.	
  Accuracy	
  of	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  (NGAL)	
  in	
  diagnosis	
  and	
  prognosis	
  in	
  acute	
  kidney	
  injury:	
  a	
  systematic	
  review	
  and	
  meta-­‐analysis.	
  American	
  journal	
  of	
  kidney	
  diseases	
  :	
  the	
  official	
  journal	
  of	
  the	
  National	
  Kidney	
  Foundation	
  2009;54:1012-­‐24.	
  77.	
  Haase	
  M,	
  Bellomo	
  R,	
  Haase-­‐Fielitz	
  A.	
  Neutrophil	
  gelatinase-­‐associated	
  lipocalin:	
  a	
  superior	
  biomarker	
  for	
  detection	
  of	
  subclinical	
  acute	
  kidney	
  injury	
  and	
  poor	
  prognosis.	
  Biomarkers	
  in	
  medicine	
  2011;5:415-­‐7.	
  78.	
  Haase	
  M,	
  Devarajan	
  P,	
  Haase-­‐Fielitz	
  A,	
  et	
  al.	
  The	
  outcome	
  of	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin-­‐positive	
  subclinical	
  acute	
  kidney	
  injury:	
  a	
  multicenter	
  pooled	
  analysis	
  of	
  prospective	
  studies.	
  Journal	
  of	
  the	
  American	
  College	
  of	
  Cardiology	
  2011;57:1752-­‐61.	
  79.	
  Nickolas	
  TL,	
  O'Rourke	
  MJ,	
  Yang	
  J,	
  et	
  al.	
  Sensitivity	
  and	
  specificity	
  of	
  a	
  single	
  emergency	
  department	
  measurement	
  of	
  urinary	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  for	
  diagnosing	
  acute	
  kidney	
  injury.	
  Annals	
  of	
  internal	
  medicine	
  2008;148:810-­‐9.	
  80.	
  Schmidt-­‐Ott	
  KM,	
  Mori	
  K,	
  Li	
  JY,	
  et	
  al.	
  Dual	
  action	
  of	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin.	
  Journal	
  of	
  the	
  American	
  Society	
  of	
  Nephrology	
  :	
  JASN	
  2007;18:407-­‐13.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  41	
  81.	
  Shemin	
  D,	
  Dworkin	
  LD.	
  Neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  (NGAL)	
  as	
  a	
  biomarker	
  for	
  early	
  acute	
  kidney	
  injury.	
  Critical	
  care	
  clinics	
  2011;27:379-­‐89.	
  82.	
  Singer	
  E,	
  Elger	
  A,	
  Elitok	
  S,	
  et	
  al.	
  Urinary	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  distinguishes	
  pre-­‐renal	
  from	
  intrinsic	
  renal	
  failure	
  and	
  predicts	
  outcomes.	
  Kidney	
  international	
  2011;80:405-­‐14.	
  83.	
  Sise	
  ME,	
  Forster	
  C,	
  Singer	
  E,	
  et	
  al.	
  Urine	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  identifies	
  unilateral	
  and	
  bilateral	
  urinary	
  tract	
  obstruction.	
  Nephrology,	
  dialysis,	
  transplantation	
  :	
  official	
  publication	
  of	
  the	
  European	
  Dialysis	
  and	
  Transplant	
  Association	
  -­‐	
  European	
  Renal	
  Association	
  2011;26:4132-­‐5.	
  84.	
  Tuladhar	
  SM,	
  Puntmann	
  VO,	
  Soni	
  M,	
  Punjabi	
  PP,	
  Bogle	
  RG.	
  Rapid	
  detection	
  of	
  acute	
  kidney	
  injury	
  by	
  plasma	
  and	
  urinary	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  after	
  cardiopulmonary	
  bypass.	
  Journal	
  of	
  cardiovascular	
  pharmacology	
  2009;53:261-­‐6.	
  85.	
  Wheeler	
  DS,	
  Devarajan	
  P,	
  Ma	
  Q,	
  et	
  al.	
  Serum	
  neutrophil	
  gelatinase-­‐associated	
  lipocalin	
  (NGAL)	
  as	
  a	
  marker	
  of	
  acute	
  kidney	
  injury	
  in	
  critically	
  ill	
  children	
  with	
  septic	
  shock.	
  Critical	
  care	
  medicine	
  2008;36:1297-­‐303.	
  86.	
  Waring	
  WS,	
  Moonie	
  A.	
  Earlier	
  recognition	
  of	
  nephrotoxicity	
  using	
  novel	
  biomarkers	
  of	
  acute	
  kidney	
  injury.	
  Clinical	
  toxicology	
  2011;49:720-­‐8.	
  87.	
  Brock	
  PR,	
  Knight	
  KR,	
  Freyer	
  DR,	
  et	
  al.	
  Platinum-­‐induced	
  ototoxicity	
  in	
  children:	
  a	
  consensus	
  review	
  on	
  mechanisms,	
  predisposition,	
  and	
  protection,	
  including	
  a	
  new	
  international	
  society	
  of	
  pediatric	
  oncology	
  Boston	
  ototoxicity	
  scale.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  2012;30:2408-­‐17.	
  88.	
  Lewis	
  MJ,	
  DuBois	
  SG,	
  Fligor	
  B,	
  Li	
  X,	
  Goorin	
  A,	
  Grier	
  HE.	
  Ototoxicity	
  in	
  children	
  treated	
  for	
  osteosarcoma.	
  Pediatric	
  blood	
  &	
  cancer	
  2009;52:387-­‐91.	
  89.	
  Ruiz	
  L,	
  Gilden	
  J,	
  Jaffe	
  N,	
  Robertson	
  R,	
  Wang	
  YM.	
  Auditory	
  function	
  in	
  pediatric	
  osteosarcoma	
  patients	
  treated	
  with	
  multiple	
  doses	
  of	
  cis-­‐diamminedichloroplatinum(II).	
  Cancer	
  research	
  1989;49:742-­‐4.	
  90.	
  Stohr	
  W,	
  Langer	
  T,	
  Kremers	
  A,	
  et	
  al.	
  Cisplatin-­‐induced	
  ototoxicity	
  in	
  osteosarcoma	
  patients:	
  a	
  report	
  from	
  the	
  late	
  effects	
  surveillance	
  system.	
  Cancer	
  investigation	
  2005;23:201-­‐7.	
  91.	
  Li	
  Y,	
  Womer	
  RB,	
  Silber	
  JH.	
  Predicting	
  cisplatin	
  ototoxicity	
  in	
  children:	
  the	
  influence	
  of	
  age	
  and	
  the	
  cumulative	
  dose.	
  European	
  journal	
  of	
  cancer	
  2004;40:2445-­‐51.	
  92.	
  Yancey	
  A,	
  Harris	
  MS,	
  Egbelakin	
  A,	
  Gilbert	
  J,	
  Pisoni	
  DB,	
  Renbarger	
  J.	
  Risk	
  factors	
  for	
  cisplatin-­‐associated	
  ototoxicity	
  in	
  pediatric	
  oncology	
  patients.	
  Pediatric	
  blood	
  &	
  cancer	
  2012.	
  93.	
  Bertolini	
  P,	
  Lassalle	
  M,	
  Mercier	
  G,	
  et	
  al.	
  Platinum	
  compound-­‐related	
  ototoxicity	
  in	
  children:	
  long-­‐term	
  follow-­‐up	
  reveals	
  continuous	
  worsening	
  of	
  hearing	
  loss.	
  Journal	
  of	
  pediatric	
  hematology/oncology	
  2004;26:649-­‐55.	
  94.	
  Moreira	
  Dias	
  L.	
  Pantoprazole:	
  a	
  proton	
  pump	
  inhibitor.	
  Clinical	
  drug	
  investigation	
  2009;29	
  Suppl	
  2:3-­‐12.	
  95.	
  Katsuda	
  H,	
  Yamashita	
  M,	
  Katsura	
  H,	
  et	
  al.	
  Protecting	
  cisplatin-­‐induced	
  nephrotoxicity	
  with	
  cimetidine	
  does	
  not	
  affect	
  antitumor	
  activity.	
  Biological	
  &	
  pharmaceutical	
  bulletin	
  2010;33:1867-­‐71.	
  96.	
  De	
  Milito	
  A,	
  Fais	
  S.	
  Proton	
  pump	
  inhibitors	
  may	
  reduce	
  tumour	
  resistance.	
  Expert	
  Opin	
  Pharmacother	
  2005;6:1049-­‐54.	
  97.	
  Luciani	
  F,	
  Spada	
  M,	
  De	
  Milito	
  A,	
  et	
  al.	
  Effect	
  of	
  proton	
  pump	
  inhibitor	
  pretreatment	
  on	
  resistance	
  of	
  solid	
  tumors	
  to	
  cytotoxic	
  drugs.	
  J	
  Natl	
  Cancer	
  Inst	
  2004;96:1702-­‐13.	
  98.	
  Suzuki	
  K,	
  Doki	
  K,	
  Homma	
  M,	
  et	
  al.	
  Co-­‐administration	
  of	
  proton	
  pump	
  inhibitors	
  delays	
  elimination	
  of	
  plasma	
  methotrexate	
  in	
  high-­‐dose	
  methotrexate	
  therapy.	
  British	
  journal	
  of	
  clinical	
  pharmacology	
  2009;67:44-­‐9.	
  99.	
  Bacci	
  G,	
  Longhi	
  A,	
  Versari	
  M,	
  Mercuri	
  M,	
  Briccoli	
  A,	
  Picci	
  P.	
  Prognostic	
  factors	
  for	
  osteosarcoma	
  of	
  the	
  extremity	
  treated	
  with	
  neoadjuvant	
  chemotherapy:	
  15-­‐year	
  experience	
  in	
  789	
  patients	
  treated	
  at	
  a	
  single	
  institution.	
  Cancer	
  2006;106:1154-­‐61.	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  42	
  100.	
  Leung	
  KS,	
  Fung	
  KP,	
  Sher	
  AH,	
  Li	
  CK,	
  Lee	
  KM.	
  Plasma	
  bone-­‐specific	
  alkaline	
  phosphatase	
  as	
  an	
  indicator	
  of	
  osteoblastic	
  activity.	
  The	
  Journal	
  of	
  bone	
  and	
  joint	
  surgery	
  British	
  volume	
  1993;75:288-­‐92.	
  101.	
  Rauch	
  F,	
  Middelmann	
  B,	
  Cagnoli	
  M,	
  Keller	
  KM,	
  Schonau	
  E.	
  Comparison	
  of	
  total	
  alkaline	
  phosphatase	
  and	
  three	
  assays	
  for	
  bone-­‐specific	
  alkaline	
  phosphatase	
  in	
  childhood	
  and	
  adolescence.	
  Acta	
  paediatrica	
  1997;86:583-­‐7.	
  102.	
  Wang	
  J,	
  Pei	
  F,	
  Tu	
  C,	
  Zhang	
  H,	
  Qiu	
  X.	
  Serum	
  bone	
  turnover	
  markers	
  in	
  patients	
  with	
  primary	
  bone	
  tumors.	
  Oncology	
  2007;72:338-­‐42.	
  103.	
  Limmahakhun	
  S,	
  Pothacharoen	
  P,	
  Theera-­‐Umpon	
  N,	
  et	
  al.	
  Relationships	
  between	
  serum	
  biomarker	
  levels	
  and	
  clinical	
  presentation	
  of	
  human	
  osteosarcomas.	
  Asian	
  Pacific	
  journal	
  of	
  cancer	
  prevention	
  :	
  APJCP	
  2011;12:1717-­‐22.	
  104.	
  Morgan	
  KP,	
  Buie	
  LW,	
  Savage	
  SW.	
  The	
  role	
  of	
  mannitol	
  as	
  a	
  nephroprotectant	
  in	
  patients	
  receiving	
  cisplatin	
  therapy.	
  The	
  Annals	
  of	
  pharmacotherapy	
  2012;46:276-­‐81.	
  105.	
  Santoso	
  JT,	
  Lucci	
  JA,	
  3rd,	
  Coleman	
  RL,	
  Schafer	
  I,	
  Hannigan	
  EV.	
  Saline,	
  mannitol,	
  and	
  furosemide	
  hydration	
  in	
  acute	
  cisplatin	
  nephrotoxicity:	
  a	
  randomized	
  trial.	
  Cancer	
  chemotherapy	
  and	
  pharmacology	
  2003;52:13-­‐8.	
  106.	
  DeLaney	
  TF,	
  Park	
  L,	
  Goldberg	
  SI,	
  et	
  al.	
  Radiotherapy	
  for	
  local	
  control	
  of	
  osteosarcoma.	
  International	
  journal	
  of	
  radiation	
  oncology,	
  biology,	
  physics	
  2005;61:492-­‐8.	
  107.	
  Schwarz	
  R,	
  Bruland	
  O,	
  Cassoni	
  A,	
  Schomberg	
  P,	
  Bielack	
  S.	
  The	
  role	
  of	
  radiotherapy	
  in	
  oseosarcoma.	
  Cancer	
  treatment	
  and	
  research	
  2009;152:147-­‐64.	
  108.	
  Harris	
  MB,	
  Gieser	
  P,	
  Goorin	
  AM,	
  et	
  al.	
  Treatment	
  of	
  metastatic	
  osteosarcoma	
  at	
  diagnosis:	
  a	
  Pediatric	
  Oncology	
  Group	
  Study.	
  Journal	
  of	
  clinical	
  oncology	
  :	
  official	
  journal	
  of	
  the	
  American	
  Society	
  of	
  Clinical	
  Oncology	
  1998;16:3641-­‐8.	
  109.	
  Karrison	
  TG,	
  Maitland	
  ML,	
  Stadler	
  WM,	
  Ratain	
  MJ.	
  Design	
  of	
  phase	
  II	
  cancer	
  trials	
  using	
  a	
  continuous	
  endpoint	
  of	
  change	
  in	
  tumor	
  size:	
  application	
  to	
  a	
  study	
  of	
  sorafenib	
  and	
  erlotinib	
  in	
  non	
  small-­‐cell	
  lung	
  cancer.	
  J	
  Natl	
  Cancer	
  Inst	
  2007;99:1455-­‐61.	
  110.	
  Muller	
  KE,	
  Peterson	
  BL.	
  Practical	
  methods	
  for	
  computing	
  power	
  in	
  testing	
  the	
  multivariate	
  general	
  linear	
  hypothesis.	
  Computat	
  Stat	
  Data	
  Analysis	
  1984;2:143-­‐58.	
  111.	
  Muller	
  KE,	
  LaVange	
  LM,	
  Ramey	
  SL,	
  Ramey	
  CT.	
  Power	
  calculations	
  for	
  general	
  linear	
  multivariate	
  models	
  including	
  repeated	
  measures	
  applications.	
  J	
  Am	
  Stat	
  Assoc	
  1992;87:1209-­‐26.	
  112.	
  Chaturvedi	
  S,	
  Farmer	
  T,	
  Kapke	
  GF.	
  Assay	
  validation	
  for	
  KIM-­‐1:	
  human	
  urinary	
  renal	
  dysfunction	
  biomarker.	
  International	
  journal	
  of	
  biological	
  sciences	
  2009;5:128-­‐34.	
  113.	
  McCarthy	
  DM.	
  Proton	
  pump	
  inhibitor	
  use	
  and	
  Clostridium	
  difficile	
  colitis:	
  cause	
  or	
  coincidence?	
  Journal	
  of	
  clinical	
  gastroenterology	
  2012;46:350-­‐3.	
  114.	
  Deshpande	
  A,	
  Pant	
  C,	
  Pasupuleti	
  V,	
  et	
  al.	
  Association	
  between	
  proton	
  pump	
  inhibitor	
  therapy	
  and	
  Clostridium	
  difficile	
  infection	
  in	
  a	
  meta-­‐analysis.	
  Clinical	
  gastroenterology	
  and	
  hepatology	
  :	
  the	
  official	
  clinical	
  practice	
  journal	
  of	
  the	
  American	
  Gastroenterological	
  Association	
  2012;10:225-­‐33.	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  43	
  APPENDIX	
  1	
  SAMPLE	
  TREATMENT	
  DELIVERY	
  MAP	
  Protocol'No.NameVersion'DateMRNDOBC1/D1C1/D22C2/D1C2/D22Cycles1'and'2Weight'(kg)Treatment'Arm1Height'(cm)BSA'(m2)DrugDoseRouteScheduleCycleCycle4DaysDexrazoxane375'mg/m2IVover'15'min1'and'21'and'2DOXOrubicin37.5'mg/m2IVover'15'min1'and'21'and'20.3'mg/kgIVover'15'min1'and'21'and'21.3'mg/kgIVover'4'h1'and'21'and'2CISplatin60'mg/m2IVover'4'h1'and'21'and'2Pegfilgrastim0.1'mg/kgSC1'and'23Methotrexate12'gm/m2IVover'4'h1'and'222'and'29Leucovorin15'mg/m2IV'or'POq6h'until'[MTX]<0.1mcM1'and'223'and'30DateCycleDay%4Dose*DoseUnits11mgmgmgmgmg12mgmgmgmgmg13mg122Methotrexateover'4'hmg23Leucovorinmg129Methotrexateover'4'hmg30Leucovorinmg21mgmgmgmgmg22mgmgmgmgmg13mg222Methotrexateover'4'hmg23Leucovorinmg229Methotrexateover'4'hmg30Leucovorinmg*'%'of'standard'dose.'100%'is'full'dose;'75%'is'a'25%'dose'reduction.DOXOrubicinPantoprazole'(loading)Pantoprazole'(infusion)CISplatinPegfilgrastim000
DexrazoxaneDOXOrubicinPantoprazole'(loading)Pantoprazole'(infusion)CISplatinDexrazoxaneDexrazoxaneDOXOrubicinPantoprazole'(loading)Pantoprazole'(infusion)CISplatinPantoprazole'(loading)Pantoprazole'(infusion)CISplatin
PegfilgrastimCommentMAX'20'gmleucovorin'must'start'24'h'after'the'start'of'the'MTX'infusionDrugDexrazoxaneDOXOrubicinMAX'6'mgJune'13,'2012
PantoprazoleTREATMENT4DELIVERY4MAPCHP12STXX
Commentinfuse'prior'to'DOXOrubicininfuse'prior'to'cisplatininfuse'with'cisplatin
	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  44	
  	
  SAMPLE	
  CORRELATIVE	
  STUDIES	
  MAP	
  
	
  Protocol'No.NameVersion'DateMRNDOBDateTimeCycleDaySpecimenTestComment11UrineAKI,'CrUrineMg,'CrPlasmaMg,'CrSerumCystatin'C12UrineMg,'CrPlasmaMg,'CrUrineAKI,'Cr17UrineAKI,'CrUrineMg,'CrPlasmaMg,'CrSerumCystatin'C122UrineAKI,'CrSerumCystatin'CUrineMTX123UrineAKI,'Cr129UrineAKI,'CrSerumCystatin'CUrineMTX130UrineAKI,'Cr21UrineAKI,'CrUrineMg,'CrPlasmaMg,'CrSerumCystatin'CPlasmaPreHalbuminHPROHArm'circ/'Skin'fold22UrineMg,'CrPlasmaMg,'CrUrineAKI,'Cr27UrineAKI,'CrUrineMg,'CrPlasmaMg,'CrSerumCystatin'C222UrineAKI,'CrSerumCystatin'CUrineMTX223UrineAKI,'Cr229UrineAKI,'CrSerumCystatin'CUrineMTX230UrineAKI,'CrPrior'to'D1'cisplatin'infusionPrior'to'D2'cisplatin'infusion
Prior'to'D22'HDMTX'infusionEnd'of'D22'HDMTX'infusion24'h'after'start'of'D22'HDMTX'infusionInstructions
End'of'D2'cisplatin'infusion
End'of'D22'HDMTX'infusion24'h'after'start'of'D22'HDMTX'infusionPrior'to'D29'HDMTX'infusionEnd'of'D29'HDMTX'infusion24'h'after'start'of'D29''HDMTX'infusionPrior'to'D29'HDMTX'infusionEnd'of'D29'HDMTX'infusion24'h'after'start'of'D29''HDMTX'infusion
Prior'to'D2'cisplatin'infusion
Prior'to'D22'HDMTX'infusionPrior'to'D1'cisplatin'infusionEnd'of'D2'cisplatin'infusionCHP12ST051,'January'10,'201301/0/1900CORRELATIVE:STUDIES:MAP:>:CYCLES:1:AND:2
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  45	
  APPENDIX	
  2	
  PEDIATRIC	
  NEUROTOXICITY	
  GRADING	
  SCALE	
  Motor	
  neuropathy:	
  • Grade	
  1:	
  Subjective	
  weakness,	
  but	
  no	
  deficits	
  detected	
  on	
  neurological	
  exam	
  • Grade	
  2:	
  Weakness	
  that	
  alters	
  fine	
  motor	
  skills	
  (buttoning	
  shirt,	
  writing	
  or	
  drawing,	
  using	
  eating	
  utensils)	
  or	
  gait	
  without	
  abrogating	
  ability	
  to	
  perform	
  these	
  tasks.	
  • Grade	
  3:	
  Unable	
  to	
  perform	
  fine	
  motor	
  tasks	
  (buttoning	
  shirt,	
  writing	
  or	
  drawing,	
  using	
  eating	
  utensils)	
  or	
  unable	
  to	
  ambulate	
  without	
  assistance.	
  • Grade	
  4:	
  Paralysis	
  Sensory	
  neuropathy	
  :	
  • Grade	
  1:	
  Paresthesias,	
  pain,	
  or	
  numbness	
  that	
  do	
  not	
  require	
  treatment	
  or	
  interfere	
  with	
  extremity	
  function.	
  • Grade	
  2:	
  Paresthesias,	
  pain,	
  or	
  numbness	
  that	
  is	
  controlled	
  by	
  non-­‐narcotic	
  medications,	
  or	
  alter	
  (without	
  causing	
  loss	
  of	
  function)	
  fine	
  motor	
  skills	
  (buttoning	
  shirt,	
  writing	
  or	
  drawing,	
  using	
  eating	
  utensils)	
  or	
  gait,	
  without	
  abrogating	
  ability	
  to	
  perform	
  these	
  tasks.	
  • Grade	
  3:	
  Paresthesias	
  or	
  pain	
  that	
  is	
  controlled	
  by	
  narcotics,	
  or	
  interfere	
  with	
  extremity	
  function	
  (gait,	
  fine	
  motor	
  skills	
  as	
  outlined	
  above),	
  or	
  quality	
  of	
  life	
  (loss	
  of	
  sleep,	
  ability	
  to	
  perform	
  normal	
  activities	
  severely	
  impaired).	
  • Grade	
  4:	
  Complete	
  loss	
  of	
  sensation	
  or	
  pain	
  that	
  is	
  not	
  controlled	
  by	
  narcotics	
  	
  	
  	
  
	
  Protocol	
  number:	
  CHP12ST051	
  	
  Amendment	
  number:	
  	
  	
  Version	
  date:	
  April	
  2,	
  2013	
  	
  
	
  46	
  APPENDIX	
  3	
  PATIENT	
  REPORTED	
  OUTCOME	
  SURVEY	
  OSTEOSARCOMA	
  PATIENT	
  SURVEY	
  	
  	
  PATIENT	
  ID____________	
  	
  	
  DATE__________	
  	
  Since	
  the	
  last	
  time	
  I	
  filled	
  this	
  form	
  out	
  .	
  .	
  .	
  Never	
  (0	
  times)	
  Rarely	
  (less	
  than	
  once	
  a	
  week)	
  Sometimes	
  	
  (1	
  to	
  3	
  times	
  a	
  week)	
  Often	
  (almost	
  daily)	
  Almost	
  Always	
  (daily)	
  I	
  feel	
  too	
  tired	
  to	
  get	
  out	
  of	
  bed	
  	
  	
  	
  	
  	
  I	
  feel	
  like	
  I’m	
  going	
  to	
  throw	
  up	
  	
  	
  	
  	
  	
  I	
  throw-­‐up	
  or	
  vomit	
  	
  	
  	
  	
  	
  My	
  stomach	
  hurts	
  	
  	
  	
  	
  	
  I	
  do	
  not	
  feel	
  as	
  hungry	
  as	
  I	
  use	
  to	
  	
  	
  	
  	
  	
  Foods	
  taste	
  different	
  or	
  funny	
  	
  	
  	
  	
  	
  I	
  have	
  diarrhea	
  	
  	
  	
  	
  	
  I	
  have	
  constipation	
  	
  	
  	
  	
  	
  I	
  have	
  a	
  ringing	
  sound	
  in	
  my	
  ears	
  	
  	
  	
  	
  	
  I	
  have	
  trouble	
  hearing	
  some	
  things	
  	
  	
  	
  	
  	
  My	
  mouth	
  or	
  throat	
  hurts	
  	
  	
  	
  	
  	
  I	
  am	
  in	
  pain	
  	
  	
  	
  	
  	
  I	
   have	
   trouble	
   keeping	
   up	
   with	
   school	
   work	
  because	
   of	
   being	
   in	
   the	
   hospital	
   or	
   feeling	
   too	
  sick	
  	
  	
  	
  	
  	
  I	
  have	
  trouble	
  falling	
  asleep	
  	
  	
  	
  	
  	
  	
  I	
  wake	
  up	
  at	
  night	
  because	
  of	
  pain	
  	
  	
  	
  	
  	
  I	
  don’t	
  see	
  my	
  friends	
  as	
  much	
  anymore	
  because	
  I	
  am	
  too	
  busy	
  with	
  doctors	
  and	
  hospital	
  visits	
  	
  	
  	
  	
  	
  I	
  don’t	
  do	
  as	
  many	
  fun	
  things	
  anymore	
  because	
  I	
  feel	
  tired	
  or	
  sick	
  	
  	
  	
  	
  	
  I	
  don’t	
  have	
  fun	
  doing	
  things	
  I	
  used	
  to	
  like	
  to	
  do	
  	
  	
  	
  	
  	
  I	
  feel	
  nervous,	
  worried,	
  or	
  anxious	
  	
  	
  	
  	
  	
  I	
   have	
   trouble	
   doing	
   daily	
   activities	
   like	
   eating,	
  drinking,	
  putting	
  on	
  clothes	
  	
  	
  	
  	
  	
  I	
  have	
  answered	
  these	
  questions	
  before	
  	
  (circle	
  one)	
  YES	
  NO	
  I	
  Don’t	
  Know	
  Compared	
  to	
  the	
  last	
  time	
  I	
  answered	
  these	
  questions,	
  I	
  feel	
  	
  	
  (circle	
  one)	
  	
  BETTER	
  WORSE	
  THE	
  SAME	
  I	
  DON’T	
  KNOW	
  I	
  would	
  like	
  to	
  meet	
  with	
  someone	
  at	
  the	
  hospital	
  talk	
  about	
  how	
  I	
  feel	
  	
  (circle	
  one)	
  	
  YES	
  NO	
  I	
  DON’T	
  KNOW	
  I	
  AM	
  ALREADY	
  MEETING	
  WITH	
  SOMEONE	
  	
  